Biotechnology Annual Review Volume 3
This Page Intentionally Left Blank
Biotechnology Annual Review Volume 3
Editor:
M. Raafat El-Gewely Department of Biotechnolgy University of Tromsra Tromsra, Norway
1997 ELSEVIER Amsterdam -Lausanne -New York - Oxford - Shannon -Tokyo
01997Elsevier ScienceB.V. All rights reserved. No part of this publicationmay be reproduced, stored in a retrievalsystem or transmittedin any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher, Elsevier Science B.V., Permissions Department, PO.Box 521, 1000 AM Amsterdam,TheNetherlands. No responsibilityis assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from use or operation of any methods, products, instructionsor ideas containedin the material herein. Because ofrapid advancesin the medical sciences, the Publisher recommendsthat independentverificationofdiagnosesand drugdosagesshouldbe made. Special regulationsfor readers in the USA - This publication has been registeredwith the Copyright Clearance Center Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA. Information can be obtained from the CCC about conditionsunder which photocopies of parts of this publication may be made in the USA. All other copyright questions, including photocopying outside the USA should be referred to the copyright owner, Elsevier ScienceBY, unless otherwise specified.
ISBN 0-444-82773-0 This book isprintedon acid-freepaper. Published by: Elsevier ScienceB.V. PO.Box211 1000AE Amsterdam The Netherlands
In order to ensure rapid publication this volume was prepared using a method ofelectronictext processing known as Optical Character Recognition (OCR). Specific accuracy and consistencyof style were handled by the author.Time did not allow for the usual extensive editingprocess ofthe Publisher. Printed inThe Netherlands
V
Preface This series, as the title implies, aims at covering the development in the field of biotechnology in the form of comprehensive, illustrated and well-referenced reviews. With the expansion in the field of biotechnology both in industry as well as in education, coupled with the increase in the number of new journals reporting new results in the field, the need for a publication that is continuously providing reviews is urgent. The goal of Biotechnology Annual Review is to fill this gap. Naturally, all aspects of biotechnology cannot be reviewed extensively in each issue every year, but each volume will have a number of reviews covering different aspects of biotechnology Reviewed topics will include biotechnology applications in medicine, agriculture, marine biology, industry, bioremediation and the environment. Fundamental problems dealing with enhancing the technical knowledge encountering biotechnology utilization, regardless of the field of application, will be emphasized. Examples of such vital topics are promoters, vectors, media, induction, genetic stabilization during heterologous gene expression, and any relevant new technique. Essential information dealing with the utilization of data banks, such as protein and nucleic acid data banks, will be reviewed. Homology studies as related to biotechnology, as well as issues dealing with the characterization of motifs and motif databases will also be dealt with. New developments in protein engineering, optimization of protein function, and protein design will be addressed. Problems dealing with protein functionality are important not only for the production of active recombinant proteins and enzymes, but also for the purpose of drug development and design based on screening using such proteins, whether by employing in vitro or in vivo assays. Newly discovered open reading frames or proteins identified by two-dimensional gel electrophoresis will be updated whenever possible*. Other issues, dealing with policy and regulation of biotechnology as well as the problems of development in developing countries, as related to biotechnology, will be included in the various issues. The “Editorial Board” of Biotechnology Annual Review encourages suggestions and contributions of articles from industry or from academic institutions that would constitute a comprehensive covering of a relevant topic in biotechnology. Please contact me or any of the editorial board members for any suggestions about chapter contributions. M. Raafat El-Gewely, PhD Professor of Biotechnology Institute of Medical Biology University of Tromss, 9037 Tromss, Norway Tel.: +47-776-44654. Fax: +47-776-45350 E-mail:
[email protected] *Downstream processing, purification and scale-up operations are of great interest.
This Page Intentionally Left Blank
vii
Biotechnology Annual Review Volume 3 Editor
Dr M.R. El-Gewely Department of Biotechnology Institute of Medical Biology University of Tromse MH-Bygget 9037 Tromspl Norway Tel.: +47-77-64-46-54 Fax: +47-77-64-53-50 Associate editors
Dr Thomas M.S. Chang Artificial Cells & Organs Research Centre McGill, 3655 Drummond St. Room 1005 Montreal, Quebec Canada H3G 1Y6 Tel.: + 1-514-398-3512 Fax: + 1-514-398-4983
Dr E Felici IRBM P Angeletti Via Pontina km 30.600 00040 Pomezia, Rome, Italy Tel.: +39-672-594/319(office)/307(lab.) Fax: +39-620-23500 Dr Shigehiro Hirano Department of Agricultural Biochemistry and Biotechnology Tottori University Tottori 680, Japan Tel.: +81-857-280321 (ext. 5200) Fax: +8 1-857-315347 Dr Kuniyo Inouye Department of Food Science and Technology Faculty of Agriculture Kyoto University Sakyo-ku, Kyoto 606-01 Japan Tel.: +81-75-753-6267 Fax: +81-75-753-6265
Dr Thomas T. Chen Biotechnology Center University of Conneticut 184 Auditorium Road U-149 Storrs CT 06269-3149, USA Tel.: +1-203-486-5011/5012 Fax: +1-203-486-5005
Dr Guido Krupp Institut fur Allgemeine Mikrobiologie Christian-Albrechts-Universitat Am Botanischen Garten 9 D-24118 Kiel, Germany Tel.: +49-431-880-4330 Fax: +49-431-880-2194
Dr. Roy H. Doi Section of Biochemistry and Biophysics University of California, Davis Davis, CA 95616-8535, USA Tel.: +1-916-752-3191 Fax: + 1-916-752-3085
Dr Eric Olson Department of Biotechnology Warner-Lambert, 2800 Plymouth Road Ann Arbor MI 48105, USA Tel.: +1-3 13-998-5961 Fax: +1-313-998-5970
...
Vlll
Dr Steffen B. Petersen Department of Biotechnology Aalborg University 9000-Aalborg, Denmark Tel.: +49-459-635-8469 Fax: +49-459-814-2555
G. Kristen Rosendal The Fridtjof Nansen Institute PO. Box 326 1324 Lysaker, Norway Tel.: +47-67-53-89-12 Fax: +47-67-12-50-47
Dr Jack Preiss Department of Biochemistry Michigan State University Biochemistry Building East Lancing, MI 48824-1319 USA Tel.: +1-517-353-3137 Fax: +1-517-353-9334
Dr Shiva M. Singh Department of Zoology and Division of Medical Genetics 307 Western Science Centre The University of Western Ontario London, Ontario, Canada N6A 5B7 Tel.: +1-519-661-3135 Fax: + 1-519-661-2014
ix
List of contributors Dr J. William Anderson Plant Biotechnology Institute National Research Council of Canada 110 Gymnasium Place Saskatoon, Saskatchewan Canada S7N OW9 Tel.: +1-306-975-5248 Fax: +1-306-975-4839 Dr Marcel B. Sally Department of Advanced Therapeutics British Columbia Cancer Agency Vancouver British Columbia Canada Dr Raju Datla Plant Biotechnology Institute National Research Council of Canada 110 Gymnasium Place Saskatoon, Saskatchewan Canada S7N OW9 Rl.: +1-306-975-5248 Fax: +1-306-975-4839
Dr Marc Giband Laboratoire de biologie cellulaire INRA Centre de Versailles Versailles Cedex France Peik Haugen Department of Molecular Cell Biology Institute of Medical Biology University of Tromsnr N-9037, Norway Tel.: +47-77-64-53-67 Fax: +47-77-64-53-50 Dr Finn Haugli Department of Molecular Cell Biology Institute of Medical Biology University of Tromss N-9037, Norway Tel.: +47-77-64-47-19 Fax: +47-77-64-53-50 E-mail:
[email protected]
Christer Einvik Department of Molecular Cell Biology Institute of Medical Biology University of Tromsnr N-9037, Norway Rl.: +47-77-64-47-18 Fax: +47-77-64-53-50
Dr Boglarka Kajuk Wageningen Agricultural University Department of Food Science Food and Bioprocess Engineering Group PO.Box 8129 6700 EV Wageningen The Netherlands Telefax: +3 1-317-48223
Morton Elde Department of Molecular Cell Biology Institute of Medical Biology University of Tmmsnr N-9037, Norway Rl.: +47-77-64-53-67 Fax: +47-77-64-53-50
Dr H. Kreipe Institute of Pathology University of Wiirzburg Josef-Schneider-Str.2 D-97080 Wurzburg Germany Fax: +49-931-201-3440
X
Dr Ravinder K. Jain Plant Biotechnology Institute National Research Council of Canada Saskatoon, Saskatchewan Canada S7N OW9 Tel.: +1-306-975-5495 Fax: +1-306-975-4839 E-mail:
[email protected] Dr S. Johansen Department of Molecular Cell Biology Institute of Medical Biology University of Tromsra N-9037, Norway Tel.: +47-77-64-53-67 Fax: +47-77-64-53-50 E-mail:
[email protected] Dr Lise Jouanin Laboratoire de biologie cellulaire INRA Centre de Versailles Versailles Cedex France Dr Tiziana Maggi Sezione di Microbiologia Dipartimento di Biologia Molecolare Universita di Siena Siena Italy Dr Riccardo Manganelli Sezione di Microbiologia Dipartimento di Biologia Molecolare Universita di Siena Siena Italy Dr Vftor A.P. Martinos dos Santos Wageningen Agricultural University Department of Food Science Food and Bioprocess Engineering Group PO.Box 8129 6700 EV Wageningen The Netherlands Tel.: +31-317-484372 Fax: +31-317-482237
Dr Marianne Mazier Station d'amklioration des plantes maraichires INRA, BP 94 84143 Montfavet Cedex France Fax: +33-90-31-63-98 Dr Donata Medaglini Microbiologia/Universitl di Siena Via Laterina 8 53100 Siena, Italy Tel.: +39-577-26-3874 Fax: +39-577-26-3870 Dr S. Muller-Deubert Institute of Pathology University of Wiirzburg Josef-Schneider-Str.2 D-97080 Wiirzburg Germany Fax: +49-931-201-3440 Dr Thomas Munder Hans-Knoll-Institut fur Naturstoff-Forschunge.K Department of Cell and Molecular Biology Beutenbergstr. 11 D-07745 Jena Germany Tel.: +49-3641-65-66-92 Fax: +49-3641-65-66-94 E-mail:
[email protected] Dr Milena Ninkovic Department of Cell and Molecular Biology Hans-Knoll-Institut fur Natursoff-Forschunge.K, Jena Germany Dr Catherine Pannetier Laboratoire de biologie cellulaire INRA Centre de Versailles Versailles Cedex France
xi Dr Gianni Pozzi Sezione di Microbiologia Dipartimento di Biologia Molecolare Universiti di Siena Siena, Italy Dr Marco R. Oggioni Sezione di Microbiologia Dipartimento di Biologia Molecolare Universita di Siena Siena, Italy Dr Dorothy L. Reimer Department of Advanced Therapeutics British Columbia Cancer Agency 600 West 10th Ave.,Vancouver British Columbia, Canada V5Z 4E6 Tel.: +1-604-877-6010/3155 Fax: +1-604-877-6011 E-mail:
[email protected] Dr Susanna Ricci Sezione di Microbiologia Dipartimento di Biologia Molecolare Universiti di Siena Siena, Italy Dr Vincenzo Romano-Spica Institute of Hygiene and Public Health Faculty of Medicine of the Catholic University L.E Vito 1, Rome 00168, Italy Tel.: +39-6-30154396 Fax: +39-6-3058202 E-mail:
[email protected] Dr Biirbel Rudakoff Department of Cell and Molecular Biology Hans-Knoll-Institut fur Natursoff-Forschung e.V Jena, Germany Dr Catherine M. Rush Sezione di Microbiologia Dipartimento di Biologia Molecolare Universita di Siena Siena, Italy
Dr Hiroshi Sano Nara Institute of Science and Technology Ikoma, Nara 630-01 Japan Fax: +81-298-38-7044 Dr Shigemo Seo Nara Institute of Science and Technology Ikoma, Nara 630-01 Japan Fax: +81-298-38-7044 Dr Gopalan Selvaraj Plant Biotechnology Institute National Research Council of Canada Saskatoon, Saskatchewan Canada S7N OW9 Tel.: +1-306-975-5495 Fax: +1-306-975-4839 E-mail :
[email protected] Dr S.M. Singh Department of Zoology and Division of Medical Genetics 307 Western Science Center University of Western Ontario London, Ontario Canada N6A 5B7 Tel.: + 1-519-661-3135 Fax: + 1-519-661-2014 E-mail:
[email protected] Dr Jacques Tourneur Laboratoire de biologie cellulaire INRA, Centre de Versailles Versailles Cedex France Dr Johannes Tramper Wageningen Agricultural University Department of Food Science Food and Bioprocess Engineering Group PO. Box 8129,6700 EV Wageningen The Netherlands Fax: +31-317-48223
xii Anna Vader Department of Molecular Cell Biology Institute of Medical Biology University of Tromse N-9037, Tromse Norway Tel.: +47-77-64-47-18 Fax: +47-77-64-53-50 Dr Vikram N. Vakharia Center for Agricultural Biotechnology University of Maryland Biotechnology Institute MD 20742-37 1 1 USA Fax: + 1-301-935-6079
Dr Tatjana Vasilevska Wageningen Agricultural University Department of Food Science Food and Bioprocess Engineering Group PO. Box 8129, 6700 EV Wageningen The Netherlands Telefax: +31-317-48223 Dr Jan Vijg Division on Aging Harvard Medical School and Gerontology Division Beth Israel Hospital 330 Brookline Avenue Boston, MA 02215 USA
...
Xlll
Contents Preface Two-dimensional DNA electrophoresis: state of the art and applications K Romano-Spica and J Vijg The two-hybrid system in yeast: applications in biotechnology and basic research I: Munder, M. Ninkovic and B. Rudakoff Human gene therapy: principles and modern advances D. L. Reimer, M. B. Bally and S.M Singh Group I introns in biotechnology: prospects of application of ribozymes and rare- cutting homing endonucleases S. Johansen, C. Einvik, M. Elde, E! Haugen, A. Vader and l? Haugli Development of recombinant vaccines against infectious bursal disease KN Vakharia Molecular methods in diagnostic pathology S. Muller-Deubert and H. Kreipe Transgenic manipulation of signaling pathways of plant resistance to pathogen attack S. Seo, H Sano and X Ohashi Production and characterization of double-layer beads for coimmobilization of microbial cells Tramper VA.R Martins dos Santos, I: Vasilevska, B. Kajuk, .l and R.H. Wiyfels Molecular genetic improvement of salt tolerance in plants R.K. Jain and G. Selvaraj Plant promoters for transgene expression R. Datla, J William Anderson and G. Selvaraj Recombinant Gram-positive bacteria as vehicles of vaccine antigens D. Medaglini, S. Ricci, I: Maggi, C.M. Rush, R. Manganelli, M. R. Oggioni and G. Pozzi The expression of Bacillus thuringiensis toxin genes in plant cells M. Mazier, C. Pannetier, J Tourneur, L. Jouanin and M. Giband
V
1
31 59 111 151 169 197
227 245 269 297 313
Index of Authors
349
Keyword index
35 1
This Page Intentionally Left Blank
01997 Elsevier Science B.V. All rights reserved. Biotechnology Annual Review Volume 3 M.R. El-Gewely, editor.
1
Two-dimensional DNA electrophoresis: state of the art and applications Vincenzo Romano-Spica' and Jan Vijg2 'Institute of Hygiene and Public Health, Dir Prof: G.C. Vanini, Faculty of Medicine of the Catholic Universitj Rome, Italy; Division on Aging, Harvard Medical School and Gerontology Division, Beth Israel Hospital, Boston, USA
Abstract. Two-dimensional DNA electrophoresis allows the analysis of multiple DNA fragments based on both their size and sequence properties. The often complex gel separation patterns represent information-rich data sets that may be analyzed with dedicated image analysis systems. The introduction of a denaturing gradient in the second dimension enhances the capability of the method to identi@sequence variations, and the recent construction of automated instruments opens up new ways for the diffusion of the procedure into the laboratory routine. In this review, the state of the art of the technique, its general principles and basic methodology will be discussed together with major applications in different fields, including environmentalmicrobiology, mutation detection and human genetics. Keywords: denaturing gradient gel electrophoresis (DGGE), DNA polymorphism, DNA fingerprinting, gene mutation, gene scanning, genetic variation, genetic typing, genetic epidemiology, genetics, genome scanning, genotoxicity, heteroduplex analysis, hospital infection, linkage, microbiology, mutation detection, mutational spectroscopy, polymerase chain reaction, restriction fragment length polymorphism, tumor analysis, two-dimensional DNA electrophoresis.
Introduction The recent explosive development of molecular biology has opened original and productive lines of research in different disciplines. The possibility of investigating genetics and cell biology at a molecular level has created a growing demand of more informative and efficient methods of analysis. Genotyping has become an important approach in medical genetics, forensic medicine, microbiology, as well as in the characterization of animal and plant species. Genome projects for human, animals, plants and microorganisms, require and depend upon the availability of rapid and cost-effective methods for large-scale analysis of individual DNA sequence variation. For this purpose, nucleotide sequencing will not sufice. Indeed, even if the determination of nucleotide sequence would provide the ultimate tool, it requires dramatic improvements to become routinely applicable for genome scanning or screening purposes [1-31. More rapid methods for sequencing have been suggested, but are still under development [4- lo]. Address for correspondence: Dr Vincenzo Romano-Spica, Institute of Hygiene and Public Health, Faculty of Medicine of the Catholic University, L.F. Vito 1, Rome, 00168, Italy. Tel.: +39-630154396. Fax: +39-6-3058202. E-Mail:
[email protected]
2 Sequencing methods provide much unnecessary information, since virtually all of the comparatively analyzed sequence may appear identical. The development of techniques that are able to identify deviations from a particular wild-type sequence of interest, in a sensitive and specific manner, is therefore opportune. Several approaches for mutational scanning have been adopted, such as restriction fragment length polymorphism (RFLP) analysis [11-131, hybridization analysis [14- 161, single-strand conformation polymorphism (SSCP) analysis [171 and denaturing gradient gel electrophoresis (DGGE) [18]. To date, methods to detect DNA sequence variation have been mostly based on the possibility of recognizing differences in the size of the fragments to be analyzed (RFLP) or in their nucleotide sequence by exploiting physical properties as intrastrand interactions (SSCP), melting behavior (DGGE), and ability to form an heteroduplex molecule with a labeled nucleic acid probe (hybridization). Two-dimensional DNA electrophoresis is a procedure originally described by Fischer and Lerman in a paper published in the January 1979 issue of Cell [181. It combines size separation in polyacrylamide or agarose gel (first dimension) with sequence separation of the fragments in a DGGE gel (second dimension), finally generating a panel of spots on a gel instead of a succession of bands in a lane (Fig. 1) [19,20]. Each spot is determined by the nucleotide number and the melting temperature of the fragment. Other forms of two-dimensional DNA electrophoresis, based on different separation criteria, have been described, but although they are able to reveal minute differences, they achieve only a low resolution and/or are impractical [20,21]. In general, when identical separation criteria are used in twodimensional electrophoresis the fragments would cluster along a straight diagonal (Fig. 2A). Restriction enzyme or S1 nuclease digestion have been used as a basic principle for the second dimension separation criterion [21,22]. This procedure necessitates the incubation of the first dimension gel with a solution containing the modifjling enzyme, followed by an electrophoretic run in the second dimension. This approach is still based on size separation in both dimensions and generates a pattern of spots only within a restricted area of the gel below the above-mentioned diagonal (Fig. 2B,C). Even if only half of the gel area can be used for the resolution of the fragments, several hundreds of spots can still be detected using this enzyme-digestion approach. Protocol modifications have been applied as electroblotting, endlabeling of the fragments, pulsed field gel electrophoresis or field inversion gel electrophoresis [23-291. This general approach has been used to analyse and isolate repetitive sequences in Drosophila DNA [30,31], and to estimate genome sizes of simple prokaryotic organisms [22,25,32-341. Analysis of more complex genomes has been facilitated by transferring the separation pattern onto a membrane and by subsequent hybridization analysis [23,24,35-371. As in two-dimensional protein electrophoresis the key point in determining the effectiveness of two-dimensional DNA electrophoresis is an independent separation criterion in the second dimension (Fig. 2D). Several approaches have been
Mrst dimenslon
B
I
IICB B B B I B
D
0
A
First dimension
G 0
0
F
0 0
C
-
3
.
0
E
Fig. I. Two-dimensional DNA electrophoresis, according to Fischer and Lerman [18,19]. A: Schematic depiction - first dimension is on the basis of fragment size and an agarose or polyacrylamide gel is used for separation. A denaturing gradient gel is used for the second dimension and DNA fragments are separated on the basis of sequence variation. Spots D and E represent fragments with different nucleotide sequences but identical molecular weight. B: Example of an ethidium bromide-stained gel pattern. A pool of restriction enzyme-digested fragments (HaeIII, RsaI, BglI) from phage lambda DNA was loaded. The experimental, semiautomated apparatus indicated in Fig. 4A was used. The first dimension was run on a 6% acrylamide gel, at 200 V (0.18 A) for 3 h at 60°C; and the second dimension on a 6% acrylamide gel with a 0-75% UF denaturing gradient,
proposed to combine different, independent separation criteria on the basis of conformational variation of DNA molecules under different circumstances, such as the presence of intercalating dyes [38,39], different electric field strengths, buffers, matrices [39--411. Although these methods may reveal minute differences, they maintain low resolution, ?re usually cumbersome and do not allow largescale scanning of genomic regions. The introduction of DGGE as the second dimension criterion is technically important to obtain an optimal distribution of spots across the entire area and a good resolution based on small sequence variation. DGGE involves separation in a polyacrylamide gel containing a gradient of denaturants (i.e., urea and formamide) at a fixed and elevated temperature [18,19]. The double-stranded DNA
4 first dimension
d = i e m c e O n “
8
.-.:‘., . . . .. . _ .
1;:.
m
d i 0
n
. , .. A
Fig. 2. Schematic depiction of the DNA fragment distribution after two-dimensional gel electrophoresis using identical or independent separation criteria for the first and second dimension. 1: Identical first and second separation criteria. 2: Separation criteria are identical for first and second dimensions, but fragments have been digested between the two separations. 3: Separation criteria are identical for frst and second dimension, but the gel matrices are different and fragments have been digested between separations. 4 First and second dimension separation criteria are independent. (Modified from Uitterlinden and Vijg, 1994 [20].)
fragments migrate through the gel according to their size until they encounter a specific denaturants concentration able to dissociate their double-helical state in a particular domain. Once part of the molecule is melted, the conformation change causes a reduction in its electrophoretic mobility Therefore, at a certain position in the denaturing gradient, migration of a particular fragment in the DGGE gel becomes no longer size-dependent, but is a fhction of the base-pair sequence. Melting of DNA fragments is not a gradual process, but proceeds in discrete steps, due to the presence of so-called melting domains: stretches of 50-400 base pairs that will denature at nearly identical melting temperatures. The melting behavior of a particular sequence can be calculated using a computer algorithm (MELT87, MELT95) based on thermodynamic stability values of a given base pair with its neighboring base pairs [18,42,43]. The prediction of the computer program has been shown to be reasonably accurate and comparable to the observed gel position of a specific fragment compared to its variants, even if differing only by a single point mutation [43,44-461. The ability to identi@ small mutations is improved by the attachment of a GC-rich sequence (“GCclamp”), that modifies the melting behavior of the fragment, preventing monodomain molecules from complete dissociation and guarantees that the adjacent
5
sequence is always the first melting domain [42,44,45]. Although DGGE is capable of detecting single base differences by comparing homoduplexes, its sensitivity can be enhanced by introducing base pair mismatches as they occur in heteroduplexes [42,47]. In its second dimension, two-dimensional DNA electrophoresis, takes advantage of the potential of DGGE. In principle, fragments of identical size may be resolved by two-dimensional electrophoresis as a function of their sequence diversity. Even if more complex, the final result of a two-dimensional electrophoresis is highly informative and allows the simultaneous analysis of many genes or genomic sites for sequence variations, with a resolution in the order of lo2 spots per gel area depending on the size of the gel [47-501. Once optimized for a specific study requirement, it may become the method of choice for complex gene and genome scanning. The interpretational analysis of the distribution of the spots on a two-dimensional area can be facilitated by image analysis of the digitalized pattern [51-531. Thus, different exons of genes of interest can be analyzed in parallel by two-dimensional DNA electrophoresis searching for minor differences such as, for example, point mutations [54-561. Studies have shown its capability to perform genetic typing [28,57,58], detect mutations in neoplastic tissues [59-611 and furnish information in linkage studies [62]. However, the technology available to analyse DNA fragments by two-dimensional electrophoresis is still laborious and requires particular care to obtain reproducibility and an optimal resolution of the fragment mixture [63]. The recent progress in the design of an appropriate electrophoresis apparatus and dedicated software for image analysis are the first promising steps toward the Ml automation of the procedure and its introduction in routine laboratories [64]. Even if not yet a fully automated and easily adoptable procedure in a laboratory routine, two-dimensional DNA electrophoresis, constitutes a highly informative and promising approach for gene and genome scanning. In this paper we will discuss recent developments in DNA two-dimensional methodology and the application of these procedures in gene or genome analysis of prokaryotic or eukaryotic organisms. Equipment: electrophoresis apparatus and image analysis software
The original equipment described by Fischer and Lerman was based on an acrylic frame (Fig. 3) [19]. In the cathode chamber, about 100 ml of electrolyte was constantly recirculated by means of a peristaltic pump. The negative electrode was made by highly purified graphite, while a platinum wire parallel to the trough was used as anode. The denaturing gradient gel was prepared with a digitally controlled gradient maker, in which the two solutions were linearly mixed from two 50-ml glass syringes. The gel temperature was measured using a needle-mounted thermometer. Several modified versions based on the original two-dimensional apparatus are available today from several companies (e.g., C.B.S. Scientific, Solana Beach,
6
Fig. 3. Two-dimensional DNA gel electrophoresis apparatus, as originally realized by Fischer and Lerman [18,19]. Left panel: front view. Right panel: schematic depiction of the side view. A, acrylic frame; B, trough; C, gradient gel; D, stainless-steel screws; E, screwforce spreader; F, cathodebuffer chamber; G, agarose gel strip; H,carbon cathode; I, rubber gasket; J, cathode buffer chamber inlet; K, cathode buffer chamber outlet; L, 90 mg/ml acrylamide plug; M, tabbed inner glass plate; N, outer glass plate; 0, 10 mg/ml agarose seal. (Reproduced with permission [18].)
CA, USA; Ingeny B.Y., Leiden, The Netherlands). The introduction of small improvements in the design of the apparatus made the procedure more simple and reproducible, but the general technique remains unchanged. The first and second dimensions are run separately, and after size separation of the DNA fragments the lane containing the separation pattern must be excised from the gel and placed on the denaturing gradient gel, for the second electrophoresis. A landmark toward a possible realization of an automated system is the prototype made by Ingeny B.Y. (Leiden, The Netherlands) and described by Mullaart et al. in 1993 [a]. This instrument consists of two pairs of electrodes and four separate buffer chambers. The first commercially available instrument based on this prototype is depicted in Fig. 4. This automated system is capable of running 10 gels simultaneously and consists of two pairs of platinum electrodes and four separate buffer chambers: two side reservoirs for the first dimension, and the middle and bottom reservoirs for the second dimension. A heating element equipped with thermostat helps in maintaining the set buf€er temperature during electrophoresis, and a system of valves, pumps and shunts
7
Fig. 4. Automatic two-dimensionalelectrophoresis apparatus (Ingeny BY,Leiden,The Netherlands). A: Prototype. The instrument consists of four electrodes and of a system of valves, pumps and heater able to keep the correct buffer levels and temperature during the fmt and second dimensions. One of the two cartridges, on the side of the apparatus, have been loaded with dummi gels. In this picture the buffer tank and the power supply are not shown. B: Recently commercializedautomated version. In this instrument the electrophoresisconditions can be programmed at the beginning of the experiment, avoiding any further manual intervention during the electrophoresis.
guarantees recirculation and correct levels of the buffer. Gels are cast outside the instrument within a glass-plate sandwich, then slid between silicone sealings in two cartridges capable of five gels each and inserted into the instrument.
8
Samples are loaded in aV-shaped slot and run first horizontally in an acrylamide nondenaturant portion of the gel and then vertically in a denaturing gradient (Fig. 5). This simple strategy avoids the laborious step of cutting and transferring lanes containing the size separation pattern. Another major advantage of this electrophoresis unit is the possibility to run 10 gels simultaneously under identical conditions. Although this instrument opens up new promising paths for large-scale two-dimensional electrophoretic analysis, the general procedure is still time consuming, requires skilled personnel and may therefore need further improvements in automation and consistency of the electrophoresis parameters. Depending on the specific experimental requirements, a two-dimensional polyacrylamide separation pattern can be visualized directly after staining (ethidium bromide, silver-staining) or by hybridization, after electro-blot transfer to a nylon membrane. Whatever apparatus and protocol is used, the final evaluation of the spot patterns is a complex and time-consuming process. Computerized image analysis systems may provide a helphl alternative to process information obtained from multiple gels. Several systems able to compare two-dimensional gel patterns, are commercially available, such as the Tycho system [51,52] the Quest system [53],
First dimension
Second dimension
Fig. 5. Examples of a one- and two-dimensional separation pattern of phage lambda marker fragments obtained with the automatic instrument. In order to obtain the one-dimensional pattern, the automatic two-dimensional process was interrupted and the gel stained. Then, another gel that wad allowed to run completely in two dimensionswas stained to obtain the two-dimensionalpattern..
9 the Masterscan (Scanalytics) and the IngenyVision system (Ingeny BY). The last one has been specifically developed for interpretation of spot patterns generated after a two-dimensional DNA electrophoresis. General obligatory steps in the computerized image analysis process are: 1) image acquisition, 2) spot detection, 3) calibration, 4) matching, and 5) database generation and searching [20]. Images of ethidium bromide stained gels and autoradiographs can be acquired by means of scanners or video cameras. The spots originated from radioactive hybridization filters can be detected and captured also by means of phosphor storage screens with the advantage of fast exposure times and possible quantitative determinations (Molecular Dynamics, Fuji, Biorad). Today, image acquisition is a relatively simple and accurate step which is valuable not only for computerized image analysis but also for storage of results. Once the image has been acquired, the identification of the correct spots involves the definition of their location within the gel and the recognition of possible artifacts. The increased intensity of a spot against the threshold background is the basis for spot detection, and several procedures have been adopted to improve the process [51]. The location of a spot in a two-dimensional gel can be defined along x-y coordinates, by a process called calibration (Fig. 6). In particular, the “x” value is related to the size of the fragment and the “y” to its melting temperature. The assignment of the correct coordinates is essential for the identification of the right spot and the comparison of the results. However, the relative position of an individual spot and/or groups of spots, may differ due to inter-gel variations. Even if such deviations are reduced by standardizing experimental conditions, computerized calibration is necessary and allows gel comparison for the presence or absence of a particular spot. Matching of spot patterns has the ultimate purpose of scoring the presence or absence of spots. It is based principally on spot position, but can also be done on the basis of several other criteria, such as intensity or morphology In general, computerized image analysis systems represent helphl tools for analyzing groups of two-dimensional gels, but require a consistent, correct and optimized input of the electrophoresis results. Methodological considerations: general protocols, optimization of the parameters
Two-dimensional DNA electrophoresis, as first described by Fischer and Lerman [18,193 and hrther improved by others [64], can be considered a highly informative, sensitive, but also complex methodology Not only the interpretation of the final spot patterns, but any step in the protocol requires particular care to obtain optimal, accurate and consistent results, starting from the preparation of the sample. It is important to start with good-quality DNA, avoiding single- and double-strand breaks, that may negatively influence the second and first run, respectively Frequently cutting restriction enzymes, such as “four-cutters”, are
10
Fig. 6. The automated image analysis: the calibration step. The calibration allows the assignment of the correct location of a spot along x-y coordinates and is an essential step in comparing several gels in parallel. The x value is related to the size of the fragment and the y to its melting temperature.The middle pattern shows the actual gel picture, on the left is a reference database and on the right the resulting calibrated pattern. This procedure is based on a triangle-transformation routine. This example has been obtained using the image analysis system IngenyVision (Ingeny BY, Leiden, The Netherlands). After completing the calibration step, it is possible to analyze a group of gels in parallel, an example of group analysis is shown in Fig. 8.
most suitable for analyzing genomic DNA, because after digestion they generate a pool of small fragments which can be optimally resolved by two-dimensional electrophoresis into a highly informative spot pattern. The distribution of the spots in the first dimension (x-axis), depends on the size of the fragments to be separated, and can be modified by varying the polyacrylamide (or agarose) concentration. Currently we are using 6% polyacrylamide for size-separating fragments between 100 and 900 bp and 10% polyacrylamide for fragments between 150 and 350 bp. Agarose is more suitable for fragments of 1-2 kb or larger. In the second dimension, 6% polyacrylamide is currently used and the concentration may be increased if the fragments to be analyzed are all included within a small size range (100-400 bp). Optimal resolution of the fragments of interest can be achieved by varying
11
electrophoresis parameters along the first and/or the second dimension: time, buffer concentration, polyacrylamide concentration, temperature and denaturing gradient. We found it crucial to accurately maintain the ionic strength of the buffer (TAE 0 . 5 ~pH 8.0 at 1530 pS; TAE = 0.02 M Tris; 0.01 M Na-acetate; 0.5 mM Na2EDTA, pH 8.0 by addition of acetic acid), and to use reverseosmosis purified water. Electrophoresis is generally carried out at 200 V for 1.5-4 h (0.15 A) along the first dimension and at 200 V for 4-12 h (0.5 A) along the second dimension, at 60°C. The most critical and important variable, however, is the preparation of an appropriate denaturing gradient. Several possibilities are available to modifL the distribution of the spots over a gel (Fig. 7), but the critical point is the range of denaturants concentration over which the fragments of interest would be optimally distributed. Starting from two solutions at different denaturants concentration, the gradient can be obtained using any suitable gradient mixer. Commonly used denaturing gradient gels are made with a linear gradient ranging from 10% (top) to 75% (bottom) (100% = 7 M urea, 40% v/v formamide deionized by incubation with mixed bed resin). The denaturing window can be modified to optimize the specific conditions of the experiment [54-561. The spot pattern may be directly visualized by ethidium bromide, silver staining, SYBR-Green, or by hybridization with labeled probes after transferring of the spot pattern onto a nylon membrane using electroblotting [20]. The reproducibility of this method was tested in intra/interlaboratory experiments performed in the Laboratory of Molecular Biology of the Institute of
Fig. 7. Denaturing gradient gel constellations.Several modifications of the originallydescribed twodimensional DNA separation experiments have been performed to improve resolution and avoid the condensation of spots in the upper left part of the two-dimensional pattern (fragments with high molecular weight and low denaturants concentration).To address this aim, linear denaturing gradients perpendicular to the first dimension can be modified using linear or exponentialgradients (smaller increments of denaturant at the top of the gel and larger increments at the bottom), in a diagonal orientation to the first dimension separation.The schematicrepresentation shows the predicted modifications in the shape and direction of the denaturing gradient and their influence on the separation pattern. (Modified from Uitterlinden and Vijg, 1994 [20,57].)
12 Hygiene of the Catholic University, Rome, Italy and in the Ingeny Laboratories, Leiden, The Netherlands, and it appeared sufficiently high (> 95%) to support large-scale genome and gene-scanning experiments (Fig. 8). Such reproducibility is guaranteed by maintaining identical experimental conditions. This can be achieved by following optimized protocols and by standardizing all steps: from the preparation of samples, buffers and gels to the electrophoresis conditions and the manipulation of gels. Preparation of large stocks of master solutions and minimizing manual handling are two basic points for an efficient daily routine. Applications in different fields
In principle, almost any pool of DNA fragments can be efficiently separated by two-dimensional electrophoresis, which generates a highly informative pattern of spots under optimized conditions. Genomic DNA isolated from plants, animals, bacteria or viruses can be analyzed after enzymatic digestion or amplified by polymerase chain reaction using specific or arbitrary primers [65-671. The
Fig.8. Gel analysis and reproducibility, Comparison of reproducibility has been performed in several inter- and intralaboratory experiments. A simplified example of computerized analysis of the spot patterns is shown. The gels are representative of different electrophoresisruns or of different gels within the same run (up to 10 gels). For this experiment the semiautomated prototype (Fig. 4) and the After the calibration step Ingenyvision image analysis system described in the text were used [a]. (Fig. 6), computer analysis makes it possible to compare up to 16 gels in parallel. On the upper left is a reference database containing different spots corresponding to different restriction fragments (phage lambda DNA).
13 possibility to generate a fingerprint on the basis of both the size and the sequence of the obtained fragments, represents a powerll tool for genetic typing of microorganisms, animals and plants, and can contribute to medical genetics and forensic medicine. The complex spot patterns obtained after hybridization with highly polymorphic multilocus probes represent displays for analysis of genomic instability, assessment of mutation rates and possible association studies. Variants within particular genomic regions can be identified and hrther analyzed by matching the spot patterns with a computer database or after direct isolation and characterization of the spot of interest. The observation that some spots corresponding to particular traits can segregate following a mendelian model provides new perspectives in linkage analysis, and the availability of linkage-dedicated software enhances the informativity of the approach. The possibility to analyse fragments of the same size in one gel simultaneously allows gene-scanning experiments in which all possible mutations can be visualized in parallel [24,54-561. Electrophoresis of GC-clamped fragments makes it feasible to identif) point mutations and opens up promising new ways for diagnosis and screening of susceptibility genes, in genetic epidemiology studies. Environmental and clinical microbiology
The possibility to distinguish microorganisms at the strain level is of basic importance for environmental microbiology and epidemiologic or clinical studies [68]. Several molecular methods are available based on proteins, lipid analysis, antibiogram or biochemical profiles [69]. Nucleic acid analysis and genetic typing can be performed following different approaches like ribotyping, plasmid profiling, RFLP analysis or comparison of DNA fingerprints generated by polymerase chain reactions with arbitrary primers [70,713. Also, denaturinggradient gel electrophoresis (DGGE) has been successllly used for studying genetic diversity of several microorganisms [72-741. In principle, any pool of DNA fragments already informative for typing different microbial strains could be resolved on a two-dimensional gel in a more complex and informative pattern of spots. Interestingly, in the first two-dimensional experiment, Fischer and Lerman used Eco RI digested E. coli genomic DNA and demonstrated the possibility to resolve over 250 fragments in a length-independent way (Fig. 9) [18,19]. A similar experiment was performed with the digested genome of other schizomycetes: Mycoplasma capricolum, Acholeplasma laidwaii, Haemophilus influenzae and Bacillus amyloliquefuciens [75]. In these experiments, the total number of DNA restriction fragments and their distribution as a function of the fragment size allowed the calculation of the genome size of the microorganism. Two-dimensional electrophoresis has been applied for typing the viral genome of the bacteriophage lambda and of the BHV-1 (bovine herpesvirus type-1) (Fig. 10) [64,76]. Spot differences detected after two-dimensional electrophoresis of the digested genome of different BHV-1 isolates, have been associated with
14
Fig. 9. The original experiment of Fischer and Lerman: E. coli and E. coli h DNA have been compared by two-dimensionalDNA electrophoresis.(Reproducedwith permission [181.)
the presence of different strains. A computer algorithm (Melt program, by L. Lerman) was successllly used to design a melting map of the entire genome of the bacteriophage lambda and theoretically evaluate the presence of melting domains able to determine the focusing of restriction fragments along the second dimension [20,77]. The relatively small size of viral and bacterial genomes (bacteriophage lambda, 4.8 x lo4 bp; E. coli, 4.4 x lo6 bp) allows direct detection of the restriction fragments after ethidium bromide staining (Fig. 11). The same visualization method generates an unresolvable cloud of different fragments, when analyzing digested genomic DNA isolated from lower eukaryotes such as yeast (Succhuromyces cerevisiue, 1.5 x lo7 bp). Electroblotting and hybridization analysis with
15
Strain A
Strain B
Fig. 10. Bovine herpes virus identification. Example of genetic typing by two-dimensional DNA
electrophoresis. The viral genome was digested with a restriction enzyme, analyzed by two-dimensional electrophoresis and stained with ethidium bromide. (Reproduced with permission [76].)
microsatellite core probes or probes for transposable elements have been successWly used to study two-dimensional electrophoresis gels containing Hae I11 digested genomic DNA isolated from Aspergillus niger and Saccharomyces cerevisiae [20,78,79]. DGGE analysis of amplified 16s rDNA fragments (Fig. 12) has been used to identify different microorganisms and to study the genetic diversity of microbial populations isolated from a range of different environments, such as from experimental bioreactors and intertidal sediments [72,73]. This approach provides a direct display of the sample composition in both a qualitative and a semiquantitative way, allowing studies on genetic diversity and popula-
16
I Identification of Microorganisms
k
Small k200 kb)
Lame b200 kb)
Fig. 11. Schematic representation of techniques for identification of microorganisms.
tion dynamics of mixed microbial communities.Two-dimensional electrophoresis can expand the potential of this strategy, allowing the simultaneous analysis of several DNA fragments. In conclusion, several microbial genomes have now been studied by twodimensional DNA electrophoresis, after digestion with restriction enzymes.
30% UF
50% UF Fig. 12. Example of determination of genetic diversity using DGGE analysis.The PCR-fragments of 16s rDNA were amplified from different Cundidu species.
17 While the entire field of genetic typing and in particular DGGE-based analysis is in expansion, the introduction of two-dimensional electrophoresis opens up new perspectives in acquiring data from more complex pools of fragments. Epidemiological studies of small community or hospital-acquired infections, genotyping of clinical isolates, taxonomy studies, and analysis of environmental samples may take advantage of the introduction of two-dimensional genomic fingerprinting. The capability to distinguish between different strains of the same microorganism and the possibility to associate genetic variation with specific phenotypes, is important to investigate specific properties as virulence and oncogenicity, and to identifi the source and the transmission ways of the disease. Medical genetics: linkage analysis and gene scanning
Diagnosis, genetic counseling and gene therapy prospects are strongly connected with the progress in molecular biology and with the availability of new techniques suitable for identifiing the exact molecular defect causing a disease. The complexity of the human genome, the distribution of gene exons among large intronic regions, and the genetic heterogeneity of mendelian disorders necessitate the development of rapid, sensitive, informative and economical genetic analysis tools. In recent years, positional cloning has led to the isolation of a growing number of genes from humans and other higher organisms, using the serial analysis of polymorphic marker loci such as micro- and minisatellites [80-821. Linkage analysis of cosegregation of a particular phenotype with a marker locus is of basic importance to localize traits of interest. Two-dimensional DNA electrophoresis has been shown to be suitable for linkage analysis [62]. The main advantage of this approach is its high information density per gel. High molecular weight genomic DNA isolated from white blood cells of pedigree members can be resolved on a two-dimensional gel after digestion with a restriction enzyme [24]. A complex pattern of heritable spots is generated after electroblotting and hybridization of the filter with micro- and/or minisatellite core probes. Several core probes detect 300-400 spots, corresponding to a similar number of alleles. In principle, by rehybridizing each filter with different nonoverlapping core probes, a high resolution and a very informative map can be obtained in a relatively short period of time, at relatively low costs. More realistically, the effective resolution power, even if very high (at least 40- 100 spots), is lower than the theoretical one, because not all spots detected represent alleles from polymorphic loci. Moreover, cross-hybridization between different probes can occur, as well as comigration of different fragments. The main limitation of this approach in linkage studies is due to the lack of immediate information on the detected spot: each spot in the pattern represents a single or double copy of a specific allele, or may represent unrelated alleles fortuitously comigrating in the gel. A significantly more efficient linkage analysis, based on two-dimensional DNA typing, would require single unknown alleles to be immediately specified and the presence of a spot to be correlated with a situation of heterozygosityor homo-
18 zygosity, for the corresponding allele. Nevertheless, even without this additional information, the procedure remains highly informative. The copresence of a specific spot in the patterns of the parents and its absence in a child, for example, implies that the parents share only one allele at that locus. More detailed knowledge on the different alleles represented by variant spots may be reached by several approaches, such as investigations directed towards the identification of complemeptary alleles from the same locus, and the definition of haplotypes of closely linked spots. Moreover, a spot of interest can be directly isolated from the two-dimensional typing pattern and developed into a locus-specific marker, after elution of the DNA from gel pieces excised from the area of the gel corresponding to the spot localization, cloning, rehybridization for confirmation, and fbrther characterization. Another advantageous application of two-dimensional DNA electrophoresis in medical genetics is the possibility to analyse, in one gel, single or multiple genes for the presence of all possible mutations. There are at least two ways in which this can be accomplished. The first approach is based on the hybridization of genomic DNA digested with different restriction enzymes after two-dimensional electrophoresis and electroblotting. In this case, the capability to detect mutations depends on the melting behavior of the restriction fragments in the denaturing gradient gel, because it is not possible and convenient to try to modifl it by adding GC-clamps. An alternative approach is based on the high accuracy of the denaturing gradient principle in detecting small sequence variations, such as different point mutations in DNA fragments, PCR-amplified with GC-clamped primers [MI. This approach has already been applied for diseases caused by multiple mutations distributed over several exons, such as cystic fibrosis, hereditary nonpolyposis colorectal cancer and retinoblastoma (Fig. 13) [54-561. Multiplex PCR enhances the power of this approach and reduces the labor time, allowing the coamplification of different DNA fragments under identical conditions in the same reaction. This approach has been successllly used for the retinoblastoma gene, obtaining a mixture of GC-clamped fragments from 26 exons optimally resolved over a two-dimensional gel [83]. The possibility to perform a gene scanning for diseases caused by multiple mutations distributed over several exons, is essential to identlfl the precise molecular alterations underlying the phenotypes, expecially in population-based studies (Fig. 14). A major issue is the availability of relatively simple and inexpensive technology for detecting all possible mutations. Two-dimensional DNA electrophoresis is applicable to large disease genes, and could become the first practical way to screen simultaneously several disease genes for a broad-spectrum of mutations. Indeed, it proved possible to analyse simultaneously in one gel, all the possible mutations distributed over the different exons of a gene, identifling them on the basis of position alone. Under optimized conditions, the comigration of different mutations seems a remote possibility However, more extensive studies are necessary to confirm this.
19
17
100
100
@PI
9Do
Fig. 13. Multiplex PCR products obtained after amplification of the retinoblastoma gene. On the left is shown the theoretical two-dimensional electrophoresispattern of the RBI gene, as predicted from the sizes and melting profiles of the 25 amplicons. On the right is the empirical pattern as observed on the two-dimensional gel, after ethidium bromide staining.
Genetic analysis of cancer The pathogenesis of tumors can be considered as a multistep process, in which the accumulation of mutations in time can progressively modifj the growth properties of a cell toward neoplastic transformation [84,85]. The identification of genetic lesions involving proto-oncogenes and tumor suppressor genes has been correlated with a wide range of cellular fbnctions including growth control, invasion, metastasis [86,87]. The recently acquired new insights into the mechanisms involved in such complex phenomena as cell proliferation or apoptosis, could be of clinical relevance for diagnosis, prognosis or prevention. Searching for genetic variations between neoplastic and normal cells has been implemented by the introduction of analysis with highly polymorphic markers such as microand minisatellite probes [80-821. This general approach has been utilized to detect genetic alterations occurring in human cancers by two-dimensional DNA typing [60,61]. Genomic DNA from tumor and normal cells (obtained from peripheral blood lymphocytes of the patient), was compared in parallel after two-dimensional separation of digested fragments, electroblotting and hybridization analysis with mini- and microsatellite core probes (Fig. 15). This approach allowed the identification of several variations in the tumor spot patterns as compared to the control: it was possible to identi@ deletions (absence of spot), amplifications (higher intensity) and presence of new spots [61]. The recurrence of a particular spot change in several patients suggests a correspondence with an
20
Multiplex Long PCR
J Multiplex Short PCR
\1
Automated 2-D separation under one defined set of experimental conditions JI 1-D size
Low UF
>
Gradient
1
High UF
600 bp
size
>
100 bp
Post electrophoresis Processing (e.g., staining, hybridization analysis)
' L
Diagnostic Image rocessing using Computerized Gene Mutational Database Fig. 14. Schematic depiction of two-dimensional gene scanning.
allelic imbalance at loci involved in tumorigenesis or tumor progression. Characterization of each spot can be performed after its direct isolation from the gel. It is possible, in this way, to compensate the lack of immediate information about a particular spot change [20]. The total number of differences between tumor and normal DNA can be considered as an indicator of genetic instability and can be related, in principle, to the malignancy of the neoplasm and to clinical or prognostic parameters [88,89]. The availability of information on specific mutations occurring in specific tumors, has opened up the possibility to perform specific tests for already known deletions, amplifications or point mutations. Denaturing gradient gel electrophoresis has been shown to represent a useful tool for molecular genetic analysis of oncogenes and mutations observed in a given neoplasm [90,91]. The expanding pool of information provided by DGGE analysis constitutes the basis for
21
Fig. 15. An example of amplification of a marker allele in breast cancer, as revealed by a 4 x intensity increase from a two-dimensional hybridization pattern generated from the restriction enzyme digested tumor DNA. The observed amplification was confirmed by the isolation of the spot-giving fragment from the gel and its subsequent use as a locus-specific probe on the same two-dimensional blot.
future development and applications of two-dimensional electrophoresis. Taking advantage of the previously determined melting properties, a complex mixture of fragments, carrying information on several mutations in several oncogenes, may be optimally resolved in a two-dimensional gel.
22 Studies regarding combination or modification of standardized procedures may contribute to the development of molecular oncology, and may be taken into consideration for future projects. A major target of cancer research is to develop biotechnology tools able to correlate an oncogene sequence with specific biological functions, as well as tools able to transfer cell and molecular biology information into prognostic and early diagnosis markers or into pharmaceutical therapy The possibility to investigate the genetic basis of cancer pathogenesis is of fundamental importance and requires informative technical tools for measuring predisposition and designing programs of prevention for individuals at risk. Mutation analysis Mutagenesis is a guarantee of survival of a species in our ever-changing environment, and is the basis for any detection of genetic differences in and between populations. The complex interactions between fitness, selection, heritable background and changes in the environment are critical for any living being, from viruses to humans. Great effort has been dedicated in understanding the mechanisms of spontaneous or induced mutagenesis and identify genotoxic agents. The characterization of mutations at the sequence level is considered indispensable to clarify the relationship between the mutagenic event and cellular or physiological endpoints. Several experimental models for mutagenesis in vivo have been described using micr-oorganisms, yeasts, Drosophila, cell lines or small animals such as rodents [92,93]. The time required for detection depends on the exposure conditions and the replication rate of the used species, about 5 days for bacteria to years for small mammals. Assays for gene reversion, recombination, sister chromatid exchange, chromosomal aberrations, and tests for specific mutations have been used to detect differences in the DNA of exposed compared to controls. The laboratory models simplify the complexity of variables involved in real exposure situations in which several confounding factors are present, such as mixtures of compounds at different concentrations, unpredictable physical-chemical interactions and host populations with heterogeneous genetic background. These confounding factors complicate any study on human populations exposed to a given genotoxic agent. Mutation at selectable genes, such as HPRTand MHC, has been used as a biomarker for monitoring DNA damage in human populations [94,95]. Although informative, this approach has disadvantages because it involves selection of cells in culture, and because the analysis of coding genes may constitute an insensitive indicator for permanent genetic damage, due to their inherent stability; moreover, in this kind of assay, mutations are measured at only a single site in the genome [96]. The assessment of human DNA mutation rates by two-dimensional DNA typing could offer a complementary device in addition to current detection systems. Naturally unstable (hypermutable) sequences spread over the genome, as micro- or minisatellites, may represent an ideal indidator to measure mutation rates. These sequences constitute about 1% of the human genome and display instability both in somatic
23 cells as well as in the germline [59,97-991. Genomic DNA fingerprints can be generated using micro- and minisatellite probes for Southern blot hybridization analysis [80]. This informative procedure has been extensively used for several purposes, such as identity testing in forensic medicine, linkage studies in medical genetics, and the detection of mutations during tumor development or aging [97,100]. One-dimensional DNA fingerprinting has been applied in mutagenesis studies with chemical and physical agents employing minisatellite probes for Southern analysis of treated, as well as untreated, cell lines or animals [101-1031. Two-dimensional DNA typing has been shown to have a higher resolution than Southern blot analysis, reaching 625 spots per probe against the 20-30 bands resolvable in a single dimension, allowing the generation of highly informative DNA fingerprints [24]. In principle, the same general procedure already extensively used for Southern blot analysis can be applied to two-dimensional electrophoresis, by electroblotting the DNA fragments distributed on the twodimensional gel onto a nylon membrane. This procedure has been applied to study mutation frequencies in fibroblasts from the skin of old vs. young rats, confirming previous results that indicated an average mutation rate for micro- and minisatellite loci between and 10- [1041. However, large-scale twodimensional DNA typing studies on treated cells have not yet been performed, and specific experiments on cell lines exposed to environmental carcinogens are in progress. In mutagenesis studies, an additional application field for two-dimensional DNA electrophoresis is the mutational spectra technology [105,106]. The mutational spectrum, first described by Seymour Benzer and Ernst Freese, consists of a specific and reproducible pattern of genetic changes observable when exposing a homogeneous cell population to a given mutagen at particular conditions of exposure [107]. A set of specific mutations has been described for the genome of the T4 bacteriophage as well as for bacteria, yeast, rodents and human cells. The introduction of denaturing gradient gel electrophoresis allows detection of several mutant sequences, separate from each other and from an excess of wildtype, avoiding selection of individual mutant colonies [105,108-1121. The general procedure is based on the amplification with nested primers of a target sequence with a high-fidelity polymerase. The template DNA is isolated from the mixture of exposed cells, avoiding subcloning and sequencing of several colonies. The pool of amplified fragments will include subpopulations characterized by specific point mutations detectable by DGGE. The sequencing of each band can reveal the point-mutational spectrum of the test agent. This strategy can be extended to any locus and if necessary can be implemented by the inclusion of GC-clamped primers. In principle, it can also be introduced in different studies using different hosts, from viral and bacterial to mammalian cell populations. While this procedure has a high sensitivity in detecting point mutation and small insertion/deletions within the amplified target sequence, it is not reliable in detecting chromosomal rearrangements or major deletions. The
24
combination of size separation and DGGE analysis in a two-dimensional gel can increase the informative power of the general method, allowing the analysis of several target regions in parallel, which in turn allows the establishment of a more complex mutational spectrum. Conclusion and critical evaluation Two-dimensional DNA electrophoresis can be considered an informative procedure capable of resolving a pool of fragments according to their size and sequence properties. The introduction of a denaturing gradient gel for the second dimension increases the potential of the technique, opening promising horizons for gene and genome studies. Preliminary results have demonstrated the applicability of the general procedure to different fields such as microbiology, medical genetics, molecular oncology and mutation analysis, and have proven that it is possible to optimize experimental conditions for each specific aim. The final result, represented by a pattern of spots on a surface area, is highly informative, but also complex to interpret. A computerized image analysis system may accelerate the comparison between many gels offering a suitable alternative for large scale experiments. Genomic DNA isolated from humans as well as from plants, animals, bacteria or viruses can be analyzed after restriction enzyme digestion or PCR amplification with specific or arbitrary primers. Spots of interest can be visualized directly after staining with a DNA dye, or by hybridization and autoradiography after electroblotting. So far, the major limit to this procedure is the lack of immediate information on a given spot, even if this can be supplied by its isolation from the gel, and further characterization. In general, two-dimensional DNA electrophoresis requires skilled personnel and particular care in keeping all the electrophoresis parameters constant, due to the sensitivity of the method and to the number of variables involved, such as temperature, denaturing gradient, and buffer conductance. Direct experience has shown, however, that reproducible results can be obtained using standard optimized protocols and taking care in keeping the experimental parameters constant. Designing automated devices, able to run several gels in parallel and under identical electrophoretic conditions, has been a landmark toward a possible diffusion of the method into routine laboratories. Although genotyping and gene scanning represent major applications, the versatility of the procedure suggests further applications in a wide range of situations. A currently explored example is the possibility to study mutations at cDNA level, by increasing resolution of differential display This is a technique aiming at the identification of those genes which are differentially expressed between different cell types, or in the same cell population under different conditions as, for example, after exposure to specific agents [113]. In conclusion, several biotechnological areas may take advantage of the introduction of two-diwnsional DNA electrophoresis, and especially those fields in which denaturing gradient gel electrophoresis is already being exploited. The
25 addition of a GC-clamp enhances the sensitivity of the method, allowing detection of sequence differences as small as point mutations. The high information density per gel provides new opportunities in performing complex screenings on large populations, searching for induced mutations, genetic polymorphisms or affected alleles. The recent, rapid and expanding developments in molecular and cell biology as well as the mathematical-statistical advances in genetic epidemiology open up new ways for a comprehensive understanding of the pathophysiology of multifactorial diseases such as cancer, hypertension and diabetes [114,1151. Linkage analysis on extensive pedigrees, association studies based on the inclusion of multiple DNA markers, and biotechnology tools able to hrnish comprehensive information at the molecular level, are essential to investigate complex phenotypes carried by polygenic systems. Such a multidisciplinary approach provides new contributions to studies on the interaction between environmental agents and genetic predisposition. Acknowledgements We thank everyone who supported the background work necessary for the preparation of this manuscript and in particular Revd Luigi Ferlauto and all the collaborators of the Oasi Institute of Troina, Italy; the collaborators of the research team of Prof Giancarlo Vanini at the School of Hygiene and Public Health of the Catholic University in Rome; the Mastelli srl, San Remo, Italy; and all collaborators at Ingeny B.V., Leiden, The Netherlands, and in the Molecular Genetics Section, Gerontology Division, Beth Israel Hospital, Boston, Massachusetts, USA. References 1. Maxam AM, Gilbert W. A new method of sequencing DNA. Proc Natl Acad Sci USA 1977;74 560-564. 2. Gilbert W. DNA sequencing and gene structure. Science 1981;2141305-1312. 3. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:463-5467. 4. Mathies RA, Huang XC Capillary array electrophoresis: an approach to high-speed, highthroughput DNA sequencing. Nature 1992;359:167- 169. 5. Chetverin AB, Russel Kramer E Oligonucleotide array: new concepts and possibilities. BioTechnology 1994;12:1093- 1099. 6. Fodor SPA, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CL. Multiplexed biochemical assays with biological chips. Nature 1993;364555-556. 7. Drmanac R, Labat I, Brukner I, Crkvenjakov R. Sequencing of megabase plus DNA by hybridization: theory of the method. Genomics 1989;4:114-128. 8. Strezoska Z, PauneskuT, Radosavljevic D, Labat I, Dramanac R, Crkvenjakov R. DNA sequencing by hybridization: 100 bases read by a non-gel-based method. Proc Natl Acad Sci USA 1991;88:10089-10093. 9. Drmanac R, Drmanac S,Strezoska Z, PauneskuT,Labat I, Zeremski M, Snoddy I, Funkhouser
26
10. 11.
12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30.
WK, Koop B, Hood L, Crkvenjakov R. DNA sequence determination by hybridization: a strategy for efficient large-scale sequencing. Science 1993;260: 1649- 1652. Davis LM, Fairfield FR, Harger CA, Jett JH, Keller RA, Hahn JH, Krakowski LA, Marrone BL, Martin JC, Nutter HL, Ratliff RL, Brooks Shera E, Simpson DJ, Soper SA. Rapid DNA sequencing based upon single molecule detection. Genet Anal Tech Appl 1991;8:1-7. Flavel RA, Kooter JM, De Boer E, Little PFR, Williamson R. Analysis of the beta-delta-globin gene loci in normal and Hb Lepore DNA. direct determination of gene linkage and intergene distance. Cell 1978;15:25-41. Kan YW, Dozy AM. Polymorphisms of DNA sequence adjacent to human beta-globin structural gene: Relationship to sickle mutation. Proc Natl Acad Sci USA 1978;75:5631-5635. Jeffreys AJ. DNA sequence variants in the Ggamma-, Agamma- and beta-globin genes of man. Cell 1979;18:1- 15. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Molec Biol 1975;98:503-517. Wallace RB, ShaKer J, Murphy RF, Bonner J, Hirose T, Itakura K. Hybridization of synthetic oligodeoxyribonucleotidesto X174 DNA: the effect of single base pair mismatch. Nucl Acid R ~ 1979;6:3543-3557. s Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci USA 1989;86:62306234. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989;86:2766-2770. Fischer SG, Lerman LS.Length-independent separation of DNA restriction fragments in twodimensional gel electrophoresis. Cell 1979;16:191-200. Fischer SG, Lerman LS. Two-dimensional electrophoretic separation of restriction enzyme fragments of DNA. Meth Enzymol 1979;68:183-191. Uitterlinden AG, Vijg J. Two dimensional DNA typing. A parallel approach to genome analysis. Chichester: Ellis Horwood, 1994. Yee T, Inouye M. Ik.0-dimensional S1 nuclease heteroduplex mapping: detection of rearrangements in bacterial genomes. Proc Natl Acad Sci USA 1984;81:2723-2727. Poddar SK, Maniloff J. Chromosome analysis by two-dimensional fingerprinting. Gene 1986; 49:93-102. Sheppard RD, Montagutelli X,Jean WC, Tsai J-Y; Rose A, Gunet EL, Cole MD, Silver LM. Two-dimensional gel analysis of complex DNA families: methodology and apparatus. Mamm Genome 1991; 1:104- 111. Uitterlinden AG, Slagboom PE, Knook DL, Vijg J. Two-dimensional DNA fingerprinting of human individuals. Proc Natl Acad Sci USA 1989;86:2742-2746. Yi M, Au L-C, Ichikawa N, Ts’o POP. Enhanced resolution of DNA restriction fragments: a procedure by two-dimensional electrophoresis and double-labeling. Proc Natl Acad Sci USA 1990;87:3919-3923. Woolf T, Lai E, Kronenberg M, Hood L. Mapping genomic organization by field inversion and two-dimensional gel electrophoresis: application to the murine T-cell receptor gene family Nucl Acid Res 1988;16:3863-3875. Kamiura S, Nolan CM, Meruelo D. Longe-range physical map of the Ly-6 complex: mapping the Ly-6 multigene family by field-inversion and two-dimensional gel electrophoresis. Genomics 1992;12:89- 105. Walter MA, Cox DW A method for two dimensional DNA electrophoresis (2D-DE): application to the immunoglobulin heavy chain variable region. Genomics 1989;5:157- 159. BautschW Rapid physical mapping of the Mycoplasma mobile genome by two-dimensional field inversion gel electrophoresis. Nucl Acid Res 1988;16:11461--11467. GilroyTE, Thomas CA. The analysis of some new Drosopkilu repetitive DNA sequences isolated
27 and cloned from two-dimensional agarose gels. Gene 1983;23:41-51. 31. Hatada I, Hayashizaki Y; Hirotsune S,Komatsubara H, Mukai T. A genomic scanning method for higher organisms using restriction sites as landmarks. Proc Natl Acad Sci USA 1991;88: 9523-9527. 32. Potter SS, Bott KF, Newbold JE. Two dimensional restriction analysis of the Bacillus subtilis genome: gene purification and ribosomial ribonucleic acid gene organization. J Bacteriol 1977;129:492-500. 33. YeeT, Inouye M. Tko-dimensional electrophoresisapplied to the study of DNA methylation and the analysis of genome size in Myxococcus xanthus. J Molec Biol 1982;154 181-196. 34. Boehm TLJ, Drahovsky D. Two-dimensional restriction mapping by digestion with restriction endonucleases of DNA in agarose and polyacrylamide gels. J Biochem Biophys Meth 1984;9: 153-161. 35. Huvos PE, Aquiles Sanchez J, Kramer KM, Karrer KM, Wangh LJ. Two-dimensional DNA gel electrophoresis as a method for analysis of eukaryotic genome structure: evalutation using lktrahymena thermophilae DNA. Biochim Biophys Acta 1988;949:325-333. 36. Rogan PK, Lemkin PL, Klar AJS, Singh J, Strathern JN. Two-dimensional agarose gel electrophoresis of restriction-digestedgenomic DNA. Methods: Comp Meth Enzymol 1991;3:91-97. 37. Sakaki Y; KurataY; MiyakeT, Saigo K. Two-dimensional gel electophoreticanalysis of the Hind I11 1.8 kb repetitive-sequence family in the human genome. Gene 1983;24:179-190. 38. Meyer G, Hildebrandt A. Xvo-dimensional gel analysis of repetitve nuclear DNA sequences in the genome of Physarum polycephalum. Eur J Biochem 1986;157:507-512. 39. VanWye JD, Bronson EC, Anderson JN. Species-specific patterns of DNA bending and sequence. Nucl Acid Res 1991;19:5253-5261. 40. Bell L, Byers B. Separation of branched from linear DNA by two-dimensional gel electrophoresis. Anal Biochem 1983;130:527-535. 41. ShinomiyaT, Ina S.Analysis of chromosomal replicons in early embryos of Drosophila melanogarter by two-dimensional gel electophoresis. Nucl Acid Res 1991;19:3935-3941. 42. Lerman LS, Fischer SG, Hurley I, Silverstein K, Lumelsky N. Sequence-determined DNA separations. Ann Rev Biophys Bioeng 1984;13:399-423. 43. Lerman LS, Silverstein K, Grinfield E. Searching for gene defects by denaturing gradient gel electrophoresis. Cold Spring Harbor Symp Quant Biol 1986;51:285-297. 44. Myers RM, Fischer SG, Maniatis T, Lerman LS. Modification of the melting properties of duplex DNA by attachment of a GC-rich DNA sequence as determined by denaturing gradient gel electrophoresis. Nucl Acid Res 1985;13:3111-3129. I Nearly all single base substitutions in DNA 45. Myers RM, Fischer SG, Lerman LS, Maniatis ' fragments joined to a GC-clamp can be detected by denaturing gradient gel electrophoresis. Nucl Acid Res 1985;13:3131-3145. 46. Abrams ES, Murdaugh SE, Lerman LS. Comprehensive detection of single base changes in human genomic DNA using denaturing gradient gel electrophoresisand a GC clamp. Genomics 1990;7:463-475. 47. Uitterlinden AG, Vijg J. Denaturing gradient gel electrophoreticanalysis of the human cHa-ras 1 proto-oncogene. Appl Theor Electrophor 1990;1:175- 179. 48. Vijg J, Uitterlinden AG. A search for DNA alterations in the aging mammalian genome: an experimental strategy Mech Aging Dev 1987;41:47-63. 49. Uitterlinden AG, Vijg J. Two-dimensional DNA typing. TIBTECH 1989;7:336-341. 50. Uitterlinden AG, Mullaart E, Morolli B, Vijg J. Genome scanning of higher eukaryotesby twodimensional DNA typing using micro- and minisatellite core probes. Methods: Comp Meth E I U Y ~1991 O ~;3:83-90. 51. Anderson NL, Taylor J, Scandora AE, Coulter BP, Anderson NG. The Tycho system for computer analysis of two-dimensional gel electrophoresis patterns. Clin Chem 1981;27:1807-1820. 52. Anderson NL. 'Rvo-dimensional electrophoresis: operation of the ISO-DALT System. Rockville: Large Scale Biology Press, 1991.
53. Garrels JI. The QUEST system for quantitative analysis of two-dimensional gels. J Biol Chem 1989;264:5283-5299. 54. Li D, Vijg J. Multiplex co-amplification of 24 retinoblastoma gene exons after pre-amplification by long-distance PCR. Nucl Acid Res 1996;24:538-539. 55. WuY, Hofstra RMW, Scheffer H, Uitterlinden AG, Mullaart E, Buys CHCM,Vijg J. Comprehensive and accurate mutation scanning of the CFTR-gene by two-dimensional DNA electrophoresis. Hum Mutat 1996;8:160-167. 56. Nystrom-Lahti M, WuY, Moisio AL, Hofstra RMW, Osinga J, Mecklin JP, Jarvinen HJ, Leisti J, Buys CHCM, de la Chapelle A, Peltomaki P. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Molec Genet 1996;5:763-769. 57. Uitterlinden AG, Slagboom EP, Mullaart E, Meulenbelt 1,Vijg J. Genome scanning by twodimensional DNA typing: The use of repetitive DNA sequences for rapid mapping of genetic traits. Electrophoresis 1991;12:119-134. 58. Uitterlinden AG, Vijg J. Denaturing gradient gel electrophoretic analysis of minisatellite alleles. Electrophoresis 1991;12:12- 16. 59. Armour JAL, Patel I, Thein SL, Fey MF, Jeffreys AJ. Analysis of somatic mutations at human minisatellite loci in tumors and cell lines. Genomics 1989;4:328-334. 60. Hovig E, Mullaart E, Borresen AL, Uitterlinden AG, Vijg J. Genome scanning of human breast carcinomas using micro- and minisarellite core probes. Genomics 1993;17:66-75. 61. Verwest AM, de Leeuw WJF, Molijn AC, Andersen TI, Borresen AL, Mullaart E, Uitterlinden AG, Vijg J. Genome scanning of breast cancers by two-dimensional DNA typing. Br J Cancer 1994;69:84-92. 62. te Meerman GJ, Mullaart E, van der Meulen MA, den Daas JHG, Morolli B, Uitterlinden AG, Vijg J. Linkage analysis by two-dimensional DNA typing. Am J Hum Genet 1993;53:12891297. 63. Hampe J, Marczinek K, Preuss A, Nuruberg P. Marker pattern instabilities as a major cause of reproducibility problems in two-dimensional DNA fingerprinting. Electrophoresis 1996;17: 659-666. 64. Mullaart E, de Vos GJ, te Meerman GJ, Uitterlinden AG, Vijg J. Parallel genome analysis by two-dimensional DNA typing. Nature 1993;365:469-471. 65. Welsh J, McClelland M. Fingerprinting genomes using PCR with arbitrary primers. Nucl Acid Res 1990;18:7213-7218. 66. Williams JGK, Kubelik AR, Livak KJ, Rafalski JA,Tingey SV.DNA polymorphisms amplified by arbitrary primers are useful as genetic marker. Nucl Acid Res 1995;18:6531-6535. 67. Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook JA, Trutte A, Parker D, Barbara JAJ, Contreras M, Aloysius S. Detection of hepatitis C viral sequences in blood donations by ‘Nested’ polymerase chain reaction and prediction of infectivity Lancet 1990;335:1419-1422. 68. Aber RC, Mackel DC. Epidemiologic typing of nosocomial microorganisms. Am J Med 1981; 70~899-905. 69. Brokop CD, Farmer JJ. In: Doget RG (ed) Clinical Manifestation of Infection and Current Therapy 1. New York: Academy Press, 1979;89-133. 70. Schlichting C, Branger C, Fournier JM, Witte W, Boutonnier A, Wolz C, Goullet P, Doring G. Typing of Staphylococcus uureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J Clin Microbiol 1993;31:227-232. 71. Pitt TL. State of the art: typing of Serrutiu murcescens. J Hosp Infect 1982;3:9-14. 72. Muyzer G, Teske A, Wirsen CO, Jannasch HW. Phylogenetic relationships of Thiomicrospiru species and their identification in deep-sea hydrothermal vent samples by denaturing gradient gel electrophoresis of 16s rDNA fragments. Arch Microbiol 1995;164:165-172. 73. Muyzer G, de Waal EC, Uitterlinden AG. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16s rRna. Appl Environ Microbiol 1993;59:695-700.
29 74. Wawer C, Muyzer G. Genetic diversity of Desulfovibrio spp. in environmental samples analyzed by denaturing gradient gel electrophoresis of [NiFe] hydrogenase gene fragments. Appl Environ Microbiol 1995;61:2203-22 10. 75. Poddar SK, Maniloff J. Determination of microbial genome sizes by two-dimensional denaturing gradient gel electrophoresis. Nucl Acid Res 1989;17:2889-2895. 76. Vijg J. Two-dimensionalDNA typing. Molec Biotechnol 1995;4275-295. 77. Venema I? User Manual for the Melting Program Melt 95. Leiden: Ingeny B.V., 1995. 78. Moroz-Williamson V. Transposable elements in yeast. Int Rev Cytol 1983;83:1-24. 79. Genbauffe FS, Chisholm GE, Cooper TG. Tau, sigma and delta: a family of repeated elements in yeast. J Biol Chem 1984;259:10518-10525. 80. Jeffrey AJ, Wilson V, Thein SL. Hypervariable ‘minisatellite’ regions in human DNA. Nature 1985;31467-73. 81. NakamuraY; Leppert M, OConnell P, Wolff R, HolmT, Culver M, Martin C, Fuijmoto E, Hoff M, Kumlin E, White R. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 1987;235:1616- 1622. 82. Tautz D, Trick M, Dover GA. Cryptic simplicity in DNA is a major source of genetic variation. Nature 1986;322:652-656. 83. Van Orsouw NJ, Li D, van der Vlies P, Scheffer H, Eng C, Buys CHCM, Li Fp,Vijg J. Mutational scanning of large genes by extensive PCR multiplexing and two-dimensional electrophoresis: application to the RB1 gene. Hum Molec Genet 1996;5:755-761. 84. Peto R, Roe FJC, Lee PN, Levy L, Clack J. Cancer and aging in mice and man. Br J Cancer 1975;32:411-426. 85. Weinberg RA. Oncogenes, anti-oncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713-3721. 86. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64.235-248. 87. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-8 19. 88. Nowell I? The clonal evolution of tumor cell populations. Science 1976;194:23-28. 89. Volpe JPG. Genetic instability of cancer: Why a metastatic tumour is instable and a benign tumour is stable. Cancer Genet Cytogenet 1988;34125-134. 90. Shirasawa S, Urabe K, Yanagawa Y; Toshitani K, Iwama T, Sasazuki T p53 gene mutations in colorectal tumors from patients with familial polyposis coli. Cancer Res 1991;51:2874-2878. 91. Cotton RGH. Current methods of mutation detection. Mutat Res 1993;285:125-144. 92. Bridges BA. Mutagenesis after exposure of bacteria to ultraviolet light and delayed photoreversal. Molec Gen Genet 1992;233:331-336. 93. Gossen JA, de Leeuw WJF, Vijg J. LacZ transgenic mouse models: their application in genetic toxicology Mutat Res 1994;307:451-459. 94. Branda RF, Sullivan LM, ONeill JP, Falta MT, Nicklas JA, Hirsch B, Vacek PM, Albertini RJ. Measurement of HPRT mutant frequencies in T-lymphocytes from healthy human populations. Mutat Res 1993;285:267-279. 95. Grist SA, McCarron M, Kutlaca A, Turner DR, Morley AA. In vivo human somatic mutation: frequency and spectrum with age. Mutat Res 1992;266:189- 196. 96. Nee1 JV, Satoh C, Myers R. Report of a workshop on the application of molecular genetics to the study of mutation in the children of atomic bomb survivors. Mutat Res 1993;291:1-20. 97. Thein SL,Jeffreys AJ, Gooi HC, Cotter F, Flint J, O’Connor NTJ, Weatherall DJ, Wainscoat JS. Detection of somatic changes in human cancer DNA by DNA fingerprint analysis. Br J Cancer 1987;55:353-356. 98. Jeffreys AJ, Royle NJ, Wilson V, Wong Z. Spontaneous mutation rates to new length alleles at tandem-repetitive hypervariable loci in human DNA. Nature 1988;332:278-28 1. 99. Nurnberg P, Roewer L, Neitzel H, Sperling K, Popper1 A, Hundrieser J, Poche H, Epplen C, Zischler H, Epplen J T DNA fingerprinting with the oligonucleotide probe (CAC)s/(GTG)s: somatic stability and germline mutations. Hum Genet 1989;84:75-78.
30 100. de Jong D, Voetdijk BMH, Klein-Nelemans JC, van Ommen GJB, Kluyn PM. Somatic changes in B-lymphoproliferative disorders (B-LPD) detected by DNA fingerprinting. Br J Cancer 1988;58:773-775. 101. Honma M, Kataoka E, Ohnishi K, Kikuno A, Hayashi M, Sohni T, Mizusawa H. Detection of recombinational mutations in cultured human cells by Southern blot analysis with minisatellite DNA probes. Mutat Res 1993;286:165-172. I Detection of 102. Kikuno T, Honma M, Kataoka E, Ohnishi K, Inoue A, Mizusawa H, Sofuni ' minisatellite DNA mutations induced by MNNG treatment with DNA fingerprint analysis. Mutat Res 1992;272:267. 103. Dubrova YE, Jeffrey AJ, Malashenko AM. Mouse minisatellite mutations induced by ionizing radiation. Nature Genet 1993;5:92-94. 104. Slagboom PE, Mullaart E, Droog S, Vijg J. Somatic mutations and cellular aging: twodimensional DNA typing of rat fibroblast clones. Mutat Res 1991;256:311-321. 105. Coller HA, Thilly WG. Development and applications of mutational spectra technology. Environ Sci Techno1 1994;28:478-487. 106. Coulondre C, Miller JH. Genetic Studies of the lac Repressor. J Molec Biol 1977;117:577-606. 107. Benzer S, Freese E. Induction of specific mutations with 5-bromouracil. Roc Natl Acad Sci USA 1958;44:112- 119. 108. Keohavong P, Liu VF, Thilly WG. Analysis of point mutations induced by ultraviolet light in human cells. Mutat Res 1991;249:147-159. 109. Keohavong P, Thilly WG. Mutational spectrometry: A general approach for hot-spot point mutations in selectable genes. Proc Natl Acad Sci USA 1992;89:4623-4627. 110. Chen J, Thilly W Mutational spectrum of chromium (VI) in human cells. Mutat Res 1994; 323:21-27. 111. Oller AR, Thilly WG. Mutational spectra in human B-cells. J Molec Biol 1992;228:813-826. 112. Cariello NF, Keohavong P, Kat AG, Thilly WG. Molecular analysis of complex human cell populations: mutational spectra of MNNG and ICR-191. Mutat Res 1990;231:165-176. 113. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992;257:967-971. 114. Khoury MJ, Beaty TH,Cohen BH. Fundamentals of genetic epidemiology. New York: Oxford University Press, 1993. 115. Weiss KM. Genetic variation and human disease. New York: Cambridge University Press, 1993.
01997 Elsevier Science B.V. All rights reserved. Bwtechnology Annual Review Yolume 3 M.R.El-Gewely, editor.
31
The two-hybrid system in yeast: applications in biotechnology and basic research Thomas Munder, Milena Ninkovic and Barbel Rudakoff Department of Cell and Molecular Biology, Hans-Knoll-Institut fur Naturstofl-Forschung e. K, Jena, Germany
Abstract. The two-hybrid system in Saccharomyces cerevisiae is a powerful technology for probing of protein-protein interactions in vivo. It offers several advantages compared to biochemical in vitro methods. Many applications are conceivable, both in basic and applied research. These include the screening for proteins interacting with a given target protein, characterization of protein binding sites, and the fimctional analysis of whole genomes by generating three-dimensional interaction maps. The two-hybrid system in yeast is well-suited for the development of compound screening assays. Drugs can be identified which interfere in the interaction of therapeutic relevant proteins. Keywords: P-galactosidase, Ace 1, Cdc25, combinatorial libraries, drug screening, Gal4, glycosylation, green fluorescent protein, immunoprecipitation, interaction trap, interaction matrix, metallothionein, nuclear hormone receptors, one-hybrid system, phosphorylation, posttranslational modification, protein linkage map, protein-DNA interactions, protein-linkage map, protein-protein interaction, Ras, reporter gene, Saccharomyces cerevisiae, therapeutic intervention, transactivation assay, transcription factor, tribrid system, two-hybrid system, yeast.
Introduction Protein-protein interactions are involved in many cellular processes like signal transduction pathways leading to the expression of cellular genes. Other examples are the synthesis of DNA and RNA molecules, development of cellular structures like cell membranes, spindle pole body formation and nuclear pore complexes, as well as specific enzymatic reactions. The interaction between proteins is therefore an important regulatory mechanism for the cell. The scientific community invests increasing effort elucidating these various interactions to get detailed insight into the cellular protein network. The dissolving of this network is important to understand the formation and maintenance of human disorders. Many diseases are based on genetic defects concerning specific proteins involved in the cellular metabolism. Figure 1 gives a general overview of the processes occurring in a cell when specific signals, such as growth factors or hormones, reach the cellular surface.When a signal binds to a specific receptor, the receptor is activated and stimulates a signal transduction cascade involving numerous protein-protein interactions. This casAddress for correspondence: T. Munder, Hans-Knoll-Institut fur Naturstoff-Forschung e.\, Department of Cell and Molecular Biology, Beutenbergstr. 11, D-07745 Jena, Germany Bl.: +49-364165-66-92. Fax: +49-3641-65-66-94. E-mail:
[email protected]
32
Fig. 1. Signal transduction mechanisms in eukaryotic cells. Black box = mutated protein (e.g., an oncoprotein). Grey boxes = proteins regulated by the activity of the mutated protein.
cade finally leads to an induction or repression of gene transcription by activation of transcription factors. A modification of this cascade by a truncated protein results in an enhanced or reduced interaction with its target protein. This can have dramatic effects on the expression levels of certain genes. These defects can be treated, for example, with biologically active compounds interfering in this particular interaction. For the identification of such compounds, simple and efficient assays have been developed, which allow the fast screening of a large number of chemicals. These screening systems have found a broad range of applications in the field of biotechnology research and are currently used by the pharmaceutical industry for drug discovery This review will focus on the development of screening assays based on the reconstitution of protein-protein and protein-DNA interactions in vivo. In 1989 Fields and Song published a novel genetic system for the detection of proteinprotein interactions in the budding yeast Succharomyces cerevisiae, which was called the two-hybrid technology [ 11. This method offers many applications in basic and applied research. As described below, it can be used for identification of both new drugs and new protein targets for therapeutic intervention. 'ho-hybrid systems General overview
Several methods are available for the detection of protein-protein interactions in vitro (for a recent review see [2]). For special applications these techniques are
33 not sensitive enough and require purified proteins and specific reagents such as high-affinity antibodies for coimmunoprecipitation, which may not be available for a specific protein. Additionally, efficient bacterial or eukaryotic systems for expression of the proteins are necessary Some interactions render to be undetected, because these proteins may need specific cofactors for binding, which are not provided by the in vitro approach. In vitro assays can lead to the identification of artificial protein-protein interactions, which do not occur in vivo. Interactions detected by in vitro methods do not reflect the natural situation in living cells. This is of particular importance if posttranslational modifications are essential for the interaction with other proteins. The two-hybrid system allows the detection of protein-protein interactions in vivo. Thus, it offers a powerful alternative to in vitro methods. Figure 2 describes the main components of this method. The two-hybrid systems developed in yeast, bacteria and higher eukaryotes are based on the properties of a defined class of acidic transcription factors [3,4]. They have the unique feature to function in all eukaryotes tested so far [5-81. Transcription factors are composed of at least two domains, a DNA-binding and an acidic activation domain [3,9,10]. The molecular organization of these proteins has been established by combining the DNA-binding domain of one factor with the activation domain of another factor, yielding a transcription factor with novel properties. This was shown by the construction of a chimera between the DNA-binding domain of the bacterial repressor lexA and the activation domain of the yeast Gal4 protein [ 111. The DNA-binding domain of a transcription factor determines its specificity, which is given by the recognition elements located within the DNA. Binding domains were characterized intensively through X-ray diffraction analysis of single crystals or nuclear magnetic resonance spectroscopy [12]. The precise function of activation domains remains still obscure: it is not clear whether they modulate the activity of the transcriptional initiation complex composed of RNA polymerase I1 and the basic transcription factors by recruiting those factors to the promoter or by altering their activity state. Alternatively they may function in a more indirect way by modulating the chromatin structure allowing the assembly of the transcriptional machinery on the DNA [ 131. For the function of the two-hybrid system it is important that both transcription factor domains act independently. The DNA-binding domain interacts with DNA even in the absence of the transactivation part of the protein which has been demonstrated for the Gal4 DNA-binding domain [lo]. The activation domain retains its ability to activate transcription by itself. This was shown by generating hybrid proteins with both domains of transcription factors of different origin, for example, between the yeast Gal4 DNA-binding domain and the activation domain of herpes simplex virus protein Vp16 [14]. Induction of transcription only occurs if the activation domain can be recruited to a specific DNA element. This function is mediated by the DNA-binding domain. Expression of both domains separately does not activate transcription because it fails to localize the activation domain to the promoter.
34
A
B
promoter
UAS
[
B-D
I
]
UAS
reporter gene
promoter
reporter gene
n
C
UAS
promoter
reporter gene
D
UAS
promoter
reporter gene
Fig. 2. The two-hybrid system. BD,AD = DNA-bindingdomain and activation domain of a transcription factor; UAS = upstream activating sequences; XXZ = proteins !%ed to the DNA-binding domain or activation domain. A: Binding of the complete transcription factor to its specific UAS leads to the expression of a reporter gene. B: The reporter gene is not activated when the transcription factor domains are expressed separately C: Generation of two hybrids composed of the interacting proteins X or Y and the DNA-binding or activation domain results in expression of the reporter. D: Fusions of two noninteracting proteins X and Z to the transcription factor domains do not stimulate reporter gene expression.
For analyzing a possible interaction of two proteins, they are fused to the DNAbinding domain and the activation domain to generate in-frame hybrid proteins. The binding of one hybrid protein to the other results in a reconstitution of an active transcription factor complex, indicated by the expression of a reporter
35 gene. A failure in transactivation is based on a missing contact between the two foreign proteins (Fig. 2). Reporter genes Several reporter genes have been described for the detection of protein-protein interactions in yeast. They are listed in Table 1. The product of the lacZ gene from Escherichiu coli, p -galactosidase, is a widely distributed reporter system [1,15- 191. The enzymatic activity is easily monitored by a direct staining of yeast colonies on 5-bromo-4-chloro-3-indolyl-~-~ -galactopyranoside containing agar plates or, alternatively, after transfer of yeast cells onto filter papers, permeabilization of cells and incubation in presence of the chromogenic substrate [20]. A quantification of p-galactosidase is possible by cultivation of yeast cells in liquid media [21]. This is important when using the two-hybrid technology as a drug screening system (see section: Drug discovery using one- and two-hybrid systems in yeast). Apart from the p-galactosidase, enzymes of the biosynthetic pathway of amino acids or nucleotides are also frequently used as reporters. These include HIS3 [15-17,221, LEU2 [18,23], and URA3 [24]. For example, in a histidin auxotrophic yeast mutant lacking the endogenous HIS3 gene product the activity of a reconstituted transcription factor can simply be monitored through growth of transformants on minimal medium lacking histidine. The URA3 gene product can be measured quantitatively and allows a negative selection scheme using 5fluoro-orotic acid [25], which is metabolized by URA3 to a toxic product. This reporter has been applied for the identification of interaction between nuclear hormone receptors and transcriptional intermediary factors [24,26]. The CUPl gene coding for the yeast metallothionein [27--291 has also been used in two-hybrid approaches [30]. Cup1 confers resistance of yeast cells to heavy metals, especially to copper ions [31,32].The CUPl gene differs from the other reporter systems in that it allows different strengths of protein-protein interactions to be monitored: a strong binding affinity can be detected by the growth of yeast cells under high copper stress conditions, whereas weak interactions result in a weak resistance to exogenously added copper [30]. Recently, a novel reporter system has been described: the green fluorescent protein (GFP) produced by the bioluminescent jellyfish Aequoreu victoria lhble 1. Reporter systems used in the yeast two-hybrid technology. Gene
Product
laCZ HIS3 LEU2 uRA3 CUPl
f3-galactosidase imidazole glycerol phosphate dehydratase f3-isopropylmalatedehydrogenase orotidine-5’-monophosphatedecarboxylase metallothionein
36 [33-361. The GFP also functions in yeast [37,38]. GFP has found many applications, including gene expression and protein localization studies in living organisms. The expression of GFP can simply be monitored by measuring the emitted fluorescence. There is no addition of exogenous cofactors or substrates required for its activity and the lysis of cells can be omitted. Thus, it is an interesting reporter for high-throughput compound screening systems (see section: Drug discovery using one- and two-hybrid systems in yeast). The use of GFP in twohybrid assays has not been demonstrated to date. A commonly used reporter system for two-hybrid studies in mammalian cells is the bacterial chloramphenicol acetyltransferase [39-411. Other reporters are gene products inducing hygromycin B resistance or the coding sequences of human CD4, which can be monitored by fluorescence-activated cell sorting using, for example, a mouse antihuman CD4 monoclonal antibody and a phycoerythrin-conjugatedgoat antimouse IgG antiserum [40]. Transcriptionfactors
The strategy to exploit transcription factors for analyzing protein-protein interactions is based on the observation of Ma and Ptashne that a fusion of the yeast Gal80 repressor to an acidic activation domain induces transcription via the Gal4 DNA-binding domain and Gal4 operator sequences indicating an interaction between Gal4 and Gal80 [42]. In the original two-hybrid assay developed by Fields and Song the Gal4 protein was selected as the transcriptional activator protein [ 11. Gal4 induces transcription of genes required for galactose catabolism in yeast through binding to specific DNA sequences located in the promoter of these genes [43]. For most two-hybrid applications this protein is split in its amino terminal located DNA-binding portion (residues 1-147) and the carboxy terminal activation function (residues 768-88 1). Fields and Song verified their system by probing for the binding of the serine-threonine-specificprotein kinase Snf 1 with its associated protein Snf4 [11. It has been shown that the two-hybrid system also works with transcription factors that differ from Ga14. The transcription factor Vp16 from the herpes simplex virus contains a strong activation domain, which functions very efficiently in yeast [14]. Vp16 together with the DNA-binding domain of the bacterial lexA repressor has been used to analyze, for example, the protein-binding activities in the yeast transcriptional corepressor complex Qc8-Tupl [44]. Gyuris et al. developed a modified version of the GalCbased two-hybrid system called the interaction trap [23], which uses the lexA DNA-binding domain and the bacterial B42 acidic activation domain [45]. Fusions of foreign proteins to a DNA-binding domain are termed bait, whereas hybrids between an activation domain and other proteins are called prey The B42 tag is not as strong as the activation sequences of Gal4 or Vp16, respectively, thus eliminating the possibility of strong semitoxic gene activation [46-481. The expression of at least one hybrid protein under control of the inducible Gall promoter allows the
37 detection of heterologous protein-protein interaction with partners which might be toxic to yeast cells. Reporter gene expression of lacZ and LEU2 in the interaction trap was driven in the presence of ColEl lexA operators [49]. The interaction trap was successhlly applied to detect interactions between the human Cdil protein phosphatase and cell cycle regulated proteins like Cdc2 and Cdk3 [23]. It has also been used to identlfl the human Mxil protein, which specifically binds to the mammalian Max protein, involved in regulation of cell growth [18]. Munder and Furst applied the characteristics of the yeast Acel transactivator for its use in the two-hybrid system [30]. Acel stimulates the transcription of the yeast CUPl gene mentioned above by binding to the CUPl promoter [50-521. Like the Gal4 protein the Acel transcription factor is composed of an aminoterminal DNA-binding and a carboxyterminal transactivation domain [49,53]. The interaction between the DNA-binding domain of Acel and the DNA strongly depends on copper. It has been postulated that copper induces a conformational change in Acel, allowing the protein to bind to DNA [49]. This unique property makes the Acel-based two-hybrid system highly usell for drug screening assays (see section: Drug discovery using one- and two-hybrid systems in yeast). Munder and Furst validated the Acel-based system showing the complex formation between a variety of proteins [30]. Thus, it was proven that the regulatory subunit of the yeast cyclic AMP-dependent protein kinase forms homodimeric complexes in vivo. Furthermore, the interaction of the murine pl 1 Ca2+-bindingEF-hand protein with the annexin I1 or p36 protein was demonstrated with the Acel -based two-hybrid system. The aminoterminal 14 residues of p36 were sufficient for the binding to pl 1 [30]. Subsequently, the Acel system was applied to detect a variety of other protein-protein interactions [54-561. More recently the DNA-binding domain of the human estrogen receptor together with the activation domain of Vp16 was used to demonstrate the ligand-dependent interaction between the retinoid acid receptor and potential cellular transcription factors [24,26]. Interaction was monitored by expression of a reporter gene via estrogen receptor response elements within a yeast promoter lacking natural upstream activating sequences (UAS). The practical aspects of the work with the yeast two-hybrid system can be read in detail in recently published articles, which describe the use of numerous vectors, different yeast strains and various yeast promoters controlling reporter gene expression [57-601. Applications
The two-hybrid technology is an attractive method to check for protein-protein interactions in vivo (Table 2). For this purpose the cDNA sequences of proteins of interest are inserted into plasmids coding for the DNA-binding and activation domain of a transcription factor to obtain in-frame fusions. This methodology has been successhlly applied to numerous proteins from different organisms, including viruses, yeasts, higher plants, flies and mammals [61].
38 Table 2. Main applications of the two-hybridtechnology.
Interactions between two proteins. Mapping of interacting protein domains. 0 Protein interaction screen. 0 Functional genome analysis. 0 Network analysis. 0 High-throughputcompound screening. 0 0
A wide-spreading approach is the probing for interaction domains of given protein partners. Tzamarias and Struhl, for example, found that the yeast proteins Cyc8 and Tupl, involved in transcriptional repression, associate in the two-hybrid assay [MI. To identifl the region of Tupl interacting with Cyc8, several derivatives of a lexA-Tupl hybrid have been constructed and probed with a Cyc8-Vp16 fusion. It turned out that the 72 aminoterminal residues of the 713 amino acids of Tupl are necessary and sufficient to mediate interaction with Cyc8. Using a similar approach Chien et al. found that 7% of the 111-length Sir4 protein of yeast are sufficient to induce homodimerization [62]. The two-hybrid system has been successfully applied to analyze specific mutations in genes, which influence the binding capacity of the target protein. Munder and Furst examined the interaction of the yeast Cdc25 protein with specific mutations of the Ras2 protein. They demonstrated that Cdc25 binds stronger to catalytically inactive Ras2, locked in its GDP-bound or nucleotidefree state, than to dominant activating mutations characterized by bound GTP [301. The application of the two-hybrid system as a protein interaction screen was first demonstrated by Chien et al. [62]. Genomic and cDNA libraries from various tissues and organisms are available for this purpose. The foreign DNA in these libraries is tagged to the activation domain of a transcription factor. It has to be considered that statistically only one-third or one-sixth (dependent on the generation of the library) of the entire library is represented as an in-frame fusion to the activation domain. To cover the complete genome of an organism more inserts must be present in the library and more clones must be screened as compared to conventional methods. Plasmids containing the bait construct and the library are transformed either successively or by cotransformation into a reporter yeast strain. Interacting proteins are usually detected by a combination of two reporter genes. Their expression is regulated by different promoters to reduce the occurrence of false positives. The HIS3 reporter allows a very efficient screening of interacting proteins. The strength of interaction can be influenced by cultivating the cells in the presence of the inhibitor of the HIS3 gene product, 3-aminotriazole (3-AZ, [63]). A low concentration of 3-AZ suppresses a large number of false positives and weak interactions between proteins. The higher the concentration of 3-AZ in the medium of growing yeast colonies the stronger the interaction
39
of the proteins to be identified [22]. In a similar way the CUP1 gene can be used as a reporter for a two-hybrid screen. Only Cupl-expressing cells can grow on mediums containing copper. As in the case of 3-AZ it is possible to vary the amount of copper in the growth medium to influence the stringency of interaction: yeast cells expressing hybrids of strong interacting proteins confer resistance to a higher copper concentration than do cells containing no or low-interacting proteins. Positive signals can be subsequently checked by determination of the P-galactosidase activity Generally, a positive cDNA clone does not contain the whole sequence information of one genuine protein. The entire protein has to be identified, for example, by screening of a phage library containing large DNA fragments by plaque hybridization using the identified sequence as a probe. A two-hybrid interaction screen can be applied to characterize proteins of unknown functions. The sequencing of the entire yeast genome led to the identification of many essential genes, which are usually analyzed with difficulty by phenotypic assays of mutant yeast strains. Identification of interacting proteins helps to clarifjr their cellular function. Related investigations can be accomplished with expressed sequence tags arising form the human genome sequencing project. Such an approach may also lead to the identification of new mammalian genes altered in disease states. The two-hybrid system can be used as a genetic tool to reveal a molecular network of interacting proteins. An initial protein serves as a bait to find interacting partner proteins which are involved in ordered cellular pathways. Such experiments have been performed to clarifjr the protein network of components of the yeast pheromone-response signal transduction pathway (reviewed in [MI). These experiments are laborious using the classical screening approaches, based on transformation of the library into yeast cells carrying the baits. To simplifjr the whole procedure, Finley and Brent developed a novel selection scheme [65]. This method relies on the fact that haploid yeast have two different mating types, MATa and MATa, which fuse to form diploid cells [66]. The bait constructs were transformed into an MATa strain, for example, and the prey constructs into a strain of opposite mating type. Cells are allowed to mate, the resulting diploids are selected on minimal media and checked for reporter gene expression. Several individual protein-protein interaction can be tested by this interaction mating procedure. The results can be displayed as two-dimensional arrays in an interaction matrix [65]. Bendixen et al. modified this approach [67]. Yeast MATa cells containing activation domain tagged libraries were spread onto agar plates, replica plated and mated with MATa cells containing the bait construct. This method eliminates the need for cotransformations and allows the search for interacting proteins to an unlimited number of bait constructions with a single transformation [67]. An interesting extension of the two-hybrid system is the identification of all possible protein-protein interactions in a cell to generate a three-dimensional interaction map of one organism. Bartel et al. constructed two libraries of the relatively small E. coli bacteriophage T7 genome, tagged with the DNA-binding
40 or the activation domain of Gal4 [68]. After excluding self-activating baits the two libraries were screened for interacting proteins against each other. Among 55 genome-encoded proteins Bartel et al. identified 25 intra- and intermolecular interactions. These initial experiments could be extended to organisms possessing a higher complexity It is particularly helpful if the genome sequence of the investigated organism is known. The respective genome size and the problems of false positives and false negatives are the limiting factors in these studies. The use of the two-hybrid technology in drug screening is discussed in the section: Drug discovery using one- and two-hybrid systems in yeast. Pros and cons
The two-hybrid assay is a fast system for determination of protein-protein interactions, usually involving only two cloning steps for the bait and prey construction. The system is highly sensitive and for some interactions it seems to be more sensitive than in vitro approaches [69,70]. For example, the cellular prion protein PrP binds to the apoptosis suppressor Bcl-2, as was shown by a yeast interaction trap. Using a monoclonal anti-Myc antibody this interaction could not be detected by immunoprecipitation of PrP and Bcl-2 tagged with an epitope derived from c-Myc [71]. Proteins involved in signal transduction pathways are usually characterized by a weak binding affinity to their target molecules. Detectable coprecipitation between yeast Ras and adenylate cyclase, for example, has never been observed [72,73], whereas the binding of mammalian h-ras to the adenylate cyclase was demonstrated with a lexA-Vp16 two-hybrid assay [171. The interaction between Ras and its guanine-nucleotide exchange protein Cdc25 can only be measured in biochemical experiments if specific Ras mutations were used, which bind more strongly to Cdc25 than do wild-type Ras [74,75]. Even cross-linking studies with h-ras binding proteins seems to be particularly ineffective [76]. Therefore one might speculate that biochemical in vitro methods may be not suitable to discover physiological relevant interactions. The minimal affinity interaction detectable in the two-hybrid system depends on several variables, including expression level of the fusion proteins, choice of the reporter gene, and the number of DNA-binding sites in the reporter promoter. The two-hybrid system may detect weak interactions with a & of less than 1 pM [77]. Estojak et al. correlated affinity data taken from two-hybrid experiments with in vitro measurements [77]. Two sets of proteins were used in their approach: mammalian Myc, Max, and Mxil, belonging to the class of helix-loop-helix proteins and the CI repressor from bacteriophage lambda. The strength of protein-protein interactions generally correlated with in vitro determinations of binding affinity High, intermediate, or low affinity interactions as determined in vitro could be similarly discriminated in yeast cells. Importantly, there was no single reporter gene for which the amount of gene expression linearly reflected the affinity measured in vitro. This suggests that it is not advisable to use differences in the reporter activity level as a direct indication of an
41 interaction afinity One has to consider these findings by evaluating interaction affinities with the yeast two-hybrid assay [77]. Compared to biochemical in vitro studies the two-hybrid system allows the discovery of protein-protein interaction in vivo. Nevertheless, in some cases it is questionable whether an interaction identified in the yeast assay is a natural interaction, reflecting the situation in the cell. It may happen that binding of two proteins was found, which are normally expressed in different cell types, localized in distinct cellular compartments, or expressed in different developmental stages [78]. To distinguish between true and false positives several methods have been developed, mainly based on the use of different bait vectors and various yeast strains. A comprehensive review about these problems was published by Bartel et al. [79]. It is therefore recommended that an in vivo interaction is confirmed by alternative methods. A fbnctional assay for a given protein-protein interaction would be additionally usefbl for the verification of cellular interactions. It may happen that an expected protein-protein interaction could not be detected due to a specific two-hybrid configuration. The candidate proteins, for example, are fbsed aminoterminal to the transcription factor domains, but the interaction may require unmasked aminotermini. Switching the protein domains to the other part of the transcription factor seems to be also critical in some instances. Mosteller et al., for example, used the yeast GalCbased two-hybrid system to analyze the interaction between yeast Cdc25 and human h-ras [80]. They found that the configuration of plasmid constructs strongly affected the results of these interaction studies. Fusions of the DNA-binding domain of Gal4 to Cdc25 and chimera between the Gal4 activation domain and h-ras did not produce a positive signal, whereas the exchange of transcription factor tags in the opposite configuration led to the detection of binding between Cdc2S and h-ras. Thus, a negative result in the two-hybrid system does not mean that the two proteins tested do not interact in principle. It indicates that they do not interact under the specific conditions examined [80]. The following parameters can be changed if an interaction is not detected: 1) the host organism; 2) another transcription factor and/or another two-hybrid approach; 3) truncated protein domains, which is of special importance if high-level expression of the protein is toxic to the cell or the protein is not stably expressed; and 4) peptide spacers located in between the transcription factor domains and the fused protein to generate a specific distance between the proteins of one hybrid, preventing the mutual influence of one domain on the activity of the other one. The two-hybrid assay is limited to proteins that can be localized to the nucleus. This does not necessarily mean that the binding of two proteins occur in this cellular compartment. An interaction can also occur immediately after protein synthesis in the cytoplasm. The whole complex is subsequently transported via nuclear pore complexes into the nucleus. However, to enhance the probability of nuclear import, vectors have been developed encoding the activation domain tagged to nuclear localization sequences of the SV40 large T antigen [62,81]. This short stretch of aminoterminally located seven amino acids is able to trans-
42 locate proteins into the yeast nucleus [82,83]. It is generally accepted that the two-hybrid system does not detect interaction between transmembrane and secreted proteins. These proteins exist in an oxidizing environment outside the cell and cannot fold properly to interact and activate reporter genes in the yeast nucleus [84]. Interestingly a recent work demonstrated that the extracellular domain of a Moloney murine leukemia virus transmembrane envelope protein is able to form dimeric complexes if analyzed by the yeast two-hybrid approach [85]. As Munder and Fiirst already reported earlier, the yeast GDP/GTP catalyst Cdc25 binds to Ras2 in vivo [30]. Both proteins are membrane associated. These studies also extended the use of the two-hybrid system to membrane localized proteins. In general, due to their activating properties, transcription factors are in many cases not suitable for a bait construction in the two-hybrid system. Additionally, there exist many proteins not involved in transcription, which can activate transcription if hsed to a DNA-binding domain. To circumvent this undesirable induction of transcription deletions at the activating parts can help. Alternatively, bacterial two-hybrid systems can be used (see section: Alternative two-hybrid systems). However, there are numerous reports demonstrating the interaction of transcription factors with other cellular proteins using transcription factors as baits, such as the viral transcription factor Tax [86,86a] and human proteins from the steroidhhyroid receptor family [87-901. Protein-protein interactions, which are dependent on specific posttranslational modifications that occur within the endoplasmic reticulum, such as glycosylation and disulfide bond formation, may not be detectable in the yeast two-hybrid system.Very little is known in yeast about the process of 0-glycosylation,whereas more information are available about N-glycosylation. Yeast as an eukaryotic organism possesses the mechanisms for protein glycosylation [91,921. These processes follow the same rules as in higher eukaryotic cells [93,94]. The protein hybrids in the two-hybrid system are generally highly expressed in yeast due to strong promoters present on multicopy plasmids, which implies that only a small portion of these proteins may be glycosylated. Therefore some protein-protein interactions remain undetected. Several proteins are posttranslationally modified by phosphorylation. S. cerevisiae expresses many serinekhreonine-specific protein kinases, but there is only limited tyrosine phosphorylation of endogenous yeast proteins [95-981. Despite the detection of interactions between autophosphorylated tyrosine kinases and other proteins [99-1011, it is difftcult to demonstrate interactions between proteins, which are dependent on tyrosine phosphorylation. To circumvent these difficulties, Osborne et al. modified the two-hybrid system to a socalled tribrid system [102]. This approach was used to examine the signal transduction mechanism induced by activation of the high affinity IgE receptor FceRI via src-homology 2 (SH2)-containing proteins leading to the release of intracellular calcium and other second messengers [1031. FcsRI contains immunoreceptor tyrosine-based activation motifs (ITAMS, [104]), which are
43 phosphorylated by the tyrosine kinases Lck and Lyn and subsequently mediate the interaction with the protein tyrosine kinase Syk, as was biochemically shown [105-1081. For the tribrid studies the cytoplasmic tail of the FceRIy subunit containing an ITAM was hsed to the DNA-binding domain of l e d and the SH2 domains of Syk were joined with the transcriptional activation region of the herpes simplex virus type I Vmw65 protein [109]. Activation of reporter gene expression occurs only in the presence of coexpressed Lck, indicating that a phosphorylation of the FceRIy ITAM by Lck was necessary for the interaction with Syk. A similar approach was described by Sun and Maurer [ 1101. They demonstrated an interaction between the transcription factor CREB and the CREB binding protein CBP using a mammalian two-hybrid system. This interaction could only be seen if cells were cotransfected with a cyclic AMP-dependent protein kinase expression vector. Thus, phosphorylation of CREB by this kinase seems to be essential for the detection of CREBKBP binding. There are several studies demonstrating that the interaction of two proteins is dependent on the presence of a third protein. The binding of yeast Ras proteins to Cdc25 has been shown to be dependent on the activation state of Ras: Cdc25 interacts predominantly with the inactive GDP-bound form of Ras, and the interaction gets lost after the conversion in the activated GTP-bound state [30]. The yeast Iral protein converts GTP-Ras to GDP-Ras [ 1111. The binding of Cde25 to Ras proteins in an iral-disrupted strain was considerably lower compared to an Iral wild-type strain [30]. This indicates that Iral participates in the interaction of Cdc25 with Ras. The serine-threonine specific protein kinase Raf is a downstream effector molecule of h-ras in mammalian signal transduction pathways. The Map kinase kinase Mek can be activated by Raf, which leads to phosphorylation of the Map protein kinase. Van Aelst et al. found in the yeast Gal4 two-hybrid system that h-ras interacts specifically with the aminoterminus of Raf, whereas Mek binds to the carboxyterminal half of Raf [112]. No direct binding of h-ras to Mek was found. Interestingly, in presence of overexpressed wild-type Raf, h-ras interacts with Mek in the two-hybrid system, indicating a heterotrimeric complex formation between h-ras, Raf and Mek. Legrain and Chapon examined the interaction between proteins of the yeast spliceosome assembly pathway [1131. They identified binding of Prp9 to Spp91 as well as Spp9l to Prpll, but they could not detect a contact between Prpl 1 and Prp9 [113,114].The latter interaction was restored by overexpression of Spp91 in yeast, indicating a ternary protein complex. Alternative two-hybrid systems Certain proteins of bacterial of mammalian origin require specific secondary modifications for their binding activity, which are not provided by the yeast cell. Some proteins are not stably expressed or degraded by the activity of specific or unspecific proteases in yeast. Additional mammalian proteins, not present in
44 yeast, may be involved in the formation of a complex between two proteins. Twohybrid systems developed in higher eukaryotes and in bacteria can be used to study interactions of proteins from these organisms [39,40,115]. The bacterial host organism is a suitable system for the detection of proteins interacting with an eukaryotic transcription factor bait, as eukaryotic activation sequences are not active in E. coli. In yeast and higher cells those sequences may stimulate transcription if they were fused to the DNA-binding domain, which interfere in the determination of protein-protein interaction with the twohybrid approach. An interesting variant of the two-hybrid approach in prokaryotes was developed recently by Gramatikoff et al. [116]. The direct interaction rescue (DIRE) relies on the minor coat protein encoded by gene 3 of a filamentous phage. This protein can be functionally separated into two parts, the Nterminal domain binds to the F’ pili allowing the infection with E. coli cells and the C-terminal domain, which is anchored to the phage. Fusion of interacting proteins to the separated gene 3 products results in reconstitution of phage infectivity The DIRE is of special importance for the interaction screening of proteins binding to a given bait, because filamentous phages allow the generation of protein domain libraries possessing a great complexity It has been applied to demonstrate the binding of the mammalian c-Jun transcription factor to the cytoskeletal tropomyosin and the ribosomal protein L18a of higher eukaryotes [117]. Recently a new variant of the two-hybrid assay has been described, the ubiquitin-based split-protein sensor technology (USPS) [1181. This system makes use of ubiquitin instead of transcription factor hsion proteins and allows the monitoring of protein-protein interaction as a hnction of time at the natural sites of this interaction in a living cell. Therefore USPS is an interesting two-hybrid alternative, especially useful for proteins, which are not able to enter the nucleus, or which contain transactivation domains. One-hybrid systems The one-hybrid system in yeast is derived from the two-hybrid assay It is used for
DNA-binding sites
prpmoter
reporter gene
Fig. 3. The one-hybrid system. BD, AD = DNA-binding domain and activation domain of a transcrip-
tion factor.
45 characterization of protein-DNA interactions. Figure 3 shows the basic principle. One-hybrid systems are composed of two basic components, a reporter construct containing cis-acting regulatory elements within an UAS-less yeast promoter and a plasmid expressing a transcription factor of interest, either alone or as a fusion to a DNA-binding domain or activation domain of another transcription factor. The concept of a one-hybrid system has been developed independently by two groups [119,120]. Li and Herskowitz used this genetic in vivo assay for isolation of novel genes encoding proteins that recognize autonomous replicating sequences in yeast (ARS). ARSs act as DNA replication origins both on chromosomes and on plasmids [121]. The reporter expression in the one-hybrid assay was controlled by multiple copies of the yeast ARS consensus sequence (ACS). To guarantee binding specificity, nonfunctional ACS has been used additionally Screening of a Gal4 activation domain tagged expression genomic yeast library led to the identification of ORC6, a component of the yeast origin recognition complex. Using a similar approach Dowel1 and co-workers found that the yeast Dbf4 gene product also interacts with ARS, either directly or through an unidentified protein [122]. Dbf4 is known to bind to the yeast protein kinase Cdc7 [123]. To determine which regions of Dbf4 are required for interaction with Cdc7 and with ARS, deletions within the Dbf4 coding regions have been made. It turned out that the Cdc7 and A R S interaction domains of Dbf4 are not coincident, implying that Dbf4 does not interact with initiation complexes through Cdc7. This study shows that one- and two-hybrid systems can be combined to characterize multiprotein complexes (Tables 2 and 3). Gstaiger et al. used a modified version of the one-hybrid assay to identif) proteins involved in tissue-specific transcriptional regulation [1241. The octamer motif, playing a central role in mediating the activity of both B-cell specific and ubiquitous promoters, was linked to promoter regions of the lacZ and HIS3 gene. Screening of a Gal4 activation domain tagged human peripheral lymphocyte library led to the identification of a novel protein named Bobl . It stimulates reporter gene transcription provided that the predominantly lymphoid-restricted octamer-binding factor Oct2 is coexpressed. It is concluded that Bobl represents a new tissue-specific transcriptional coactivator [1241. Wilson et al. have used the one-hybrid assay as an in vivo selection system for isolating DNA targets of DNA-binding proteins [125]. The feasibility of this new approach was verified by the identification of DNA fragments that contained binding sites for the well-characterized Gcn4 transcriptional activator. These cis-acting elements were pooled out of random oligonucleotides and rat genomic sequences inserted within the UAS-less GAL1 promoter upstream of the HIS3 reporter. This system was applied to identif) binding sites of the NGFI-B protein (nerve growth factor receptor-induced orphan receptor), an orphan receptor, which belongs to the steroid/thyroid hormone receptor superfamily [126,1271. To make sure that NGFI-B activates transcription in yeast, a fusion protein composed of the DNA-binding part of lexA, NGFI-B and the activation domain
46 of Gal4 was generated. This chimera still activated transcription from a lexA binding site containing reporter gene, demonstrating that the hybrid activator protein was functionally expressed in yeast. The above-mentioned approaches can be extended to any transcription factor or DNA-binding site of interest. This allows a profound characterization of transcriptional activators in vivo. Since the one-hybrid assay relies on transcriptional activation it cannot be applied to iden@ transcriptional repressors. The one-hybrid system can also be used for the characterization of the activating properties of proteins with unknown function. Such proteins can be tethered to the DNA-binding domain of Gal4 and its transcriptional activity determined by reporter gene expression through Gal4 binding sites. Since the one-hybrid assay requires only a single cloning step for each protein it presents an attractive technology for the functional characterization of a large number of proteins. Another application is envisible. The one-hybrid system should allow the identification of the whole set of acidic transcriptional activators present in an organism. For this purpose the design of DNA-binding domain tagged libraries is required. Many transcription factors are involved in the establishment of human diseases. The one-hybrid system is a tool to identifl those factors, which can be used for therapeutic intervention. Fusing E. coli genomic DNA fragments to the Gal4 DNA-binding domain Ma and Ptashne have already demonstrated in 1987 the potency of this system. They identified a variety of bacterial transcriptional activating sequences functionally active in yeast [45]. One of these sequences (B42) is commonly used as the activation domain in yeast two-hybrid assays (see section: Transcription factors). A positive response in the one-hybrid system does not necessarily indicate the activity of a transcription factor. Many studies have shown that cellular proteins not involved in transcription contain fortuitous acidic transactivation domains resulting in transcriptional stimulation. Drug discovery using one- and two-hybrid systems in yeast S. cerevisiae possess many advantages which are useful for the development of in vivo drug screening assays. Yeast cells are easy to handle and they have a short generation time. Several transformation protocols are available. Vectors for the heterologous gene expression have been developed, allowing the stable maintenance of plasmids in yeast (for recent reviews see [128,129]). S. cerevisiue is well-characterized on both genetic and cellular levels. It is the first eukaryotic Table 3. Applications of the one-hybrid system.
Identification of DNA-binding sites. Identification of transcriptional activators. 0 Mapping transactivation domains. 0D rug screening.
0 0
47 organism, for which the sequence has been determined completely [130,1311. An attractive feature for expression of many mammalian targets in yeast is that many of these proteins are completely foreign to yeast cells. Therefore yeast allows the analysis of their activities in an isolated, but in vivo system. On the other hand, the extensive homologies between basic processes in yeast and higher cells allow heterologous proteins to be functional in S.cerevisiue. This has been demonstrated, for example, with proteins belonging to the family of transcription factors. The interaction of transcriptional activators with transcription factors, adapters, and RNA polymerase I1 is a complex biochemical event that is difficult to study in cell-free systems [132,1331. These proteins are important candidates for therapeutic intervention due to three main characteristics [131. First, they have a high diversity and it is estimated that the human genome encodes for more than 3,000 gene-specific transcription factors [134]. Second, they show a high degree of specificity, which is given by their DNA-binding domains and the respective recognition sequences within the DNA. Third, many of them are involved in the establishment of human disorders, ranging from cancer, viral infections, autoimmune diseases and inflammation, for example. Detection of transcription factor activity in yeast requires two plasmids: one expresses the protein of interest and the second one carries the reporter gene fhed to a synthetic promoter containing the DNA recognition sites of the respective transcription factor. These plasmids are subsequently transformed into a yeast strain. The activity of the reporter gene product correlates directly with the activity of the transcription factor. These cells can be used to screen for biologically active drugs, which interfere in the activity of the target protein. To achieve a highly effective screening of many compounds in different concentrations this assay can be adapted to a miniaturized format, like the 96-well culture dishes, for example. Using automated equipment several thousands of compounds can be analyzed within a short period of time. Transactivation assays in yeast have been described for the detection of antiviral drugs and new ligands for nuclear hormone receptors, for example (reviewed in [133]). Screens of the latter type are highly selective for receptor agonists and can detect agonistic compounds even at low concentrations [135]. These drugs have a broad application both in medicine and agriculture. It has been demonstrated by several reports that members of the steroidhhyroid receptor family are functionally expressed in yeast [136--141a]. In some instances endogenous yeast proteins may occupy the DNA recognition sites for the foreign transcription factors or they may induce reporter gene expression by themselves. A one-hybrid assay, obtained by a fusion of the transcription factor to the Gal4 DNA-binding domain, allowing gene expression through Gal4 binding sites should avoid these problems. This could also be applied to transcription factors with unknown DNA recognition sites, e.g., orphan receptors. Fusion of a strong acidic activation domain, originating from Vp16 or Ga14, respectively, to a transcription factor supports the detection of weak transcriptional activities in yeast.
48 As a link between one- and two-hybrid drug screening assays, Dasmahapatra et al. developed an elegant genetic system for studying the activity of a proteolytic enzyme [142]. They inserted the self-cleaving 3C protease of coxsackievirus B3 [1431 between the DNA-binding and activation domain of the yeast Gal4 protein. The activity of the chimeric protease was detected by inhibition of reporter gene expression, whereas a mutated nonfunctional protease hybrid stimulated lacZ activity through Gal4 binding sites in yeast. This system can be easily adapted as a drug screening assay for identification of protease-inhibiting compounds [1331. Viral proteases induce proteolysis of the primary viral polypeptide precursors and are therefore essential for viral replication. Thus, they represent potential targets for an antiviral therapy The two-hybrid system could be used as a tool to id en ti^ specific molecules interfering in the interaction of two or more proteins. In general this sophisticated screening technique can be applied to any protein-protein interaction of therapeutic interest. As a prerequisite, the cDNA sequence of these targets has to be accessible and the interaction must be restored in the two-hybrid approach. Like in the one-hybrid assay, inhibition of protein-protein interactions by certain compounds can be detected by a miniaturized format. The problem of the GalCbased two-hybrid systems for its use in drug screening is the constitutive expression of the protein partners. This leads to an expression of the reporter during the whole fermentation process. For the two-hybrid drug screening yeast cells are grown overnight. The cultures are subsequently aliquoted into 96-well plates and the compounds to be tested are added. This implies that the effect of an inhibitory compound, resulting in reduced reporter gene expression, could hardly be detected. Therefore the Gal4-based two-hybrid system suffers from a signal-to-noise ratio. The inducibility of reporter gene expression by copper ions makes Acel very usell for development of highthroughput drug screening assays (Fig. 4). As stated above, the DNA-binding domain of Acel interacts with DNA only in the presence of copper. This implies that the transcription of the reporter in an Acel-based two-hybrid assay is only initiated by the addition of copper. The incubation of yeast cells with a drug inhibiting a given protein-protein interaction followed by the copper inducer results in a clearly distinguishable reduction of reporter gene expression compared to control cells. Two reporter systems are of interest for monitoring protein-protein interaction in drug screening assays: the green fluorescent protein and the P-galactosidase mentioned above. The activity of the latter one is usually determined by a colorimetric assay using 0-nitrophenyl-fl-D -galactopyranoside as a substrate. The detection sensitivity of j3 -galactosidase is dramatically increased through the use of the chemiluminescent 1,2-dioxetane.Dioxetane can be linked to a j3-galactosidase substrate, which becomes deglycosylated by the reporter activity under neutral pH conditions. After shifting the pH above 12 the activated intermediate becomes deprotonated and decomposes with the emission of light [144]. The chemiluminescence is measured by a luminometer or alternatively a liquid
49
Fig. 4. Comparison of the GaM-based two-hybrid system with the copper inducible Ace1 system. Explanation in the text.
scintillation counter [145,1461. This assay offers more than 1,000-fold higher sensitivity compared to the color ONPG test, which is of special interest, if weak protein-protein interactions are examined in drug screening systems. Whole cell-based systems offer significant advantages over cell-free screening assays. In vivo assays allow the identification of drugs in the cellular environment, which most closely resembles the natural conditions. Furthermore, they do not need the reconstitution of entire multiprotein complexes like in cell-free systems [133,1351. Transactivation assays using steroid hormone receptors as target proteins, for example, discriminate between agonistic and antagonistic receptor ligands, which cannot be distinguished by the classical in vitro recep-
50
tor-ligand binding assays. However, compounds, which do not penetrate the cellular membrane, are undetected in a cell-based in vivo assay It is known that yeast is relatively impermeable to many chemicals [147]. Incubation with lytic enzymes to dissolve the cell wall or the treatment with specific agents such as polymixin B leads to an enhanced permeability of yeast (reviewed in [148]). It is worthwhile to keep in mind that screening assays in S. cerevisiue have to be considered as primary screening assays, which implies that other assays have to be followed to determine the specificity of a newly identified drug. Only the combination of cell-based and in vitro assays may lead to the identification of novel lead compounds. Small-molecule lead structures are of outstanding interest for their use as therapeutic drugs. Many compounds are collected as purified products within existing libraries and can be chemically modified. Living organisms and the recently established combinatorial chemistry are important resources, since they produce new or unknown compounds. Combinatorial libraries, produced by automated synthesizers [1491, so far generate peptide sequences [1501.Work is in progress to generate nonpeptide combinatorial libraries [151-1531. Many biologically active substances are produced by a large variety of microorganisms, but also by invertebrates, algae and higher plants. Most of these natural compounds possess unknown functions and a lot of them remain undetected. Approximately 180,000 different species of microorganisms have been identified to date, but an estimated 5-10 times more species probably exist. To date, 16,500 individual microbial metabolites have been isolated and characterized. Out of this, 1%, i.e., 130-150 compounds, have found practical uses in agriculture and medicine [1541. These substances may represent a highly important pool for the treatment of mammalian disorders. The two-hybrid technology has been used to identifl small peptides interacting with given protein targets. Randomly generated peptide libraries, fused to the Gal4 activation domain are now readily available. Yang et al. identified several peptides capable of binding to the retinoblastoma protein [155]. In a similar approach peptide aptamers have been found, which recognize and inhibit the human kinase Cdk2. These aptamers bear analogies with monoclonal antibodies [156]. This approach can be applied as a screening system for the identification of peptides interfering in the interactions between pharmaceutically relevant proteins. The application could be extended to characterize the binding site of two proteins, since a peptide mimicking the interaction sites should result in a reduction of reporter gene expression.
Conc1usions The two-hybrid system in S. cerevisiue is a powerll tool for probing of proteinprotein interactions in vivo. It offers several advantages compared to biochemical in vitro methods. The possibilities of the two-hybrid technology both in basic research and for biotechnological applications are enormous. This is demon-
51
strated by accumulating data in the literature. The two-hybrid assay is used for the characterization of protein binding sites, the screening of proteins interacting with a given target protein, and the fimctional analysis of whole genomes by generating three-dimensional interaction maps. Furthermore, it is well-suited for the development of compound screening assays. Drugs can be identified interfering in the interaction of therapeutically relevant proteins. Besides the yeast system, several methods have been developed to analyze protein-protein interactions in prokaryotes as well as in higher eukaryotes. It is obvious, that the two-hybrid system leads to a better understanding of the processes that occur in living organisms.
Acknowledgements We thank Christian Zurek, Karin Adelhelm and Yvonne Berghofer-Hochheimer for many helpll comments and for critically reading the manuscript.
References 1. Fields S, Song 0-K. A novel genetic system to detect proteidprotein interactions. Nature (London) 1989;340:245-246. 2. Phizicky EM, Fields S. Protein-protein interactions: methods for detection and analysis. Microbiol Rev 1995;59:94-123. 3. Ptashne M. How eukaryotic transcriptional activators work. Nature (London) 1988;335:683689. 4. Mitchell PJ, Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 1989;245:371-378. 5. Fischer JA, Giniger E, Maniatis T, Ptashne M. GALA activates transcription in Drosophiia. Nature (London) 1988;332:853-856. 6. Kakidani H, Ptashne M. GALA activates gene expression in mammalian cells. Cell 1988;52 161-167. 7. Ma J, Przibilla E, Hu J, Bogorad L,F'tashne M. Yeast activators stimulate plant gene expression. Nature (London) 1988;334:631-633. 8. Webster N, Jin JR, Green S, Hollis M, Chambon €?Theyeast UASG is a transcriptional enhancer in human HeLa cells in the presence of the GAL4 trans-activator. Cell 1988;52:169-178. 9. Hope IA, Struhl K. finctional dissection of a eukaryotic transcriptional activator protein, GCN4 ofyeast. Cell 1986;46:885-894. 10. Keegan L, Gill G, Ptashne M. Separation of DNA binding from the transcription-activating function of a eukaryotic regulatory protein. Science 1986;231:699-704. 11. Brent R, Ptashne M. A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor. Cell 1985;43:729-736. 12. Harrison SC. A structural taxonomy of DNA-binding domains. Nature (London) 1991;353: 715-719. 13. Peterson MG, Baichwal VR. Transcription factor based therapeutics: drugs for the hture? 'Rends Biotech 1993;11:11-18. 14. Sadowski I, Ma J, Triezenberg S, Ptashne M. GALA-VP16 is an unusually potent transcriptional activator. Nature (London) 1988;335:563-564. 15. Hannon GJ, Demetrick D, Beach D. Isolation of the Rb-related p130 through its interaction
52 with CDK2 and cyclins. Genes Dev 1993;7:2378-2391. 16. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816. 17. Vojtek AB, Hollenberg SM, Cooper JA. Mammalian Ras interacts directly with the serinel threonine kinase Raf Cell 1993;74:205-214. 18. Zervos AS, Gyuris J, Brent R. Mxil ,a protein that specifically interacts with Max to bind MycMax recognition sites. Cell 1993;72:223-232. 19. Fields S, Sternglanz R. The two-hybrid system: an assay for protein-protein interactions.Trends Genet 1994;110:286-292. 20. Breeden L, Nasmyth K. Regulation of the yeast HO gene. Cold Spring Harb Symp Quant Biol 1985;50:643-650. 21. Breeden L, Nasmyth K.Cell cycle control of the yeast HO gene: cis- and trans-acting regulators. Cell 1987;48:389-397. 22. DurfeeT, Becherer K,Chen P-L,Yeh S-H, Yang Y, Kilburn AE, Lee W-H, Elledge SJ. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes Devel 1993;7:555-569. 23. Gyuris J, Golemis E, Chertkov H, Brent R. Cdi, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 1993;75:791-803. 24. Le Douarin B, Pierrat B, vom Baur E, Chambon P, Losson R. A new version of the two-hybrid assay for detection of protein-protein interactions. Nucl Acid Res 1995;23:876-878. 25. Boecke JD, Lacroute F, Fink GR. A positive selection for mutants lacking orotidine-5’-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. Molec Gen Genet 1984; 197:345-346. 26. vom Baur E, fiche1 C, Heery D, Heine MJ, Garnier JM, Vivat V, Le Douarin B, Gronemeyer H, Chambon P, Losson R. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUGl and TIFI. EMBO J 1996;15:110-124. 27. Butt TR, Sternberg EJ, Gorman JA, Clark P, Hamer D, Rosenberg M, Crooke SI. Copper metallothionein of yeast, structure of the gene, and regulation of expression. Proc Natl Acad Sci USA 1984;81:3332-3336. 28. Fogel S, Welch JW. Tandem gene amplification mediates copper resistance in yeast. Proc Natl Acad Sci USA 1982;79:5342-5346. 29. Karin M, Najarian R, Haslinger A,Valenzuela P, Welch J, Fogel S. Primary structure and transcription of an amplified genetic locus: the CUP1 locus of yeast. Proc Natl Acad Sci USA 1984;81:337-341. 30. Munder T, Fiirst P. The Saccharomyces cerevisiae CDC25 gene product binds specifically to catalytically inactive Ras proteins in vivo. Molec Cell Biol 1992;12:2091-2099. 31. Kagi JHR, KojimaY. Chemistry and biochemistry of metallothionein. In: Kagi JHR, Kojima Y (eds) Metallothionein 11. Basel, Birkhauser Verlag, 1997;25-61. 32. Hamer DH. Metallothionein. Ann Rev Biochem 1986;55:913-951. 33. Tanahashi H, Ito T, Inouye S, Tsuji FL, Sakaki Y. Photoprotein aequorin: use as a reporter enzyme in studying gene expression in mammalian cells. Gene 1990;96249-255. 34. Sheu Y-A, Kricka LJ, Pritchett DB. Measurementof intracellular calcium using bioluminescent aequorin expressed in human cells. Anal Biochem 1993;209:343-347. 35. Inouye S, l3uji FL. Aequorea green fluorescent protein: expression of the gene and fluorescent characteristics of the recombinant protein. FEBS Lett 1994;341:277-280. 36. Chalfie M,TuY, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. Science 1994;263:802-805. 37. Cubitt AB, Heim R, Adams SR, Boyd AE, Gross LA,Tsien RY. Understanding, improving and using green fluorescent proteins. Trends Biochem Sci 1995;20448-455. 38. Niedenthal RK, Riles L, Johnston M, Hegemann H. Green fluorescentprotein as a marker for gene expression and subcellular localization in budding yeast. Yeast 1996;12:773-786.
53 39. Vasavada HA, Ganguly S, Germino FJ, Wang ZX,Weissman SM! A contingent replication assay for the detection of protein-protein interactions in animal cells. Proc Natl Acad Sci USA 1991; 88:10686--10690. 40. Fearson ER, Finkel T, Gillison ML, Kennedy SP,Casella JF, Tomaselli GF, Morrow JS, Dang CV. Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells. Proc Natl Acad Sci USA 1992;89:7958-7962. 41. Yin M-J, Paulssen Ed, Seeler J-S, Gaynor RB. Protein domains involved in both in vivo and in vitm interactions between human T-cell leukemia virus type I 'Igx and CREB. J Virol 1995;69: 3420-3432. 42. Ma J, Ptashne M. Converting a eukaryotic transcriptional inhibitor into an activator. Cell 1988; 55:443-446. 43. Johnston M. A model hngal gene regulatory mechanism: the GAL genes of Saccharomyces cerevisiae. Microbiol Rev 1987;51:458-476. 44. Tzamarias D, Struhl K. Functional dissection of the yeast Cyc8-Tupl transcriptional co-repressor complex. Nature (London) 1994;369:758-761. 45. Ma J, Ptashne M. A new class of yeast transcriptional activators. Cell 1987;51:113-119. 46. Gill G, Ptashne M. Negative effect of the transcriptional activator GALA. Nature (London) 1988;334:721-724. 47. lliezenberg SJ, LaMarco KL, McKnight SL. Evidence of DNA: protein interactions that mediate HSVl -immediate early gene activation by VPl6. Genes Devel 1988;2:730-742. 48. Berger SL, Piiia B, Silverman N, Marcus GA, Agapite J, Regier JL, Triezenberg SJ, Guarente L. Genetic isolation of ADA2: a potential transcriptional adapter required for hnction of certain acidic activation domains. Cell 1992;70251-265. 49. Ebinak; TakcharaY, Kishi F, Nakazawa A, Brent R. LexA protein is a repressor of the colicin El gene. J Biol Chem 1983;258:13258-13261. 50. Fiirst P, Hu S, Hackett R, Hamer D. Copper activates metallothionein gene transcription by altering the conformation of a specific DNA binding protein. Cell 1988;55:705-717. 51. Thiele DJ. ACEl regulates expression of the Succharomyces cerevisiae metallothionein gene. Molec Cell Biol 1988;8:2745-2752. 52. Szczypka MS, Thiele D. A cysteine-rich nuclear protein activates yeast metallothionein gene transcription. Molec Cell Biol 1989;9:421-429. 53. Cizewski-CulottaV, HsuT, Hu S, Fiirst P, Hamer D. Copper and the ACEl regulatory protein reversibly induce yeast metallothionein gene transcription in a mouse extract. Proc Natl Acad Sci USA 1989;868377-8381. 54. Chaudhuri B, Hiimmerle M, Fiirst €? The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506. FEBS Lett 1995;357:221-226. 55. Chaudhuri B, Stephan C, Huijbregts RP, Martens GJ. The neuroendocrine protein 7B2 acts as a molecular chaperone in the in vitro folding of human insulin-like growth factor-1 secreted from yeast. Biochem Biophys Res Commun 1995;211:417-425. 56. Chaudhuri B, Stephan C. Only in the presence of immunophilins can cyclosporin and FK506 disrupt in vivo binding of calcineurin A to its autoinhibitory domain yet strengthen interaction between calcineurin A and B subunits. Biochem Biophys Res Commun 1995;215:781-790. 57. Ausubel FM, Brent R, Kingston R, Moore D, Seidman JJ, Smith J, Struhl K. Current protocols in molecular biology New York,Ny: John Wiley & Sons, 1993. 58. Feilotter HE, Hannon GJ, Ruddell CJ, Beach D. Construction of an improved host strain for two hybrid screening. Nucl Acid Res 1994;22:1502- 1503. 59. Legrain P, Dokhelar M-C, Transy C. Detection of protein-protein interactions using different vectors in the two-hybrid system. Nucl Acid Res 1994;22:3241-3242. 60. Bartel P, Relds S. Analyzing protein-protein interactions using two-hybrid system. Meth Enzymol 1995;254:241-263. 61. Munder T.Strategy to analyze proteinlprotein and proteinlproteinlDNA interactions in vivo.
54
62. 63.
64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80.
81. 82. 83. 84.
In: Saluz HP,Wiebauer K (eds) DNA and Nucleoprotein Structure In Vivo. Austin, New York, Hong Kong: R.G. Landes Company and Springer Verlag, 1995;ll-35. Chien T, Bartel PL, Sternglanz R, Fields S.The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proc Natl Acad Sci USA 1991; 88:9578-9582. Kishore GM, Shah DM. Amino acid biosynthesis inhibitors as herbicides. Ann Rev Biochem 1988;57:627-663. Evangelista C, Lockshorn D, Fields S.The yeast two-hybrid system: prospects for protein linkage maps. Trends Cell Biol 1996;6:196-199. Finley RL, Brent R. Interaction mating reveals binary and ternary connections between Drosophila cell cycle regulators. Proc Natl Acad Sci USA 1994;91:12980-12984. Herskowitz I. Life cycle of the budding yeast Saccharomyces cerevisiae. Microbiol Rev 1988;52 536-553. Bendixen C, Gangloff S, Rothstein R. A yeast mating-selectionscheme for detection of proteinprotein interactions. Nucl Acid Res 1994;22:1778- 1779. Bartel PL, Roecklein JA, Sengupta D, Fields S. A protein linkage map of Escherichiu coli bacteriophageT7. Natl Genet 1996;12:72-77. Koyama S,Yu H, Dalgarno C, Shin TB, Zydowsky D, Schreiber SL. Structure of the PI3K SH3 domain and analysis of the SH3 family Cell 1993;72:945-952. Li B, Fields S. Identification of mutations in p53 that affects its binding to SV40 1argeTantigen by using the yeast two-hybrid system. FASEB J 1993;7:957-963. Kurschner C, Morgan JI. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. Molec Brain Res 1995;30165-168. TodaT, Uno I, IshikawaT, Powers S,KataokaT, Broek D, Cameron S, Broach J, Matsumoto K, Wigler M. In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell 1985;40: 27-36. Field J, Nikawa J, Broek D, MacDonald B, Rodgers L, Wilson IA, Lerner RA, Wigler M. Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method. Molec Cell Biol 1988;8:2159-2165. Jones S, Wgnais M-L, Broach JR. The CDC25 protein of Saccharomyces cerevisiue promotes exchange of guanine nucleotides bound to ras. Molec Cell Biol1991;11:2641-2646. Lai C-C, Boguski M, Broek D, Powers S. Influence of guanine nucleotides on complex formation between Ras and Cdc25 proteins. Molec Cell Biol 1993;13:1345-1352. Ikawa S,Weinberg RA. An interaction between p2lras and heat shock protein hsp90, a chaperonin. Roc Natl Acad Sci USA 1992;89:2012-2016. Estojak J, Brent R, Golemis E. Correlation of two-hybrid affinity data with in vitro measurements. Molec Cell Biol 1995;15:5820-5829. Allan JB, Walberg MW, Edwards MC, Elledge SJ. Finding prospective partners in the library: the two-hybrid system and phage display find a match. Trends Biochem Sci 1995;20:511-516. Bartel P, Chien C-T, Sternglanz R, Fields S.Elimination of false positives that arise in using the two-hybrid system. BioTech 1993;14920-924. Mosteller RD, Park W, Broek D. Analysis of interaction between Ras and CDC25 guanine nucleotide exchange factor using yeast GAL4 two-hybrid system. Meth Enzymol 1995;255: 135-148. Kalderon D, Roberts BL, Richardson WD, Smith AE. A short amino acid sequence able to specify nuclear location. Cell 1984;39:499-509. Sternglanz R, Fisher PA. Signal-mediated import Benton BM, Eng W-K, Dunn JJ, Studier W , of bacteriophage T7 RNA polymerase into the Saccharomycescerevisiae nucleus and specific transcription of target genes. Molec Cell Biol 1990;10:353-360. Nelson M, Silver !F Context affects nuclear protein localization in Saccharomyces cerevisiae. Molec Cell Biol 1989;9:384-389. Luban J, Goff SP.The yeast two-hybrid system for studying protein-protein interactions. Curr
55 @in Biotechnol 1995;6:59-64. 85. Li X, McDermott B, Yuan B, Goff SP. Homomeric interactions between transmembrane proteins of Moloney murine leukemiavirus. J Virol 1996;70:1266-1270. 86. Rousset R, Desbois C, Bantignies F, Jalinot P. Effects on NF-KBl/p105 processing of the hteraction between the HTLV-1 transactivator lhx and the proteasome. Nature (London) 1996; 381~328-331. 86a.ShnGeva M, MunderT. The oncoproteinTaxof the humanT-cell leukemia virus type I activates transcription via interaction with cellular ATF- 1/CREB factors in Succharomyces cerevisiue. J Vim1 1996;707478-7484. 87. BurrisTP, Nawaz Z,Tsai M-J, O’Malley B. A nuclear hormone receptor-associatedprotein that inhibits transactivation by the thyroid hormone and retinoic acid receptors. Proc Natl Acad Sci USA 1995;92:9525-9529. 88. Lee JW, Choi H-S, Gyuris J, Brent R, Moore DD. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Molec Endocrinol 1995;9:243-254. 89. Lee JW, Ryan F, Swafield JC, Johnston SA, Moore DA. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature (London) 1995;37491-94. 90. Oiiate SA, Tsai SU, Tsai M-J, O’Malley BW Sequence and characterization of a coactivator for the steroid hormone receDtor superfamily Science 1995:270: 1354- 1357. 91. Ballou CE. Yeast cell wall and cell surface. In: Strathern JN, Jones EW, Broach JR (eds) The Molecular Biology of the Yeast Succhuromyces. Metabolism and Gene Expression. Cold Spring Harbor, NY Cold Spring Harbor Laboratory, 1982;335-360. 92. Kukuruzinska MA, Bergh MLE, Jackson BJ. Protein glycosylation in yeast. Ann Rev Biochem 1987i56915-944. 93. Lehle L, Bause E. Primary structural requirements for N- and 0-glycosylation of yeast mannoproteins. Biochem Biophys Acta 1984;799:246-251. 94. Innis MA. Glycosylation of heterologous proteins in Succhuromyces cerevisiue. In: Barr PJ, Brake AJ, Valenzuela P (eds) Yeast Genetic Engineering. Boston: Butterworth, 1989;233-246. 95. Castellanos RMP, Muon MJ. Identification of phosphotyrosine in yeast proteins and of a protein tyrosine kinase associated with the plasma membrane. J Biol Chem 1985;2608240-8242. 96. Gartner A, Nasmyth K, Ammerer G. Signal transduction in Succharomyces cerevbiue requires tyrosine and threonine phosphorylation of FUS3 and KSS1. Genes Devel 1992;61280-1292. 91. Lim M-y Dailey D, Martin GS, Thorner J. Yeast MCKl protein kinase autophosphorylatesat tyrosine and serine but phosphorylates exogenous substrates at serine and threonine. J Biol Chem 1993;268:21155-21164. 98. Navon A, SchwarzU, Hazan B, Kassir U, Nir U. Meiosis-dependent tyrosine phosphorylationof a yeast protein related to the mouse p5lfC? Molec Gen Genet 1994;244.160-167. 99. F’andey A, Lazar DF, Saltiel AR, Dixit VM. Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity J Biol Chem 1994;26930154-30157. 100. Gustafson TA, He W, Craparo A, Schaub CD, ONeill TJ. Phosphotyrosine-dependentinteraction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Molec Cell Biol 1995;15:2500-2508. 101. ONeill TJ, Craparo A, Gustafson TA. Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system. Molec Cell Biol 1995;14:6433-6442. 102. Osborne MA, Dalton S, Kochan JP. The yeast tribrid system - genetic detection of transphosphorylated ITAM-SH2-interactions. Bio/Technol 1995;13:1474- 1478. 103. Beavan MA, Metzger H. Signal transduction by Fc receptors, the FcsRI case. Immunol Today 1993;14222-226. 104. Cambier JC. New nomenclature for the Reth motif (or ARHl /TAM/ARAM/YXXL). Immuno1 Today 1995;16:110. 105. Kihara H, Siraganian RP. Src homology 2 domains of Syk and Lyn bind to tyrosine-
56 phosphorylated subunits of the high affinity IgE receptor. J Biol Chem 1994;269:22427-22432. 106. Paolini R, Renard V, Vivier E, Ochiai K, Jowain MH, Malissen B, Kinet JP. Different roles for the Fc epsilon RI gamma chain as a hnction of the receptor context. J Exp Med 1995;181: 247-255. 107. Shiue L, Green J, Green OM, Karas JL, Morgenstern JP, Ram MK, Taylor MK, Zoller MJ, Zydowsky LD, Bolen JB, Brugge JS. Interaction of ~ 7 2 ' ~with ' the y and subunits of the high-affinity receptor for immunoglobulin E FcsRI. Molec Cell Biol 1995;15:272-281. 108. Shiue L, Zoller MJ, Brugge JS. Syk is activated by phospho-tyrosine-containing peptides representing the tyrosine-based activation motifs of the high affinity receptor for IgE. J Biol Chem 1995;270:10498- 10502. 109. Dalrymple MA, McGeoch DJ, Davison AJ, Preston CM. DNA sequence of the herpes simplex virus type I gene whose product is responsible for transcriptional activation of immediate early promoters. Nucl Acid Res 1985;13:7865-7879. 110. Sun P, Maurer RA. An inactivating point mutation demonstrates that interaction of CAMP response element binding protein (CREB) with the CREB binding protein is not sufficient for transcriptional activation. J Biol Chem 1995;270:7041-7044. 111. Tanaka K, Matsumoto K, Toh-e A. IRA1, an inhibitory regulator of the RAS-cyclic AMP pathway in Succhuromycescerevisiue. Molec Cell Biol 1989;9:757-768. 112. Van Aelst L, Barr M, Marcus S, Polverino A, Wigler hf Complex formation between RAS and RAFand other protein kinases. Proc Natl Acad Sci USA 1993;906213-6217. 113. Legrain P, Chapon C Interaction between PRPl 1 and SPP91 yeast splicing factors and characterization of a PRP9-PRPl1-SPP91 complex. Science 1993;262:108-110. 114. Legrain P, Chapon C, Galisson E Interaction between PRP9 and SPP91 splicing factors identify a protein complex required in prespliceosome assembly Genes Devel 1993;7:1390-1399. 115. Ma J. Detecting interactions between eukaryotic proteins in bacteria. Gene Expres 1992;2: 139-146. 116. Gramatikoff K, Georgiev 0,Schaffner W. Direct interaction rescue, a novel filamentous phage technique to study protein-protein interactions. Nucl Acid Res 1994;22:5761-5762. 117. Gramatikoff K, Schaffner W, Georgiev 0.The leucine zipper of c-Jun binds to ribosomal protein L18a: a role in Jun protein regulation? Biol Chem Hoppe-Seyler 1995;376:321-325. 118. Johnsson N, Varshavsky A. Split ubiquitin as a sensor of protein interactions in vivo. Proc Natl Acad Sci USA 1994;91:10340-10344. 119. Li JJ, Herskowitz I. Isolation of ORC6, a component of the yeast origin recognition complex by a one-hybrid system. Nature (London) 1993;262:1870- 1874. 120. Wang MM, Reed RR. Molecular cloning of the olfactory neuronal transcription factor Olf-1 by genetic selection in yeast. Nature (London) 1993;364121-126. 121. Fangman WL, Brewer BJ. Activation of replication origins within yeast chromosomes. Ann Rev Cell Biol 1991;7:375-402. 122. Dowel1 SJ, Romanowski P, Diffley JFX. Interaction with Dbf4, the Cdc7 protein kinase regulatory subunit, with yeast replication origins in vivo. Nature (London) 1994265:1243-1246. 123. Jackson AL, Pahl P, Harrison K, Rosamond J, Sclafani RA. Cell cycle regulation of the yeast Cdc7 protein kinase by association with the Dbf4 protein. Molec Cell Biol 1993;12:28992908. 124. Gstaiger M, Knoepfel L, Georgiev 0,Schaffner W, Hovens CM. A B-cell coactivator of octamer-binding transcription factors. Nature (London) 1995;373:360-362. 125. Wilson TE, Fahrner TJ, Johnston' M, Milbrandt J. Identification of the DNA binding site for NGFI-B by genetic selection in yeast. Science 1991;252:1296-1300. 126. Tsai M-J, O'Malley BW. Molecular mechanisms of action of steroidhhyroid receptor superfamily members. Ann Rev Biochem 1994;63:451-486. 127. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841850.
128. Hadfield C, Raina KK, Shashi-Menon K, Mount RC The expression and performance of
57 cloned genes in yeast. Mycol Res 1993;897-944. 129. Hinnen A, Buxton F, Chaudhuri B, Heim J, HottigerT, Meyhack B, Fbhlig G. Gene expression in recombinant yeast. In: Smith A (ed) Gene Expression in Recombinant Microorganisms. NewYork, Basel, Hong Kong: Marcel Dekker Inc., 1995;121-193. 130. Johnston M. Genome sequencing: the complete code for a eukaryotic cell. Curr Biol 1996;6: 500-503. 131. Oliver SG. From DNA sequence to biological hnction. Nature (London) 1996379597-600. 132. Martin K. The interactions of transcription factors and their adapters, coactivators, and accessory proteins. Bioessays 1991;13:499-503. 133. Hertzberg RF? Whole cell assays in screeningfor biologically active substances. Curr Opin Biotechno1 1993;4:80-84. 134. Faisst S, Meyer S. Compilation of vertebrate-encoded transcription factors. Nucl Acid Res 199220~3-26. 135. Kirsch DR. Development of improved cell-based assays and screens in Succhuromyces through the combination of molecular and classical genetics. Curr Opin Biotechnol 1993;4:543-552. 136. Metzger C, White JH, Chambon F? The human oestrogen receptor hnctions in yeast. Nature (London) 1988;3@3 1-36. 137. Schena M, Yamamoto KR. Mammalian glucocorticoid receptor derivatives enhance transcription in yeast. Science 1988;251:965-967. 138. Mak P, McDonnell DP, Weigel NL, Schrader WT,OMalley BW Expression of functional chicken oviduct progesterone receptors in yeast (Succhuromycescerevisiue). J Biol Chem 1989; 2W.21613-21618. 139. McDonnell DP, Pike JW, Drutz DJ, Butt TR, OMalley BW Reconstitution of the vitamin Dresponsive osteocalcin transcription unit in Succhuromyces cerevisiue. Molec Cell Biol 1989;9: 3517-3523. 140. F’urvis IJ, Chotai D, Dykes CW, Lubahn DB, French FS, Wilson EM, Hobden AN. An androgen-inducible expression system for Succhuromyces cerevisiue. Gene 1991;106:35-42. 141. Lyffle C, Damian-Matsumura P, Juul H,Butt T Human estrogen receptor regulation in a yeast model system and studies on receptor agonists and antagonists. J Steroid Biochem Molec Biol 199342~677-685. 141a.Berghijfer-HochheimerY, Zurek C, Langer G, Munder T Expression of the human vitamin D and the retinoid X receptors in Saccharomyces cerevisiae: alternative in vivo models for ligand-induced transactivation. J Cell Biochem 1997;(In press), 142. Dasmahapatra B, DiDomenico B, Dywer S, Ma J, Sadowski I, Schwartz J. A genetic system for studying the activity of a proteolytic enzyme. Roc Natl Acad Sci USA 1992;89:4159-4162. 143. Dasmahapatra B, Rozhon EJ, Hart AM, Cox S,Tracy S, Schwartz J. Cell-free expression of the coxsackievirus 3C protease using the translational initiation signal of an insect virus RNA and its characterization.Virus Res 1991;20:237-249. 144. JainVK, Magrath ITA. A chemiluminescent assay for the quantification of P-galactosidase in the femtogram range: application to quantitation of P-galactosidase in lacZ-transfected cells. Anal Biochem 1991;199:119- 124. 145. Fulton R, van Ness B. Luminescent reporter gene assays for luciferase and P-galactosidase using a liquid scintillation counter. BioTechniques 1993;19762-763. 146. Nguyen W, Morange M, Bensaude 0. Firefly luciferase luminescence assays using scintillation counters for quantitation in transfected mammalian cells. Anal Biochem 1988;171:404-408. 147. Boguslawski G. Effects of polymixin B sulfate and polymixin B nonapeptide on growth and permeability on the yeast Succhuromyces cerevisiue. Molec Gen Genet 1985;199:4O1-405. 148. Mendelsohn A, Brent R. Applications of interaction trapskwo-hybrid systems to biotechnology research. Curr Opin Biotech 1994;5:482-486. 149. Zuckermann RN, Kerr JM, Siani MA, Banville SC,Santi DV. Identification of highest-afinity ligands by affinity selection from equimolar peptide mixtures generated by robotic synthesis. Proc Natl Acad Sci USA 1992;89:4505-4509.
150. Lam KS, Salmon E, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity Nature (London) 1991;35482-84. 151. Simon RJ, Kania RS, Zuckermann RN, Hiibner VD, Jewel1 DA, Banville S, Ng S,Wang L,
Rosenberg S,Marlowe CK, Spellmayer DC, ’Ign R, Frankel AD, Santi DV, Cohen FE, Bartlett PA. Peptoids: a modular approach to drug discovery Proc Natl Acad Sci USA 1992;89:93679371. 152. Zuckermann RN, Kerr JM, Kent SBH, Moos WH. Efficient method for the preparation of
peptoids [oligo(N-substitutedglycins)] by submonomer solid-phase synthesis. J Am Chem SOC 1992; 1 1 4 10646- 10647. 153. De Witt SH, Kiely JS, Stankovic CJ, Schroeder MC, Cody DM, Pavia MR. ‘Diversomers’: an approach to nonpeptide, nonoligomeric chemical diversity Proc Natl Acad Sci USA 1993;90: 6909-691 3. 154. Tanaka Y, Omura S. Agroactive compounds of microbial origin. Ann Rev Microbiol 1993;47: 57-87. 155. Yang M, Wu Z, Fields S. Protein-protein interactions analyzed with the yeast two-hybrid system. NucI Acid Res 1995;23:1152-1156. 156. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. (London) 1996;380: 548-550.
01997 Elscvier Science B.V. All rights reserved. Biotechnology Annual Review Volume 3 MR. El-Gewely, editor.
59
Human gene therapy: principles and modern advances Dorothy L. Reimer', Marcel B. Bally' and Shiva M. Singh2 'Departmentof Advanced Therapeutics,British Columbia Cancer Agenq Vancouver,British Columbia; and 'Molecular Medical Genetics Program, London Health Sciences Center and Molecular Genetics
Unit,Department of Zoology and Division of Medical Genetics, Universityof Western Ontario,London, Ontario, Canada
Abstract. The treatment of human diseases by gene therapy is logical, given the fact that it is possible to introduce nucleic acids into human cells. More importantly, genetic manipulations are able to eIicit relevant biological responses. Despite the potential for gene therapy in the future, numerous technological problems still exist that limit its acceptance as a mainstream therapeutic option. Every problem, however, has a logical and practical solution. We focus this review on issues related to the hdamental problems of gene transfer. Given the progress and potential impact of this therapeutic technology on the treatment of a large number of human diseases, it is anticipated that gene therapy will revolutionize the way in which we treat disease in the next century
Keywords: AAT, adeno-associated, adenoviral, AIDS, antisense, cancer, CF, FA, FH,gene therapy, gene transfer, herpesvirus, human, lipid-based carriers, MD, microencapsulation, oligonucleotides, PKU, receptor-mediated, retroviral, KID, vectors, viral.
Introduction Human gene therapy, defined as the introduction of genetic material into mammalian somatic cells for the purpose of treating diseases, is currently viewed as an ultimate goal of research on many diseases. Although this technology has been aimed at developing a cure for severe human diseases of single gene etiology, it is now being applied to the treatment of multifactorial diseases such as cancer, as well as infectious diseases such as AIDS. This treatment strategy differs from traditional approaches which attempt to compensate for the missing gene function and subsequent metabolic consequences by treating the disease symptom rather than the cause. The possibility of correcting a defect at the level of the gene itself, has been considered for over 2 decades and has evolved with the ability to identi@genes and gene defects responsible for diseases. The number of genes identified that are involved in the causation and predisposition of diseases has been impressive. These discoveries can be attributed to a comprehensive research program that integrates genetic principles with sophisticated Mressfor Correspondence: Dr S.M. Singh, Department of Zoology and Division of Medical Genetics, 307 Western Science Center, University of Western Ontario, London, Ontario, Canada, N6A 5B7. Tel.: +1-519-661-3135. Fax: +1-519-661-2014. E-mail:
[email protected]. or Dr D.L. Reimer, Department of Advanced Therapeutics, British Columbia Cancer Agency, 600 West 10th Av.,Vancouver, British Columbia, Canada,VSZ 4E6. Tel.: +1-604-877-6010-3155. Fax: +1-604877-6011. E-mail:
[email protected].
60
and highly sensitive molecular technologies. Today, disease gene mutations are being identified rapidly, and shortly after the genes are discovered a battery of diagnostic, prevention and effective treatment strategies are considered. This coincides with the development of molecular assays for the detection of genes, development of efficient gene delivery systems and the technology that allows for controlled gene expression.We have come a long way in our ability to identify disease-causing mutations and to manipulate and move recombinant DNA molecules at will. However, efficient transfer of a gene to target tissues and/or specific cell types, such that spatial and temporal expression are exhibited, remains the most significant problem to overcome. Conceptually, it is logical to think of DNA as the drug of choice for the treatment of many diseases, both genetic and nongenetic. Developing a gene therapy protocol is a very lengthy process which begins with cloning the gene that causes a particular disease (comparable to identifying a potential drug or target for a drug). The gene drug must be isolated, prepared using manufacturing procedures that are reproducible and appropriate for products destined for human use and evaluated in animal models for toxicity and efficacy The latter can be used to support submissions, such as an Investigational New Drug (IND) application to regulatory bodies and are required prior to initiation of early clinical testing. Along this pathway, appropriate procedures must be developed to characterize the mechanism of activity of the gene drug as well as the pharmacokinetic behaviour of the active agent. This drug development pathway is one that is comparable to any new, clinically unproven, conventional drug. What distinguishes the gene drug from a conventional drug is their molecular size. For this reason, procedures must be developed to promote effective delivery of the gene drug and this, therefore, provides the initial focus of this review. Specifically, it will include discussions on viral and nonviral approaches to gene delivery and their effectiveness, if known, as they apply to selected genetic and nongenetic diseases. During the course of this review, we will take the liberty to speculate on the challenges for the development of improved gene delivery systems. Within this context, it is important to summarize the potential dangers as well, including inadvertently altering germ cells in cases of in utero use of somatic cell gene therapy, reinfectivity and oncogenicity of the viral vector, interruption of a normal host gene with negative consequences, bacterial contamination, and only partial correction of the genetic disease (thus converting a fatal disease to a chronic progressive one), among others. Guidelines dealing with most of these concerns are not readily available and are currently being developed by committees in a number of different countries. Some of these concerns will be addressed following a comprehensive discussion on the gene delivery systems and their applications. It is important to indicate here that we are aware of the significant ethical considerations surrounding applications of gene therapy Although the implications of somatic cell gene therapy are restricted to the individual, alterations of germ line cells will lead to the information being passed down to subsequent
61 generations. The prospect of deliberately making inherited alterations in the human genome and gene pool is historically feared both by the general public as well as the scientific community. The fear and threat associated with human germ line gene therapy is magnified because we know that the technology for germ line gene transfer is already available for experimental and domesticated mammals and the technology for instituting germ line gene therapy on humans is now a reality. This review will not concentrate on these ethical concerns, rather it will focus on the lessons learned from human gene therapy studies, dealing first with the methods used for gene transfer and some of the regulatory/safety concerns associated with these gene transfer methods, and subsequently with examples of preclinical and clinical experiences with gene therapy Finally, an overview of oligonucleotide-based therapeutic strategies will be given. Although the size of the therapeutic agent is much smaller (18-24 mers) in comparison to a gene (9-30+ kb), oligonucleotides offer an alternative gene therapy approach that is reliant on turning off the expression of a particular gene. In this context, the approach is similar to strategies involving the transfer of genes to elicit a specific therapeutic response.
Gene delivery methods
In principle, there are two general approaches for the correction of a defective gene in a tissue or cell type. First, the normal gene sequence is introduced into cells cultured ex vivo, followed by reintroduction of the corrected cells into the patient being treated. Correction of gene defects by this approach is, of course, limited to cell types that can be biopsied, cultured and manipulated in vitro and in general would involve stable integration of the gene into the cellular genome. In the second approach, the normal gene or desired sequence is introduced into specific cells or tissues of the patient in vivo. In this case, any cell type could potentially be targeted, however, the fate of the introduced DNA need not involve integration into the host genome. In this part of the review, we will discuss in vivo and ex vivo approaches for the introduction of nucleic acids to correct cells and tissues. This will provide a solid foundation for understanding the variety of methods being used in ongoing gene therapy clinical studies. More importantly, it is emphasized that other variations will emanate over time, given the variety of tissues and cell types that could be subject to such therapy strategies. A comprehensive list of delivery methods is summarized in Table 1, and is discussed in some detail in the following sections. This section has been divided into two subsets, nonviral- and viral-mediated gene delivery methods. Nonviral-mediatedgene delivery Direct injection of DNA One of the simplest approaches for introducing DNA into cultured mammalian cells which can be expressed is by mechanical injection into the nucleus [l].
Table I. Summary of gene transfer methods and associated properties.
A: Nonviral Method
Max. insert size
Wget
Eficiency transfection
Direct injection of DNA
Unlimited
Skeletal muscle
LOW
LOW
Multiple
Liposome-mediatedDNA
Unlimited
Replicating and nonreplicating cells
LOW
LOW
Multiple
Receptor-mediated DNA
Unlimited
Moderate
LOW
Multiple
Adenoviral-ligand DNA
Unlimited
Hepatocytes (e.g., ASGPr, folate) Replicating cells (e.g., transferrin) Replicating cells (e.g., transferrin) Hepatocytes (e.g., ASGPr, folate)
Moderate
Moderate
Multiple
ofExpression
No. of doses
B:Vial ~~
Method
Max. insert size(kb)
DNA/ RNA
Insertional mutagenesis
Infectivity
Integration
Expression Target
No. of doses
RetrOvirUS
9.0
RNA
High
LOW
Chrom
S
Replicating cells
Single
Adenovirus
7.5
dsDNA
LOW
High
Episomal
T
Respiratory G.I.
Multiple
Adenoassoc. virus
4.5
ssDNA
High
High
Episomal/ Chrom
S/T
Respiratory G.I.
30.0
dsDNA
?
High
Chrom
S
Neurons
Herpes virus
S = stable, T = transient, Chrom = integration into the host genome.
Single
63 Although this procedure is laborious and expensive, it has been used successhlly for the introduction of genes into embryos for the production of transgenic animals [2,3]. The DNA cloning vector containing the gene of interest and often used for direct injection is a plasmid, a double-stranded, circular DNA element of bacterial origin, which replicates extrachromosomally.The direct injection of DNA approach was modified in an attempt to introduce purified and hnctional plasmid DNA directly into the tissues in vivo. Though highly specific in location, DNA is required to be taken up into the cells from the extracellular space, making its application for human somatic gene therapy limited. Recently, however, specific tissues such as skeletal muscle have been shown to express plasmid DNA following direct injection in vivo. The expression of this DNA in myofiber cells has been reported from a variety of species including fuh [4], rats [5], mice [5-81, cats and monkeys [9]. The efficiency of this process is relatively low compared to other gene transfer approaches. This may be due to the fact that the majority of transfection is localized principally along the track of injection. Despite this caveat, partial therapeutic gain was demonstrated by Ascadi et al. [lo], following direct injection of a dystrophin minigene (in free form) into the skeletal muscle of mice with muscular dystrophy There is data suggesting that the ability to incorporate and express DNA delivered in free form may be unique to muscle cells. Although the mechanism by which myofibrils take up and express free DNA is not clearly understood, it is proposed that the DNA is taken into the cytoplasm of the cell through the transverse tubules, which are unique to muscle cells and may act as diffisory conduits for the DNA [l 13. It is also possible that the mechanics of injection of DNA causes direct damage of individual myofibers, resulting in disruption of the cell membrane, allowing DNA to enter the cell [8]. Regardless of mechanism, the fact that muscle cells are so readily transfected with free DNA has an important application in the development of vaccines as discussed elsewhere [12]. Direct injection and ultimate expression of purified plasmid DNA in other tissues has been met with limited success. One exception is the thyroid where injection of a gene into the interstitial spaces of rabbit thyroid has led to its expression in follicular cells at levels equivalent to those observed in muscle [13]. Similarly, injection of large amounts of DNA into the liver (2-5 mg) have shown detectable expression of recombinant genes [14]. In these tissues, it is likely that the DNA is taken up passively during the normal course of endocytosis. Whatever the mechanism of gene transfer, the efficiency and expression after direct administration of purified DNA is relatively low compared to other gene transfer protocols.
Liposome- and DNA particle-mediated gene transfer The use of liposomes as vehicles for the delivery of genetic information began in the early 1980s and is a natural extension of their application as drug delivery agents (for reviews see [15,16]). Typically, liposomes are spherical membrane vesicles consisting of a lipid bilayer surrounding an aqueous space. Liposomes
64 can be prepared using any lipid components or mixtures capable of adopting a bilayer structure. In 1987, Felgner et al. demonstrated that liposomes prepared with positively charged lipids can be used for gene transfer in vitro. The prototype cationic lipid for gene transfer is DOTMA ("1 -(2,3-dioleyloxy)propyl]-NNNtrimethylammonium chloride) [171, although a variety of other synthetic cationic lipids have also been used for gene transfer [18-231. The positive charges of the cationic lipid interact with the negative charges of the DNA backbone, creating a DNA-liposome aggregate where the DNA binds to the liposome through ionic interactions [24]. The resulting cationic liposome-DNA aggregates are prepared to exhibit a net positive charge, and are effective in delivering DNA to cells, since they have the propensity to interact with negatively charged cell membranes (Fig. 1). The efficiency of DNA delivery using cationic liposomes depends on several variables including lipid membrane composition [25,26]. Zwitterionic phospholipids such as DOPE (dioleoylphosphatidylethanolamine) are thought to be a necessary component, since it is known that this lipid plays an important role in mediating membrane fbsion [27]. The size and overall net charge of the liposome-DNA complex is also thought to be important in developing cationic liposomes which have a high efficiency of DNA delivery [17,28,29]. The size and
hsert+x:
+
+
+
v
Plasmid DNA
cationic iiposome
Endosome
L~~~soIYw-DNA
Nucleus
Fig. I. Proposed mechanism for cationic liposome-mediated gene transfer. Plasmid DNA containing
the desired insert gene forms aggregates with cationic liposomes through ionic interactions. These liposome-DNA aggregatesexhibit a net positive charge which can interact with the negatively charged cell membranes. These complexes are internalized by the cell, through unknown mechanisms and can enter the endosomal pathway, or migrate through the cytoplasm directly to the nucleus where the plasmid DNA is transcribed and the gene expressed.
65
charge of the complexes can be optimized by altering the composition of the lipids as well as the lipid-to-DNA ratio within the complex [30]. This is thought to affect the efficiency of DNA delivery and it has been suggested that larger vesicles may be more effective than smaller vesicles for in vitro gene delivery [3 11. Although cationic liposomes with various lipid combinations exhibit quantitatively different gene delivery efficiencies in different cell types, no clear patterns have emerged concerning features of liposome carriers that are necessary for optimal gene delivery The efficiency of gene transfer using cationic liposomes can be enhanced by the encapsulation of DNA within the aqueous compartment of the liposome [24]. Although the encapsulation process is largely inefficient, this approach may be more suitable for in vivo gene therapy, since it is thought that the encapsulated DNA would be protected against enzymatic degradation in systemic circulation as well as during intracellular processing. There has been extensive research into the use of liposomes as an effective nonviral approach for gene therapy, however, the mechanism of DNA transfer across the cell membrane and subsequently to the nucleus is still not wellunderstood. It is generally believed that endocytosis is the major route of cellular uptake for DNA-liposome complexes [32,33]. This event, however, may be highly dependent on the liposomal lipid composition which can specifically effect DNA movement into the cytoplasm following fusion of the liposome-DNA complex to the cell membrane [34]. Regardless of how the DNA gains access to the cell, the efficiency of expression still depends on several variables including dissociation of the lipid from the DNA, and transfer of the DNA through the cytoplasm to the nucleus. A full understanding of the mechanisms involved in these processes is necessary before an efficient nonviral gene delivery system can be achieved. Despite our lack of complete understanding of the transfection mechanisms, liposomes have many advantages as DNA delivery agents. First, they have the potential to deliver DNA of unlimited size. Second, they are relatively nontoxic and lack the ability to recombine to form an infectious agent, avoiding the problems of mutation and oncogenesis associated with viral vectors. Finally, they are also able to transfect nondividing cells, and may evoke fewer immune responses than their viral counterparts because they lack protein constituents [35]. Their use for in vivo gene therapy, however, may be hampered by the fact that the transfected DNA remains episomal within the target cells and therefore repetitive dosing will likely be required to achieve therapeutic effects. Studies on cationic liposomes have inspired the creation of a second generation of a self-assembling nonviral lipid-based DNA particle. Under controlled conditions, the ionic interactions of cationic lipids and DNA have been shown to result in the formation of a hydrophobic lipid-DNA complex that can be readily isolated in solvents [36,37]. Subsequently, this hydrophobic complex can be used in the preparation of small and well-defined particles [38]. These particles have the potential to be used for the production of novel lipid-based carrier systems for in vivo gene therapy The biological challenge in developing these systems is to
66 control their characteristics such as size, charge, interaction with serum proteins and interaction with cell surfaces such that effective delivery of the DNA to the nucleus is achieved. Synthetic cationic polymers have also been developed as a method for gene delivery [39]. An example of a particularly useful polymer is known as a dendrimer, which is a branched cation whose diameter is determined by a number of synthetic polymerization steps. Dendrimer-DNA complexes have been shown to exhibit efficient gene delivery in vitro and is thought to enter the cells by endocytosis. The efficiency of gene delivery using dendrimers has been further enhanced by the addition of peptides that release the endosomal contents into the body of the cell [39]. Furthermore, dendrimers can be designed to home in on specific target cells by attaching sugars and proteins to the dendrimer surface. These molecules, therefore, hold great promise for the future of gene therapy as super molecules for DNA delivery whose properties are easy to manipulate and can be made to order [40]. Receptor-mediated gene transfer Receptor-mediated gene transfer has emerged as a promising approach for the introduction of DNA into cells in a tissue-specific manner in vivo. Targeting of DNA to a particular cell type is usually achieved by covalently coupling the ligand to a polycationic anchor, such as polylysine, and then forming a ligandpolylysine-DNA complex through ionic interactions between the positively charged polylysine and the negatively charged DNA [41,42].The polycation binds to and condenses the plasmid DNA to a size and conformation which is thought to enhance transfer across the cell membrane [43]. The resulting complexes have ligands which are exposed on the surface of the conjugate and retain the ability to interact specifically with cognate receptors on the surface of the target cell resulting in internalization of the complex into the cell by endocytosis (Fig. 2). Upon entry, the ligand-polycation-DNA complex could enter the nucleus and undergo gene expression, usually without integration into the cellular genome. One of the first receptors to utilize this approach was the asialoglycoprotein receptor (ASGPr) whose expression is limited to the surface of hepatocytes. These cells constitute 70-80% of the liver volume, making it a good choice for liverspecific gene targeting. Asialoglycoproteins have been used as ligands to target DNA to hepatocytes via this receptor. It has been shown that 85% of asialoorosomucoid-polylysine-DNAcomplexes were specifically endocytosed by hepatocytes within 10 min of intravenous injection and transiently expressed [41,44,45]. Although ASGPr-mediated endocytosis can deliver large quantities of DNA very rapidly to hepatocytes in vivo, the majority of the DNA is rapidly degraded following entry into the cells. This is likely due to the degradable enzymes of the lysosomal pathway to which the receptor complex is directed following the process of endocytosis. Recently, Perales et al. [46] have evaluated the specific structural features on the DNA-ligand complexes which may be important for the introduction of DNA into rat livers in vivo. They demonstrated that when plasmid DNA was complexed to polylysine and thereby condensed, effec-
67
Fig. 2. Proposed mechanism for receptor-mediated gene transfer. Plasmid DNA containing the desired gene insert undergoes condensation when complexed with a polycation, such as polylysine, covalently attached to a specific ligand. The ligand is responsible for targeting this complex to a specific cell type where internalization is primarily into the endosome. By mechanisms which are not yet clearly understood, the plasmid DNA can escape the endocytic pathway and/or make their way through the cytoplasm to the nucleus where host genome machinery acts to transcribe the gene, resultingin expression.
tive and specific targeting and expression to hepatocytes was achieved. These results suggest that condensation of the DNA-ligand complexes is the key to the successful introduction of genes into tissues by receptor-mediated endocytosis. Tmsferrin receptors have also been used as ligands to target genes to cells from specific tissues [47]. Rapidly proliferating cells such as neoplastic cells or cells of the hematopoietic lineage require elevated levels of iron and therefore overexpressthe transferrin receptor on the surface of their cells [48]. Extracellular iron is complexed to the carrier protein transferrin; this complex is then endocytosed by specific cells by binding via the transferrin receptor. This property makes them particularly useful for receptor-mediated targeting. The transferrin molecule can be modified by the addition of a polycation such as polylysine that efficiently binds and condenses DNA of a wide variety of sizes. Using this approach, polylysine-transferrimDNAcomplexes have been shown to be effective in delivering genes into various types of cells in vitro [49] including hematopoietic cells [42] and pulmonary epithelium [50]. Other ligands have also been used to generate similar conjugates that are effective in delivering genes to cells in a
68 tissue-specific manner and include surfactant B [513, antithrombomodulin [52], insulin [53], epidermal growth factor [54] and lectins [55]. These approaches, like those of transferrin and asialoglycoprotein, rely on endocytosis as the mechanism of entry A common feature for the internalization of DNA using the receptor-mediated approach depends on endocytosis, a process that directs the complex into the lysosomal compartment of the cell. The efficiency of gene delivery in this system, therefore, is limited by the fact that a large amount of the DNA is rapidly degraded following internalization. Although DNA-ASGPr-polylysine conjugates, which are endocytosed by hepatocytes following intravenous injection into rats, express the CAT reporter gene only transiently, persistent, high levels of hepatic CAT activity were achieved when partial hepatectomy was performed after gene delivery [45]. This persistence may be due to failure of the endosomal vesicles to translocate to lysosomes, thereby stabilizing episomal DNA. These studies suggest that the amount of DNA delivered to hepatocytes by this mechanism is sufficient for effective gene expression, provided that intracellular degradation can be inhibited. A new generation of molecular conjugate vectors has been developed that has the ability to overcome the limitations of endosomal entrapment [47]. This approach makes use of the natural attributes of adenoviruses. Once internalized, they can effectively escape the acidic environment of the endosome compartment by causing membrane disruption allowing virions to proceed to the nucleus to complete their life cycle. It is thought that during viral internalization, endosome acidification elicits structural changes in capsid proteins that are capable of penetrating the endosomal membrane thereby releasing endosomal contents into the cytoplasm of the cell [56,57]. When adenoviral particles were mixed with receptor-mediated complexes, including transferrin-polylysine-DNA [50], asialoglycoprotein-polylysine-DNA [58] and folate-polylysine-DNA [59], and cotransfected, up to 1,000-fold increase in the efficiency of gene delivery was observed. Incorporation of the adenoviral particle into the functional design of a new vector includes covalently binding polylysine to the surface of the virus, allowing binding of the DNA to the particle by ionic interactions. This approach has led to significantly higher DNA uptake, gene transfer and expression in primary hepatocytes than that achieved by free adenovirus [60,61]. Several approaches have now been evaluated for the enhancement of endosoma1 release without the need for the adenoviral particles, but these efforts have been largely unsuccessful. One approach that has met with some success, however, is the use of hemagglutinin peptides from the influenza virus, which like the capsid protein of the adenovirus, undergoes a conformational rearrangement in acid environments resulting in a membrane agglutination activity [62]. Results from these studies where complexes containing hemagglutinin and transferrin-polylysine-DNA were transfected to cells in vitro showed enhanced gene delivery and expression over transferrin-polylysine-DNA alone. Although in its present form, molecular conjugation can mediate high trans-
69 fection efficiencies in vitro, it is unlikely that this technology will be routinely applicable for in vivo gene therapy This is mainly due to the large size of the receptor-polycation conjugates (adenoviral-DNA conjugates being even larger) prohibiting tissue penetration. In addition, the concentrations of these conjugates, particularly those that consist of adenoviral-DNA complexes, are several orders of magnitude lower in vivo than those commonly used in vitro. Furthermore, with the use of any viral components, there is always the likelihood of direct immune response to the viral proteins used to construct the complexes. It should be noted that approaches based on receptor-mediated gene delivery are applicable to the particle-based delivery system discussed above. Other approaches Other nonviral methods for gene delivery include biolistics, jet injection, electroporation, as well as microencapsulation. Electroporation is a widely used method for gene transfer in vitro in which cells are exposed to a high voltage that creates transient pores in the cell membrane. Although this method can achieve transfection rates >90% in many cell lines, it is not suitable for in vivo gene therapy Recently, it has been shown that DNA can be delivered to cells by jet injection, a method whereby liquid droplets containing DNA are projected under pressure [63]. Although the use of this method is still in its infancy, it has been used for injection of DNA into muscles, which leads to the uptake and expression of the administered gene [64,65]. Biolistics is also a relatively new method for directly injecting DNA into cells in vitro and in vivo [66]. This method of particle bombardment using the ”gene gun” involves precipitating the DNA onto microparticles that are directed into cells using explosive or ballistic-driven devises [67,68]. Once the DNA-coated particles enter the cell, the DNA is slowly released from the particle which leads to gene expression. This method has been successful in the delivery of DNA to a variety of cell types in vitro including epithelial cells, endothelial cells, fibroblasts, and lymphocytes among others [69]. It has also been used to transfer genes into various organs in vivo including the skin, liver and muscle [70,67]. Although the use of the “gene gun” has potential for gene therapy in vivo, it is limited by the fact that it is not capable of penetrating deeply into tissues, and effective gene delivery is often only achieved in the superficial layers of the injected tissue. Many gene therapy protocols require the genetic manipulation of autologous cells. A number of reports including those from Reilly et al. [71], Chang et al. [72], Liu et al. [73], Hughes et al. [74] and al-Hendy et al. [75] among others have suggested the use of microcapsules for the delivery of a gene product to a somatic tissue. Although this approach has a number of variations, they all rely on appropriate cell lines engineered to secrete the desired gene products in vivo. Encapsulating these cells within immunoprotective biocompatible devices prior to implantation is expected to prevent rejection of the nonautologous donor cells. To facilitate the secretion of the nonsecreted gene product, a signal sequence could be hsed to the amino terminus of a nonsecreted protein, directing the
70 product into the secretory pathway for release from the cells. Using this approach Hughes et al. [74] reported activity of the secreted adenosine deaminase from microcapsules where the cells remained viable for over 5 months when implanted into a mouse. The microencapsulation approach may provide a prototype for engineering nonsecreted gene products for therapy. Other modifications of this approach include the use of universal cell lines, and immunoprotective alginatepoly-r. -1ysine-alginate microcapsules [75]. The results from the modifications of the type discussed above may offer yet another strategy for the delivery of a gene product in a protocol involving the genetic manipulation of somatic cells. Only time will tell whether this approach will gain popularity and become commonplace in gene therapy protocols. Viral-mediated gene delivery
Viruses have evolved highly efficient mechanisms to transfer their genetic material to target cells [76,77]. The design of recombinant viral gene transfer vectors has capitalized on this property The strategy for designing these gene transfer vectors has involved the incorporation of heterologous sequences into the genome of the viral parent. In the process of delivering endogenous viral sequences during the infectious process, the virion can also deliver incorporated heterologous sequences. Since these viral vectors are attenuated, the virions are therefore thought of merely as helper sequences. These sequences have been derived from DNA and RNAviruses [78,79] and have been shown to be effective in mediating gene transfer in vitro and in vivo [80]. Each vector system has distinct advantages and disadvantages for gene therapy applications. These are discussed below Retrovirus Gene delivery vectors using RNA viruses have been derived from avian [81], murine [82,83] and human sources [84-861 and are the most widely studied viral vectors. Most human gene therapy clinical protocols currently in use are based on disabled murine retroviruses [87,88]. Retroviruses contain two single-stranded copies of RNA which can replicate through a DNA intermediate in the host cell. Infectious viral particles bind to and gain entry into the host cell by a receptor-mediated mechanism [89]. Once inside the cell, the genomic RNA is reverse transcribed into DNA, called a provirus, which then enters the cell nucleus where it integrates into the cellular genome (Fig. 3). The ability of this virus to integrate genetic material directly into the host chromosome is a usehl feature towards the design of a recombinant viral-based vector. The provirus is bound at each end by a long terminal repeat (LTR) which contains enhancer and I3romoter elements in addition to signals for the initiation and termination of viral transcripts. Between these LTRs are situated the coding sequences for a series of structural genes, gag, pol and env, and the sequences coding for the packaging signal necessary for encapsidation of the viral transcripts. The first step in generating a recombinant retroviral vector is the deletion
-
71
Inserted gene
0
oooo
Recombinant Retroviral Particles
Integrated Nucleus
Gene Expression
Rg.3. Mechanism of retrovirus-mediated gene transfer. The gag, pol and env sequences are deleted from the wild-type virus containing the encapsidation signal (JI) and replaced with the desired gene. This replication deficient provirus is introduced into a packaging cell line which contains an encapsidation defective retrovirus that will provide the proteins necessary to produce recombinant viral particles. The vector, with its expression cassette, can enter the cell by receptor-mediated endocytosis. In the cytoplasm, reverse transcriptase converts the vector to proviral DNA which is then integrated randomly into the host cell genome, where transcription and gene expression takes place.
of structural genes, which not only renders the virus replication defective, but also allows replacement with desired heterologous DNA sequences coding the gene to be expressed [90]. The resulting recombinant viral vector is dependent on an alternate source of viral protein production for subsequent replication and infection. These properties are restored by supplying a retroviral packaging cell line that contains the retroviral genome from which the signals for encapsidation of the viral particles have been removed or mutated [83,91]. Although the viral genome of the packaging cell line produces all proteins necessary for viral replication and assembly, the infectivity is lost. Introduction of the proviral form of the retroviral vector into this packaging cell line results in the release of
72 recombinant retroviral particles, containing only encapsidated foreign RNA, into the culture medium. These producer cell lines can then be used to transduce target cells with recombinant retroviral sequences which are subsequently integrated into the host genome leading to the production of the new protein (see [90] for review). The major advantage of retroviral vectors for use in gene therapy is the integration of the transferred genes into cellular DNA, resulting in permanently modified target cells [87,82,92], a property which is particularly advantageous for the treatment of hereditary and chronic disorders. However, the process of genomic integration with retroviruses is associated with a risk of insertional mutagenesis and tumour formation if the proviral DNA randomly inserts next to a tumoursuppressor gene or an oncogene [93]. The use of retroviruses is also limited by the fact that target cells must be actively dividing [94] which creates an obvious drawback for the treatment of neurological diseases as well as diseases such as cystic fibrosis where the target cell is often l l l y differentiated and nonreplicating. The potential for the production of replication-competent helper virus during the production of the retroviral vectors always remains a concern and these cell lines must therefore undergo extensive preclinical testing. Adenovirus Adenoviruses, which are naturally occurring human respiratory and gastrointestinal tract pathogens [95], are currently being developed for use in gene therapy [96,97]. The wild-type adenovirus genome consists of a linear double-stranded DNA of approximately 35 kb in length. The DNA contains a series of early genes (El-E4) that are required for viral replication and a series of late genes (L1-L5) that encode viral structural proteins [95,98]. Adenoviruses, which have a lytic life cycle, are taken up by the cell through receptor-mediated endocytosis [99] thus entering via endosomes.These viruses have the innate ability to escape the endosomal pathway and instead enter the cytoplasm through a fbsion process, where they lose their protein coat. The viral DNA then translocates to the nucleus. The viral DNA does not integrate into the chromosome, remaining as a linear episomal fragment. The recombinant adenovirus that has been developed for gene therapy is made by deleting the El region [loo] which regulates adenoviral transcription and is necessary for viral replication. The El region is subsequently replaced with the foreign gene of interest. The resulting replication-deficient adenovirus requires an external source of El proteins, usually supplied by growing the virus on an adenovirus-transformed human embryonic kidney cell line. Resulting viral particles do not carry the El genes and are, therefore, incapable of replication inside the target cell [97]. They are, however, still capable of infecting many cell types and can express the foreign gene under the control of its own promoter. Adenoviruses have been extensively studied as vector systems to deliver genes to the lungs, since this is a tissue which these viruses naturally infect. This makes recombinant adenoviral gene therapy particularly attractive as an option for the
73 treatment of diseases involving the respiratory system such as cystic fibrosis (CF) [101-1031. An advantage for the use of adenoviruses is their ability to infect numerous cell types including nonreplicating as well as actively replicating cells [104]. They are particularly suitable for in vivo gene therapies because they can be produced in high titers [lo41 and have the potential to carry large segments of DNA [97]. Since the transferred genetic information remains epichromosomal, there is little risk of insertional mutagenesis due to random integration. This proper@ however, often leads to instability of gene expression due to the loss of the viral vector in subsequent daughter cells making repeated dosing necessary While repetitive dosing may be feasible, the adenoviruses in current use have evoked nonspecific inflammation and antivector immunity, both humoral and cellular [105,106]. This is the major drawback in the use of adenoviral vectors for gene therapy Adeno-associated virus (AAV) AAV has proven to be a versatile alternative to the adenovirus vectors described above [107,108]. AAV is a small single-stranded DNA virus belonging to the parvovirus family and is known to infect respiratory and gastrointestinal tracts [109]. It has the potential to be widely applicable to gene transfer strategies because it can infect many cell types, is nonpathogenic and naturally defective for replication. These viruses require coinfection with a helper adenovirus or herpesvirus in order to replicate or cause a lytic infection. In the absence of a helper virus, AAV infects a cell, integrating into the host cell genome where it remains in a latent form. The AAV genome is relatively small (4.7 kb) and consists of two genes, rep and cap, flanked by inverted terminal repeats (ITRs) which are necessary for replication and nucleocapsid formation, respectively Recombinant AAV is constructed by deleting the rep and cap genes, thereby making room for about 4.5 kb for the insertion of a foreign cDNA. Packaging is accomplished by cotransfection of adenovirus-infected cells with both the recombinant AAV and a packaging plasmid which contains only the rep and cap sequences. Only the genes flanked by the ITRs will be encapsidated. The resulting AAV particles are incapable of replication once inside the target cell, but are effective at infecting and expressing the introduced gene in a wide variety of dividing and nondividing cell types. The main advantages of the use of AAV are its nonpathogenic nature, its ability to be grown to high titers and the propensity for apparently harmless targeted integration into a region of human chromosome 19 [1101. It has been suggested, however, that although the wild-type AAV integrates into specific sites, the recombinant AAV appears to integrate into multiple random sites [1113, providing a higher risk of insertional mutagenesis than once thought. The major disadvantage of the use of AAV vectors is the fact that the amount of material that can be inserted is limited to approximately 4.5 kb. Despite the size limitations of this vector, it should be u s e l l for the transfer of genes encoding enzymes or receptors that are involved in metabolic disorders. There will be significant problems under
74 conditions where repetitive administration is required, since AAV, like other viral vectors, are highly immunogenic.
Herpesvirus Effective gene transfer vectors using DNA viruses have been derived from herpesviruses and include herpes simplex virus (HSV) and Epstein Barr virus [112- 1141. Herpes viruses naturally infect neurons and have therefore become attractive as vectors for gene therapy in the treatment of neurological disorders [115,116]. HSVs are double-stranded DNA viruses whose genome consists of about 150 kb of linear DNA [1 161. The genome consists of a long DNA strand of 126 kb and a short DNA strand of 26 kb, each segment containing unique sequences bounded by inverted repeat elements, which contain sequences needed for cutting and packaging the viral DNA into capsids. In total, the HSV genome contains about 70 genes, which are subgrouped according to the time and conditions of their expression during productive infection [117]. In general, early gene products participate in replication of the viral DNA, while late genes encode structural components of the virion, including proteins that act as trans-acting factors during infections to stimulate transcription of early genes. Although large, many of the genes in the HSV genome can be deleted without the virus losing its ability to propagate [1 181. HSV, therefore, can be extensively manipulated and the resulting recombinant virus can accommodate up to 30 kb of foreign DNA [119].These recombinant viruses are capable of infecting dividing and nondividing cells, particularly neurons, without the aid of helper viruses. More recently, the HSV vector has been modified to include enhanced endogenous expression of the herpes simplex thymidine kinase gene under the control of its viral promoter [120]. This viral enzyme is capable of phosphorylating the nucleoside analogue ganciclovir to toxic analogues which leads to inhibition of DNA synthesis and cell death. Triggering these suicide genes has been successll in the treatment of glioblastomas [121] and ovarian carcinomas [122]. The main advantages of herpes viral vectors as agents for gene transfer is that they can accommodate large amounts of foreign DNA that can be particularly targeted to cells of the central nervous system by direct local administration. Unfortunately, expression is dependent on the acute replication cycle of virus. Recently, however, long-term expression of the transgene has been achieved by incorporating the promoter of the viral gene latency-associated transcript (LAT) that remains active during the latent period of infection and thus remains in the neuron for life [123,124].The main disadvantages of the HSV vector systems concerns diniculty in manipulation of the large viral genome such that the gene of interest can be inserted and subsequently expressed. In addition, the risks associated with the use of these vectors have not been fully evaluated and it is not yet clear whether these vectors will efficiently infect other cell types. They do, however, have the potential for use in long-term expression in a limited number of cells in specific structures of the brain. Although the bulk of the studies have focused on transduction of neurons in the central nervous system, this gene ther-
75
apy approach could also be extended to treat many peripheral neuropathies. Although the specific gene delivery methods discussed here represent a spectrum of approaches as they exist today, additional strategies are continuously being considered in order to resolve the current gene transfer problems. It is said that our imagination is the only limiting factor toward finding the “perfect vector” for use in all gene therapy protocols. This vector may not be universal for all protocols, rather it may exhibit cell-type specificity and may perform differently under different circumstances. The development of specific and effective vector systems remains at the forefront of investigations involving gene therapy
Realities of gene therapy potentially, all tissues and every cell type in the body could be targets for correction by gene transfer. The efficiency of gene transfer, however, is known to differ from one cell type to another and depends on the properties of the cell type, including the potential to culture and manipulate them in vitro and the type of gene-transfer system used [79]. In many cases it may be desirable to remove a given cell type from the body, culture and correct it ex vivo and reintroduce it into the body where it can hnction to supply the required gene product. In other cases, it may be desirable to introduce the normal gene in vivo in a tissue-specific manner using a variety of delivery methods as outlined above. These methods range from simply injecting “naked DNA” into specific tissues to introducing a gene using highly specific recombinant viruses. The choice of gene transfer method and the tissue to be targeted is known to influence the ultimate fate of the transferred gene. It may follow a random or site-specific integration into the host genome, or the therapeutic gene could exist extrachromosomally or extranuclearly and will therefore not be passed on to daughter cells with high efficiency In some nondividing cell types this may not be a major concern if the transferred genes could be maintained as stable and hnctional elements. Any gene therapy program must therefore consider specific properties of the tissue and cell type to be treated. This will not only determine whether the approach taken should be in vivo or ex vivo, but it will also determine whether the method used should be viral or nonviral, and eventually whether the gene will be integrated or not into the host genome. Given the involvement of different cell types in a number of diseases, most of the gene-transfer efforts to date have focused on the correction of hematopoietic stem cells, T cells, respiratory epithelium, muscles, liver and a variety of tumour types. The discussion of gene therapy methods currently in use or under development will be undertaken in the context of a suitable cell or tissue type to be corrected or treated using examples of specific human diseases. Over the past 20 years, the promising concept of gene therapy has become a reality Although the concept is simple, it is based on sophisticated molecular technology that is only now reaching a development stage that allows safe usage in human subjects [91]. Before gene therapy can be considered as a treatment
76 option, several criteria must be met. If DNA is considered to be a drug, then the first and foremost criterion that must satisfied is the safety issue surrounding its use. There must be minimal, if any, health risks or side effects resulting from treatment using a gene therapy approach. Equally as important, it must be shown that correcting a genetic defect, usually in preclinical animal models, will result in significant therapeutic benefit. Once the potential for therapy has been confirmed, the DNA drug may enter into a phase I or phase 1/11clinical trial where toxicity and efficacy are extensively investigated in humans. In order to l l l y understand the impact that this therapeutic approach will have on disease management, it is necessary to have a complete understanding of the biochemistry and cell biology of normal functioning genes in addition to the molecular pathophysiology of the disease to be treated. Gene therapy for the treatment of many disorders, including inherited (e.g., CF) and infectious disorders (e.g., AIDS), has now resulted in clinical benefit. There are over 100 clinical trials currently under way using a variety of gene therapy strategies [125] and these have been summarized in Table 2. Therapeutic strategies include the treatment of 1) inherited monogenic disorders, 2) complex multifactorial diseases such as cancer, and 3) infectious diseases such as AIDS. Although not currently used for therapeutic gain, marking studies have also been included in Table 2 since a substantial number of clinical protocols are being evaluated for their potential use in the future. The approach taken for the treatment of a particular disease is largely dependent on the target tissue and the specific cell type which needs to be genetically modified by the gene drug. In the following section, we evaluate the treatment, or potential treatment, of specific human diseases using a gene therapeutic approach, focusing on methods which are currently being used and the specific tissues and/or cell types that are being targeted. Our aim is to provide examples of current gene therapy strategies with lessons about how modifications in the current strategies could result in improved disease management in the future. Single gene diseases Severe combined immunodeficiency disease (SCID) Severe combined immunodeficiency is associated with the inherited deficiency of adenosine deaminase (ADA) [126]. This enzyme is involved in the purine salvage pathway of nucleic acid degradation and is essential for the complete development and functioning of the immune system [127]. Absence of ADA leads to accumulation of one of its substrates, deoxyadenosine, which is preferentially converted to deoxyadenosine triphosphate in T lymphocytes. This compound, which is cytotoxic to lymphocytes, results in a disabled immune system [128- 1301 leading to SCID. Untreated, affected individuals usually die from frequent, persistent viral and fungal infections, repeated bacterial infections and cancer at an early age. An additional feature of this disease are the skeletal abnormalities, including cupping and flaring of the costochondral junctions and growth delay A less severe form of SCID, resulting in late-onset immuno-
77 able 2. Summary of the RAC-approved clinical protocols (modified from [1251).
category
Therapeutic gene
Inherited single diseases - gene 1. Severe combined immunodeficiency disease 2. Cystic fibrosis 3. Gaucher disease 4. Familial hypercholesterolemia 5. Emphysema 6. Fanconi's anemia 7. Chronic granulomatous disease 8. Hunter Syndrome
Adenosine deaminase CRR Glucocerebrosidase LDL receptor u-1-antitrypsin FACC Cytochrome B (f!) Iduronate-2-sulphatase
lbtd
Complex multifactorial diseases 1. Cancer A. antisense B. chemoprotection C. immunotherapy (ex vivo) D. immunotherapy (in vivo) E. prodrug F. tumour suppressors 2. Peripheral artery disease 3. Rheumatoid arthritis
AIDS Marking studies
A11 studies (as of Dec. 1995)
1 11 3 1 1 1 1 1 20
Example K-ras, IGF-1 MDR-1 IL-2 HLA-B7 HSV-TK P53 VEGF IL-1
lbd Infectious diseases
Number of protocols
2 4
23 7 11 4
1 1 53
Example revM 10, Hy-TK, anti-5'-UTS ribozyme, HIV IIIB env/rev Neomycin
8 25 106
deficiency has also been described and affects a minority of patients [1311. The treatment of choice for children with SCID due to an ADA deficiency is allogeneic bone marrow transplantation (BMT). Obviously, this can only be achieved when an identical HLA-matched sibling bone marrow donor is available [132,133]. Unfortunately, the availability of such donors for children with SCID is only 25-30%. For these children, ADA enzyme-replacement therapy has proven to be an effective, yet costly, therapeutic alternative. Extracellular intravenous-administered ADA generates a diffusion gradient by which its substrate leaves the cell and is degraded in plasma or extracellular fluid [134]. Adagen, the ADA replacement currently used, was designed by covalently attaching polyethylene glycol (PEG) to purified bovine ADA [135]. Treatment with PEGADA is life-saving, with most patients experiencing weight gain and a decrease in opportunistic infections [1361.Weekly injections of PEG-ADA has resulted in
78 immune recovery in at least 35 children up to 6 years of age following the initiation of the treatment program [137]. Although an increase in peripheral T lymphocytes has been routinely observed in all patients, consistent immune responses to specific antigens has been observed in only a few patients. While this is a significant step forward, the major drawback is the need for continuous lifelong treatment with this modified enzyme in order to maintain a functional immune system. ADA-SCID is an attractive model for the development of gene therapy procedures based on correction of a single gene defect. The target tissue for the ADA gene is the easily accessible hematopoietic system. The observation that during allogeneic bone marrow transplantation the only donor cells that were active in eliciting functional immunity were the T lymphocytes raised the possibility that T cell-directed gene therapy may be a possible and useful treatment. Furthermore, since PEG-ADA treatment resulted in increased levels of T lymphocytes, it was thought that this would provide a source of T cells crucial to the implementation of the gene therapy protocol [138]. T cells were obtained from SCID patients, induced to proliferate in culture using interleukin 2, transduced with Moloney murine leukemia retrovirus vector containing the h11-length 1.5 kb cDNA for human ADA, culture-expanded and reinfused into the patient after 9-12 days. Current clinical trials have shown that the human ADA efficiently transduced ADA deficient T cells in two children resulting in normal amounts of ADA expression in their T cells for 4 years [136]. This rendered the T cells resistant to the toxicity and growth inhibition when challenged with deoxyadenosine [ 139,1401. In these studies, using retroviral-mediated gene transfer, the survival of reinfused ADA transduced peripheral blood T lymphocytes is prolonged in vivo, suggesting that these cells have a survival advantage over noncorrected ADA-deficient cells. It should be noted, however, that both children treated in this manner continue to receive the PEG-ADA enzyme-replacement therapy, although the dose required to sustain normal immune function has been substantially reduced [ 1361. It is therefore difficult to attribute the benefits observed solely to the gene therapy protocol. Despite these problems, the observations are consistent with the conclusion that ex vivo gene transfer of ADA to T lymphocytes and hematopoietic stem cells elicits biological responses which are relevant to the treatment of SCID. Moreover, these studies suggest that ex vivo modification of cells to be injected into patients can be a safe and effective addition to treatment for patients with this and perhaps other debilitating diseases. Ultimately, the genetic correction of SCID resulting from ADA deficiency would be achieved by insertion of the human ADA gene into hematopoietic progenitor cells that give rise to Tand B cells. If achieved, the affected individual should show normal immunity and a lifetime cure. Recent advances in isolation and in vitro growth of stem cells have allowed researchers to focus on the challenges of low transfection efficiencies and unstable expression with this cell population [138]. Stable expression of the introduced ADA gene into stem cells has been obtained by retroviral-mediated gene transfer and this vector is the one
79 of choice for entry into clinical trials [138,141]. It should be noted, however, that wen under optimal conditions, transfection efficiencies of less that 30% are typically obtained. Recently, investigations to determine whether human cord blood stem cells may be more efficiently transduced than those from bone marrow have been initiated with the view of using these cells as gene transfer targets in prenatally diagnosed ADA-deficient newborns [1421.
Cysticfibrosis CF is one of the most common autosomal recessive disorders that affects Caucasian populations with an incidence of about one in 2,000 live births [143].Though the monogenic nature of the disease has been known for over 40 years, the gene responsible was not cloned until 1989 [144]. A defect in the epithelial CAMPregulated chloride channel (Cystic Fibrosis Transmembrane conductance Regulator (CFTR)) causes a disorder of exocrine glands that affects both mucoussecreting and sweat glands throughout the body. Major clinical manifestations of this disease are limited to two sites, the airway epithelium and pancreatic excretory ducts. Obstruction of the pancreatic ducts leads to pancreatitis, pancreatic insufficiency, malabsorption and intestinal obstruction requiring affected individuals to rely on lifelong pancreatic supplements. Vicid airway secretions lead to the other serious manifestations of the disease, namely purulent mucus, recurrent infection and bronchiectasis. Most morbidity and virtually all mortality associated with CF results from progressive damage to the respiratory epithelium following chronic infection and inflammation (see [ 145- 1471 for reviews). The CF gene codes for the CFTR protein which is a glycosylated molecule composed of two membrane-spanning segments and intracytoplasmic regions including two nucleotide binding folds and one R domain [148,149]. Mutations in this gene lead to abnormal processing and trafkking of the mutant CFTR protein, and ultimately to dysfunctional apical membrane chloride conductance in epithelial cells [1501. Analysis of genotype/phenotype relationships of the 400 mutants described to date suggests that although there is an association between specific mutations in the CF gene and pancreatic function, there is no such obvious correlation for the severity of pulmonary disease [151]. This has led to the speculation that factors other than the nature of the CF gene mutation, such as the rate of CFTR-mediated chloride secretion in each organ as well as the anatomical and physiological characteristics of the affected organ (involving additional genes), may play an important role in the clinical phenotype [152]. The individual response to pulmonary pathogens, especially Pseudomonus, is another genetically determined factor that may determine severity of CF, complicating the overall understanding of the phenotype and treatment of the disease. Current treatment regimes for this disease are largely palliative and eventually ineffective. Because CF is an autosomal recessive disorder and the respiratory epithelium is accessible for topical treatment, this disease is also an attractive target for gene therapy The respiratory epithelial cell provides a well-defined target and the objective is to restore the CAMP-activated chloride channel in
80
these cells. In vitro studies have shown that intrcduction of a normal copy of the CFTR cDNA into CF epithelial cells using retroviral vectors restored the normal chloride transport function of these cells for up to 6 months [153,154]. Since the treatment of CF is not amenable to ex vivo manipulation [155], it was, therefore, necessary to develop in vivo methodologies that were capable of delivering the normal CFTR cDNA to epithelial cells of the airways of CF patients. Numerous gene transfer vectors have been evaluated in animals for the in vivo treatment of CF and include viral vectors (such as retroviruses, adenoviruses and AAVs [156]), liposomes [ 101,1571, and receptor-mediated gene transfer vectors [ 1581. By comparison, the adenoviral vectors have been the most effective in transducing lung epithelial cells in vitro [159,160] and in vivo [96,100,161] with CFTR cDNA. This is largely due to the fact that the these viral vectors naturally infect nonreplicating cells of the respiratory tract with high efficiency Moreover, adenoviruses are able to accommodate large inserts such as the CFTR cDNA (4.5 kb), with a suitable promoter to drive transcription. The first report from a clinical trial using a CF adenovirus vector for in vivo transduction of epithelial cells by Zabner et al. [161] showed that a single dose administered to the nasal epithelium of three CF patients corrected the CAMP-dependent chloride channel defect. Despite this initial success, immune response to the adenovirus vectors of the CFTR gene has resulted in a halt to the clinical trial, and, therefore, is a clearly identified limitation of this approach. Cationic liposome-DNA complexes have been adopted as an effective method of achieving gene transfer to epithelial cells in vitro and are now being developed and considered as the only viable approach for direct gene transfer to lungs in vivo [ 102,157,1621. Cationic liposome-DNA complexes can be administered to the lungs of transgenic mice with CF as an aerosol [163] or by direct tracheal instillation [1641. In either case, a CAMP-regulated chloride channel was restored to the upper airways of transgenic mice lacking the CFTR gene [164,165]. Despite differences in electrophysiological properties between murine and human airways, there are promising insights for the potential role of in vivo cationic liposome-mediated gene transfer for the treatment of CF in humans. Results from the first cationic liposome-based gene therapy clinical trial for CF show that it is possible to transfer and express recombinant CFTR in vivo in nasal epithelial cells using cationic liposome vectors [1661. Preliminary results from a phase I clinical trial show that significant changes in the basal potential difference and sodium and chloride transport were observed in all patients with no adverse side effects [167]. However, the long-term benefits have not yet been assessed. The main advantage of using cationic liposome-mediated gene transfer is its relatively low level of toxicity and reduced likelihood of evoking inflammatory or immune responses [1681. This makes repetitive administration possible, thus offering the probability of maintaining transferred gene expression above required threshold levels despite transient expression. Moreover, genes of unlimited size can be transferred using liposome-DNA complexes. Furthermore, it is thought that only a small portion of the target cells may need to be genetically
81 modified to achieve clinical benefit in the treatment of CF [loll. A better understanding of the mechanisms of cationic liposome-mediated gene transfer will undoubtedly help in developing a more effective lipid-mediated gene transfer vector with the potential for in vivo treatment of CF [169].
Gaucher disease Gaucher disease is the most common form of lysosomal storage disease and results from autosomal recessive inheritance of a lysosomal enzyme glucocerebrosidase deficiency [1701. This deficiency produces defective hydrolysis of glucocerebroside which accumulates in reticuloendothelial cells (tissue macrophages). Excessive quantities of glucocerebroside have been observed in many organs of patients with Gaucher disease, who often present with hepatosplenomegaly, anemia, pulmonary and kidney involvement as well as extensive CNS damage, neurologic deterioration and myoclonic seizures [1711. The current treatment regime is infbsion of biochemically modified enzyme into patients [172,1731. However, like ADA-replacement therapy, this is an expensive treatment option. Since glucocerebrosides accumulate in reticuloendothelial cells and the disease is caused by mutations in a single gene, the therapeutic target is well-defined. Ideally, treatment of this disease will focus on the hematopoietic stem and progenitor cells. Retroviral vectors have been used to transduce these cells ex vivo with the glucocerebrosidase cDNA with high efficiency [1741. Long-term bone marrow cultures and long-term culture initiating cells have been efficiently transduced and exhibit sustained mRNA expression and glucocerebrosidase enzyme production in their progeny cells. These preliminary studies suggest that this ex vivo approach can be used to treat patients with Gaucher disease causing physiologically relevant levels of glucocerebrosidase activity The NIH Recombinant DNA Advisory Committee has recently approved this approach for initiation of phase I clinical trials for this disease [175], although results from these trials are not yet available. Muscular dystrophy (MD) MDs make up a well-defined, yet heterogeneous, group of progressive, primary, genetically determined myopathies that are characterized by proximal muscle weakness and incapacitation that, in several cases, leads to death [176]. No effective treatment is available, although the progressive course of the disease can be slowed by administration of oral glucocorticoids [177]. Two of the dystrophies, Duchenne and Beckers, are inherited as X-linked traits and are caused by different mutations in a single gene. The cDNA, which has been cloned and sequenced [178] is 13.9 kb, contains 79 exons and codes for dystrophin. Dystrophin is a protein which makes up a membrane complex that links the normal muscle cytoskeleton to the basal lamina [179]. In Duchenne MD, the majority of gene mutations result in premature translational termination leading to severely reduced levels or absence of dystrophin. In contrast, most gene mutations in the
82
clinically more benign Beckers dystrophy lead to in-frame deleted transcripts that generate abnormal proteins which may possess some degree of normal function. It is now thought that new mutations in the dystrophin gene are very common, making up about one-third of Duchennes and Beckers MD cases [180]. Because of major advances in our understanding of the underlying defect, and cloning of the gene responsible for the disease phenotype, Duchenne MD is a prime candidate for gene-replacement therapy. There are, however, significant challenges associated with developing viable treatment strategies for testing in clinical trials. Since the full-length dystrophin gene is very large, only the cDNA can be considered for gene therapy However, even the cDNA which is 13.9 kb exceeds the capacity for adenoviruses. Furthermore, a suitable promoter, one which is small and exhibits tissue-specificity, has not yet been identified. Although a number of delivery systems have been evaluated using mouse as a model for this disease [7,181,182], there have been no significant levels of gene expression with any of these systems. As a result, no clinical trial is in place, and a number of problems still require solutions in animal studies before gene therapy for human muscle diseases such as Duchenne MD can be considered [183]. Recent success in the use of direct injection of plasmids into muscles has led to the suggestion that this simple and direct approach may be the most viable option for the management of MD. Phenylketonuria (PKU) PKU is an autosomal recessive disorder caused by a deficiency of hepatic phenylalanine hydroxylase (PAH). The PAH catalyzes the conversion of L -phenylalanine to tyrosine and is involved in the catabolism of phenylalanine to COz and water. Deficiencies of hepatic PAH activity result in accumulation of PAH and abnormal metabolites in the blood and other tissues, leading to severe, irreversible mental retardation [1841. The conventional approach for the treatment of PKU is the dietary restriction of phenylalanine, which significantly reduces serum phenylalanine levels and can largely reduce or prevent the mental impairment if initiated early in the neonatal period. Despite the success of this treatment strategy, the efficacy is frequently limited by poor compliance of adolescent patients, leading to premature termination of treatment. This invariably results in a decline in mental and neuropsychological hnction [1851. Early experiments demonstrated the potential for gene therapy for the treatment of PKU by showing that human PAH protein can be produced in PAHdeficient hepatic cells through the introduction of human PAH cDNA [186]. Since then, recombinant retroviruses [187,1881 and adenoviruses [1891 have been used to introduce PAH activity into PAH-deficient cells in vitro and in vivo. Although recombinant retroviruses can efficiently transduce PAH-deficient cells in vitro, they are limited in their use by their low transduction efficiency in vivo. Recombinant adenoviruses, on the other hand, have been shown to efficiently transduce mouse hepatocytes in vivo [1891. However, the therapeutic effect
83 was transient and readministration had no further effect, potentially a conse-
quence of acquired immune response to the initial viral injection. Furthermore,
high antiadenoviral antibody titers were observed in treated animals. Despite these caveats, these results demonstrate that PKU, and possibly other metabolic disorders caused by deficiencies of hepatic enzymes, can be completely corrected by somatic gene therapy when more persistent vector systems are developed.
Familial hypercholesterolemia (FH) FH is a well-characterized genetic disease caused by a defect in the gene coding for low-density lipoprotein (LDL) receptor, a cell surface molecule that binds LDL, the major cholesterol transport lipoprotein in human plasma [190]. FH is transmitted as an autosomal dominant trait and therefore has manifestations in heterozygotes as well as homozygotes.The LDL receptor is located on the surface of a variety of cell types, especially hepatocytes where it facilitates the removal of LDL from plasma by receptor-mediated endocytosis and delivers it to lysosomes which release the cholesterol for metabolic use [190]. An absence or functional deficiency of LDL receptors causes reduced LDL uptake resulting in high levels of serum cholesterol. FH homozygotes make up one in 1,000,000 of the general population and have severe hypercholesterolemia. These individuals have cutaneous xanthomas before 4 years of age and succumb to premature atherosclerosis, myocardial infarction and death before 20 years of age [191]. FH heterozygotes make up one in 500 of the general population and have 2-fold elevation of plasma cholesterol. Though the clinical manifestations are less severe than the homozygotes, individuals develop tendon xanthomas and coronary artery disease by their mid-30s. Traditional approaches to control hypercholesterolemia and premature coronary heart disease such as drug and surgical intervention are largely ineffective. The most significant correction of the metabolic processes by traditional medicine involves liver transplantation, aggressive plasmapheresis or LDL apheresis [192- 1941. Homozygous familial hypercholesterolemia is particularly suited for gene therapy [195], since it has high morbidity and is refractory to traditional treatments. The current gene therapy treatment for individuals with severe LDL deficiency is liver resection, ex vivo transfection of hepatocytes and reinfusion into the body [196]. Hepatocytes are harvested by partial hepatectomy and are grown in vitro, during which time they are transfected with the normal LDL receptor gene using retrovirus vector as the transfer agent. Hepatocytes, corrected for the defect are collected and autologously transplanted via the spleen from which they assimilate into the regenerating liver [197]. Results from the first human gene therapy clinical trial for hypercholesterolemia have shown a reduction in serum LDL cholesterol and in the ratio of LDL to HDL over 18 months [198,1991. This suggests that the gene-corrected hepatocytes are functioning in vivo to internalize and metabolize the LDL cholesterol appropriately at least 4 months after gene therapy
84 Like ADA deficiency, it is difficult to evaluate the effect of gene therapy in FH patients since additional therapies are simultaneously administered [79]. However, because there is a general correlation between the levels of serum cholesterol and the severity of the disease, any reduction is serum levels may be clinically beneficial. It is thought that transduction of only 15% of hepatocytes is required to fully reverse the disease [200]. For a full evaluation of this ex vivo approach, more data on the clinical response in these patients is required. Although these clinical trials are in their infancy, recent progress in the development of in vivo approaches for the treatment of FH using animal models may lead to more effective approaches for the treatment of this and other liver metabolic diseases in humans [201,202]. Alpha-1 -antitrypsin deficiency @AT) AAT is inherited as an autosomal codominant trait [203]. It is characterized by low serum levels of a-1-antitrypsin leading to the development of pulmonary emphysema and cirrhosis of the liver [204,205]. In normal individuals, AAT protects the lower respiratory tract from destruction by neutrophil elastase by inhibiting elastase activity [206]. As a result of mutations in the coding region of the AAT gene (G to A transition in the codon for a glutamate residue, [207]), hepatocytes cannot secrete sufficient amounts of AAT to protect the lungs while accumulation of mutant AAT in hepatocytes causes cirrhosis. The conventional treatment for AAT deficiency is to infuse human AAT protein derived from spent human plasma into the blood of affected patients [208,209]. It is not known whether such protein infusions effectively arrest further pulmonary degradation and deterioration of lung function. Furthermore, this treatment protocol is expensive and also carries the risks of transferring bloodborne infections. Another strategy to treat AAT deficiency is to use gene therapy to directly transfer the AAT cDNA to somatic cells of the affected individuals. This would provide a population of cells capable of synthesizing and secreting AAT into the circulatory system. The resulting protein would diffise into the alveolar space providing the necessary antielastase function. However, this form of therapy would only be effective against the pulmonary manifestations of the disease, and would not be effective against the hepatic disease resulting from excessive accumulation of the mutant protein in the liver [210]. The hepatocytes have therefore become the target cell for gene therapy with hAAT. A variety of approaches have been developed to target hepatocytes with hAAT cDNA and include ex vivo strategies with retrovirus vectors and in vivo strategies with liposomes and adenovirus vectors [211-2131. Although the potential for gene augmentation of AAT deficiency is substantial, inefficient delivery of the hAAT gene to hepatocytes in vivo and ex vivo is a rate-limiting factor for clinical application. It has been suggested that, unlike disorders such as familial hypercholesterolemia, AAT deficiency would require a substantial number of transfected hepatocytes in order to correct the disease phenotype [2141. Administration of receptor-mediated conjugates
85 intravenously are very practical, but currently require partial hepatectomy for efficient gene expression. The use of adenoviral vectors is the most encouraging approach to date. However, as indicated for other approaches that rely on adenoviral vectors, immune response to the virus limits repetitive dosing.
Fanconi’s anemia (FA) FA is a rare autosomal recessive disorder affecting approximately three in 1,000,000 live births [215]. Symptoms of this disease are pleomorphic and may include congenital malformations, abnormal skin pigmentation, renal anomalies, aplastic anemia, bone marrow failure and susceptibility to cancer. FA is commonly referred to as a cancer-prone chromosomal instability syndrome, since cultured cells from these patients exhibit increased chromosomal instability and hypersensitivity to cross-linking agents such as mitomycin C [216]. The most profound clinical hallmark of FA is the development of aplastic anemia, which results from bone marrow failure. Although the cause of bone marrow failure is unclear, the abnormal cellular characteristics in FA have been thought to be due to defects in DNA repair [217], response to oxygen [218], and cytokine production and response [219]. The extensive clinical and cellular heterogeneity of this disease has led to the investigation of genetic heterogeneity Complementation analysis using cell fusion hybrids revealed that mutations in at least four different genes can lead to this disorder (FA-A, B, C, and D) [220]. A cDNA encoding the FA complementation group C (FACC) polypeptide has been identified by cDNA complementation cloning [221]. FACC is thought to encode a novel protein that localizes to the cytoplasmic compartment of cells ruling out the role for the gene in DNA repair [222], although the function of this protein is not well-understood. Current treatment of FA involves bone marrow transplantation from HLAbone-matched donors. This treatment, however, is largely palliative and > 75% of affected patients have no suitable bone marrow available. Recent cloning of the FACC gene has made gene therapy a viable option for the treatment of FA in affected individuals. Gene replacement therapy for FA consists of insertion of the normal FA gene into hematopoietic stem cells to correct for the hnction of the defective gene. In this approach, bone marrow stem cells and lymphoid progenitor cells are collected from peripheral blood of FA patients and transduced ex vivo using a recombinant retrovirus- [223] or adenovirus-associated expression vector [224]. Preliminary studies have shown that genetically corrected cells, following transduction using the retroviral vector containing the wild-type coding sequence of FACC were normalized for their susceptibility to MMCinduced chromosomal breakage [223]. Recent animal experiments have demonstrated that transduction of FACC into hematopoietic stem cells transplanted to bone marrow and spleens of nonmyeloablated BALB/c mice has no direct haimll effects to the hematopoietic system [225]. This approach has recently been approved by the Recombinant DNA Advisory Committee for initiation of phase I clinical trials [175]. If this procedure is deemed successful for group C
86 patients, without unacceptable complications, it has the potential for the treatment of patients from other complementation groups, once the corresponding genes have been identified. Complex multifactorial diseases - cancer
Understanding the molecular events involved in the control of normal cellular growth has revealed a plethora of genetic and cellular alterations that lead to malignant transformation.The complexity and heterogeneity of these transformations is recognized by the clonal expansion of multiple genetic changes associated with tumour development. This complexity is not limited solely to multiple genetic heterogeneity but is also enhanced by influences of other factors including responses from the immune system as well as environmental interactions. Therefore, the gene alterations which lead to cancer are often much more complex than those which cause single gene hereditary diseases. For this reason, treatment strategies based on the use of gene therapy will be more challenging. It will be important to select a target tissue or cell type for gene therapy as well as selecting an approach that may involve turning off a gene that promotes proliferation, turning on a gene that stimulates programmed cell death or introducing a new gene that will result in a therapeutic response. Nonetheless, since many cancers have now been established as having a genetic basis and are now considered to be genetic diseases, gene therapy is being evaluated as a relevant treatment option. The potential for gene therapy in cancer treatment is well recognized and more than 50% of clinical gene transfer protocols currently in place involve treatment of cancer ([125,226],Table 2). As indicated above, due to the genetic heterogeneity associated with many tumours, it is often difficult to determine which cells or tissues should become the target for a gene therapy approach. The first approved clinical trial in gene transfer was not designed to be therapeutic, but was designed to track the fate of tumour-infiltrating lymphocytes (TILs) in response to tumour growth and development [227]. TILs are lymphoid cells that are isolated from solid tumours and are capable of naturally locating and killing tumour cells [228]. These cells can be expanded ex vivo by stimulation with the T cell hormone IL2 and when readministered to the patient are known to mediate tumour regression [229]. In order to distinguish the inhsed lymphocytes from other lymphocytes in the body, they were transduced ex vivo with a retroviral vector encoding the selected marker gene, neomycin phosphotransferase gene (neoR). Once inhsed into patients with malignant melanoma, these cells were evaluated for their in vivo distribution and survival. Genetically modified TILs could be detected for up to 64 days at the site of the tumour in some patients [227]. This laid the groundwork for many of the subsequent gene therapy experiments involving ex vivo manipulation of bone marrow or peripheral leukocytes. Numerous gene-marking trials have since been initiated and most have used retrovirus vectors for transfer of selective marker genes or genes that code for cytokines. The focus of these studies
87 addresses biological principles that are relevant for treating malignant disorders [79]. Therapeutic clinical trials are aimed at transferring into target cells within sites of cancer progression, expression cassettes which carry genes that will: 1) enhance immune responses to tumours, 2) alter the proliferation rate of cancer cells, or 3) sensitize a malignant population to a cytotoxic agent or radiation. The applicable delivery system used for cancer gene therapy protocols are as varied as the strategies. Most of the therapeutic trials for cancer involving enhanced immune responses consist of introducing one of several cytokine genes into either tumour cells, bone marrow cells or TILs. These genetically modified cells will produce the desired cytokine thereby enhancing immunity [230]. Once it was shown that gene-modified TILs could be safely given to patients, attempts to increase the effectiveness of the antitumour response were undertaken. A protocol was initiated in which the gene for tumour necrosis factor (TNF)was added to the vector in hope that localized secreted TNF would enhance immune recognition and destruction of tumour cells [231].This ex vivo protocol was problematic since it was shown that the bulk of administered TIL cells were trapped in the liver, spleen and lungs. This resulted in large amounts of ectopic TNF production and associated toxicity [86]. Augmenting the antigenicity of the tumour cells themselves was an alternate approach to improving immunotherapy A number of investigators have used this “tumour vaccine” approach and initiated clinical trials involving the transfer of cytokines with histocompatability genes into tumour cells. This resulted in stimulation of immune response and systemic tumour destruction [232-2351. The preclinical results obtained using this approach have been remarkable, where distant, genetically unmodified tumours regress following injection of identical tumour cells that have been transfected with an appropriate histocompatability gene. The clinical strategy [236], therefore, consists of regional transfer of a histocompatability gene, through direct injection of plasmid DNA-liposome complex in a cancerous lesion, with hopes that an immune response will effect a therapeutic response at distal sites. Another approach in cancer therapy is to specifically inhibit or block tumour cell proliferation. Much of the research consists of in vitro studies aimed at inhibiting the expression of oncogenes by the use of antisense oligonucleotides [237,238]. Genes that have been targeted include c-myc, c-myb, bcr-abZ, bcZz and fibroblast growth factor (see section: Novel advances - therapeutic oligonucleotides). The inhibition of expression of these genes is aimed at blocking the translation of mRNA into protein, although there are multiple levels that alteration of gene expression can occur. The use of this approach is still in its infancy and a considerable amount of research needs to be done before we can recognize the impact it may have on the treatment of cancer. One area of research in gene therapy of cancer that has gained an enormous amount of attention, is the modulation of the expression of the tumour suppressor gene p53. Mutations in the p53 gene are known to occur in > 50% of human tumours, including metastatic breast cancer [239], one of the leading causes of
death in women. The p53 gene product functions as a transcriptional activator of other genes, which inhibits the progression of the cell cycle from GI to S phase in normal cells. P53 protein levels are known to be elevated in response to DNA damage [240], leading to GI arrest, terminal differentiation or apoptosis [241,242]. Mutations in the p53 gene lead to loss of wild-type p53 protein hnction associated with disruption of the normal cell cycle resulting in tumour progression and uncontrolled cell growth [243]. Since this discovery, numerous studies have been launched to evaluate the role of exogenously supplied wildtype p53 gene in human tumour cells both in vitro and in vivo [244--2481. These studies have involved a number of treatment strategies including the use of adenovirus vectors [249], retroviral vectors [250], liposome-mediated transfection [2513 and ribozyme-mediated modification of p53 [252]. Although the function of p53 has been restored efficiently in tumour cells in vitro, it has been less successhl in vivo. This is largely due to problems of in vivo targeting of p53 expression vectors to the site of tumour progression. Other problems also exist, which are specific to the delivery method used and reflect the safety concerns associated with any method currently used for gene therapy Although the results evaluated to date suggest that restoration of p53 expression in aberrant cancer cells may be significant in the treatment of many human malignancies, many conceptual and technical problems must still be solved. The remaining treatment strategies involve augmenting the cytotoxicity of chemotherapeutic drugs and two examples of this approach are provided here. One approach uses retroviruses carrying the HSV thymidine kinase gene, otherwise known as a “suicide” gene [116]. Introduction of this gene directly into tumour cells and subsequent expression renders the cell susceptible to killing by the antiviral agent ganciclovir [120]. Brain tumours are amenable to this approach, since nondividing cells are refractory to retroviruses, whereas tumour cells, which are rapidly dividing are readily infected and the viral genome is integrated and expressed. Moreover, during the process of cell death directed by HSV-TK, toxic metabolites are generated that kill nearby unmodified tumour cells in what is termed a bystander effect [253].The cytotoxic effects are therefore not limited to cells that have undergone transfection. Phase I clinical trials have been initiated using this approach for the treatment of brain cancer [121], ovarian cancer [122] as well as AIDS [254], although a full evaluation of patients receiving these treatments has not been completed. Clearly, however, the use of suicide genes in the treatment of cancers is a promising and valuable approach. A second approach for augmenting cytotoxicity of chemotherapeutic drugs involves the manipulation of the drug sensitivity of cells via the multiple drug resistance gene (MDR-l), which confers resistance to certain chemotherapeutic agents. Conventional chemotherapy for the treatment of many cancers is limited by its toxicity to normal bone marrow cells. With this treatment strategy, the MDR-1 gene is inserted into the normal bone marrow progenitor cells in an ex vivo approach using retroviruses, which confers a protective effect for these cells against high doses of chemotherapy [255]. This strategy serves to increase the
89
number of patients who can potentially benefit from high-dose chemotherapy as well as increase the amount of chemotherapeutic agents administered to patients by protecting their hematopoietic system. Although clinical trials have been initiated for the use of this MDR-1 approach in the treatment of breast cancer [256], additional genes that bestow hematopoietic cells with selective resistance to chemotherapeutic agents and radiation are now being considered for future gene therapy applications. Infectious diseases: acquired immunodeficiencysyndrome (4 IDS) AIDS, described more than 12 years ago, is now a global health problem [257]. AIDS is caused by infection of the CD4+ lymphocytes by the immunodeficiency virus-1 (HIV-1). Like other members of the retroviral family, HIV-1 transcribes its RNA genome into DNA which randomly integrates into the chromosome of the host cell [258]. Once stably integrated, the provirus retains the potential for viral expression and production of viral progeny throughout the lifetime of the infected cell. Despite the progress in understanding the causative agent at the molecular level, the continuous and rapidly changing viral populations evolving within each patient make this disease difficult to manage and inevitably fatal. The most extensively studied therapeutic approach for controlling HIV infection is inhibition of reverse transcriptase, which results in cessation of replication of the retroviral genome. This approach, however, has limited efficacy due to the fact that it is only effective against new viral particles. Previously infected cells, in patients who are given this therapy, can continue to generate viral progeny and in turn continue to generate a multitude of escape mutants, propagating the disease. A diversity of gene transfer based approaches have been evaluated for the treatment of AIDS and at present two different strategies are being explored [259]. The first is an antiviral approach and is termed “intracellular immunization’’ [260]. It is designed to render cells resistant to viral replication and to limit the spread of virus in the infected individual. It involves the efficient and stable transfer of genetic elements that inhibit viral replication into those cells of a patient that are potential targets for viral infection. This should effect a reduction in the spread of virus in the body Intracellular immunization, perhaps more correctly termed intracellular interference or intracellular inhibition, can be divided into three treatment strategies: 1) those that are protein-based, 2) those that are RNA-based, and 3) those that are immunologically based. The protein-based strategy for inhibition of viral replication stems from research from McKnight and co-workers who demonstrated that cells stably expressing a truncated form of the HSV transactivator protein VP16 did not support the replication of wild-type HSV [261]. They suggested that this mutant protein interfered with the function of a cis-acting element by wild-type protein and thus viral replication. A similar strategy was devised to inhibit HIV replication and is achieved by the expression of altered HIV gene products that have a
90 transdominant (TD) mutant phenotype [262]. TD mutant proteins that have been identified, and that inhibit HIV replication, include those that are structural kug, env) as well as regulatory (tut, rev). The most extensively studied TD mutant is revMZ0, a mutant rev protein resulting from amino acid substitutions at positions 78 and 79, that acts as a TD inhibitor of wild-type rev [263]. Retroviral vector delivered revMZ0 to human T cells has shown that cells which were stably transfected with revMZ0 were resistant to viral infection. Transfection of primary human PBLs with revMZ0 vector also conferred resistance to HIV-1 [259]. The mutant gene that encodes for the revMZ0 protein is therefore an attractive candidate gene for use in hrther preclinical testing and perhaps clinical studies in the future. A second protein-based treatment strategy focuses on the host cell. Variants of CD4, which can bind and sequester virion progeny in the cell, can limit HIV replication by providing a binding site decoy for the virus. The CD4 molecule is a receptor on inducedhelper T cells and monocyte/macrophages which HIV-1 recognizes to establish infectivity [264]. It is known that expression of an exogenous recombinant secreted form of CD4 (sCD4) produced by genetically engineered cells can block HIV-1 replication in cultured T cells [265,266]. These cells act as cellular factories to secrete sCD4 into the medium where it binds to HIV virions. This approach, using genetically engineered cells to produce sCD4 that are subsequently administered to affected individuals, has been tested in a phase I clinical trial and high plasma levels of recombinant protein were achieved in patients with HIV-1 [259]. The infusion of recombinant cells into these patients, however, failed to show efficacy, and was thought to be due to marked resistance of primary clinical isolates to the neutralizing activity of this protein [267,268]. These studies demonstrate the problems that can still arise in the development of a promising strategy from the bench to use in the clinic. RNA-based strategies, unlike protein-based inhibitors, are more advantageous since they are less likely to be immunogenic, easier to express at high levels and exhibit higher levels of target specificity. RNA-based inhibitors include antisense RNA and ribozymes which use the specificity of Watson-Crick base pairing to interfere with gene expression. Antisense RNA has been used extensively to study gene expression in viral diseases (for review see [269]). More recently, Chatterjee et al. [270] have shown that an HIV-1 antisense construct, complementary to a 63 bp sequence in the LTR which includes the tat responsive element (TAR) and part of the polyadenylation signal, transduced into human T cells using recombinant AAV inhibited replication of the HIV-1. Although a significant reduction in virus production was observed, a nonspecific general antiviral effect could not be ruled out. More extensive analyses of the antisense RNA approach are needed to more accurately determine the effectiveness of this approach. An extension of the antisense approach involves the use of RNA decoys. This strategy sequesters viral nucleic acid binding regulatory proteins by overexpressing their cognate RNAs. The two key regulatory gene products that have become common targets are tat and rev which bind to nascent viral RNA sequences, termed TAR
91
and RRE, respectively. This is known to activate gene expression [271]. Expression of short RNAs corresponding to TAR and RRE sequences in cells transduced with an antisense retroviral vector will result in binding of the TAR and RRE targets. This, in turn, prevents these proteins from binding to their physiological targets and thereby inhibits HIV replication [272,273]. Although preliminary experiments show that RNA decoys are effective at inhibiting HIV replication, one caveat identified with this approach is that additional cellular factors that bind TAR and RRE were also sequestered. This phenomenon can be eliminated by designing decoys that correspond to more specific binding domains. Despite their potential, like TD mutants proteins, RNA decoys are effective only after viral integration and therefore cannot protect the cell from initial infection. Ribozymes are now on the forefront of research for use in RNA-based strategies to inhibit HIV replication. They have the advantage of being very specific and versatile, since they allow a wide range of targets to be selected. Furthermore (as noted in the section: Novel advances - therapeutic oligonucleotides), ribozymes are known to efficiently cleave RNA targets with high specificity Because of their catalytic properties, ribozymes can be effective at much lower concentrations and obviate the need for efficient expression systems that generate excess inhibitor RNA. The first ribozyme described, the hammerhead ribozyme (named for its secondary structure), has been effectively used as an anti-HIV agent [274]. Ribozymes have been designed to target gag [274], vif [275], integrase [276] and leader sequences [277], all reporting delays or reduction in viral expression. More recently,Yu et al. [278] have constructed a hairpin ribozyme which is designed to cleave HIV-1 RNA in the 5’ leader sequence and appears to be effective in blocking virus expression from pre-existing proviral DNA.This ribozyme has the potential to be a unique intervention for the treatment of HIV infection in that it can target the replication cycle during both early (prior to provirus integration) and late (subsequent to provirus integration) phases of viral infection. This ribozyme has now been approved for clinical gene therapy trial for the treatment of AIDS and awaits fbrther assessment. The third treatment strategy using a gene therapy approach for the management of HIV infection is an immunological one aimed at enhancing antiviral immunity by using genetically modified cells that express viral gene products. This approach attempts to mimic natural infections, where infective particles are presented to class I MHC molecules which are subsequently used to generate a CTL response. Warner et al. [279] attempted to express an HIV protein in vivo for prophylactic vaccination and modulation of the immune response of infected individuals. They used an MMLV-based retroviral vector to deliver a gene encoding HIV-IIIB gp160 to murine fibroblast cell lines. Mice immunized with transduced cells developed MHC-restricted, envelope-specificCTLs and were capable of eliminating established tumour cells expressing HIV- 1 envelope protein [259]. Transduction of autologous cells have recently yielded similar results in mice and nonhuman primates [280].Retroviral gene transfer of HIV-1 gp160 has now
92 advanced to a phase I clinical trial, however, the utility of these vaccines still remains unclear. An alternative method for generating CTL responses involves the direct injection of naked DNA into the muscle of experimental animals. AIDS is currently the only infectious disease for which gene therapy clinical trials have been approved. Application of gene therapy to the HIV problem will present many challenges, however, with the increasing understanding of the mechanisms of viral infection and their associated properties, research in this area will continue to escalate. Intracellular immunization as well as gene-based immunization strategies are both potentially important approaches for the treatment of AIDS, and the therapeutic benefit of these approaches awaits imminent clinical trials. Novel advances - therapeutic oligonucleotides
It has long been recognized that short nucleic sequences can effect gene transcription and translation and induce RNA cleavage [281-2841. The ability of oligonucleotides to suppress gene expression makes them excellent candidates for the treatment of conditions involving gene overexpression such as cancer [285-2871 and infectious disorders like hepatitis B or AIDS [274,288,289]. They also have the potential for treating dominant-negative disorders in which a mutant allele is capable of saturating the normal allele, yielding a negative phenotype. There are two general classes of oligonucleotides used in gene therapy, antisense oligonucleotides and ribozymes. Antisense oligonucleotides are short nucleic acid sequences complementary to DNA or mRNA. DNA containing a homopurine/homopyrimidine stretch can form a triple helix with an oligonucleotide complementary to the purine-rich strand using Hoogsteen bonds [281]. This triplex may act either to physically inhibit transcription [290] or act as a site for specific mutagenesis [291,292]. Since only a few oligonucleotide molecules are needed to affect a gene by binding to DNA, regulation of gene expression at this level is quite sensitive. Alternatively, in the case of oligonucleotides binding to mRNA, many copies are necessary such that translation is sufficiently inhibited. This may result from an inability of the message to be transported out of the nucleus, steric hindrance of translation, direct blockage of a target sequence, or cleavage by RNase H [283,293,294]. Duplexes formed between mRNA and an oligonucleotide may also result in directed mutagenesis (gene editing) [295,296], which would allow for correction of base changes at the level of mRNA. Oligonucleotides may also act as ribozymes. Ribozymes are metalloenzymes which consist of short RNAs and have the ability to catalytically cleave specific sites of other RNA molecules. Although divalent cations, such as M 2 + and Mn2+, are required for this process, no protein moiety is involved [297,298]. The hammerhead ribozyme has been studied extensively with the intent to utilize it in gene therapy protocols. This small ribozyme is about 35 nucleotides long, with the central region (stem 11) being conserved, and forming a “handle” for
93 the “hammer”.The termini (stems I and 111) form a complementary sequence to the target site of about 15 nucleotides. This target sequence requires a UH (where H is A, C or U) at the cleavage site, but the rest of the sequence can be designed specific to one mRNA. Because of their high specificity, it is possible to design ribozymes which will specifically cleave a mutant allele, leaving the normal allele intact. This provides an effective approach for treatment of dominant-negative disorders. Once an mRNA is cleaved, no protein will be produced, and the ribozymes will continue to catalyze cleavage reactions of new mRNAs as they are transcribed. Delivery of oligonucleotides The optimal delivery method for oligonucleotides is still under investigation. However, oligonucleotides can either be directly delivered to cells, or can be transcribed from a cell transiently or permanently transfected with an expression vector. A problem facing the use of oligonucleotides for gene therapy is the rapid degradation of nucleic acids by serum and intracellular nucleases. Two approaches have been used to correct this problem. First, transfection vectors that will transcribe an RNA oligonucleotide ideally allow a continuous production of the foreign RNA, making degradation not a problem. However (as indicated in the section: Gene delivery methods), understanding the regulation of foreign genes in mammalian systems is limited, and hrther research is necessary before this becomes a common clinical procedure. Second, it is preferable to use oligonucleotides (DNA and RNA) that are synthesized using modified nucleotides. The most common modifications are at the linking phosphate molecule; a sulfur (phosphorothioate) or methyl group (methylphosphonate) can be substituted for one of the nonbridging oxygen molecules. This protects the modified oligonucleotides from degradation, since they are not efficient substrates for nucleases. For example, duplex DNA made with two phosphorothioate nucleotide bases can be transfected into cells and has a transcription efficiency of 95% compared to normal phosphodiester DNA, yet has a much longer half-life in the presence of nucleases. In fact, phosphorothioate-modified oligonucleotides appear unaffected after incubation in unpurified serum and cellular nucleases after six days of incubation [299]. This increased resistance is also true of singlestranded oligonucleotides modified with phosphorothioates, especially selfstabilized ones [300]. The efficiency of uptake of oligonucleotides into cells has been enhanced by the use of synthetic delivery systems such as liposome encapsulation [301], cationic lipids [302], coupling the oligonucleotide to polylysine or lipofectin [303] and covalent linkage to cholesterol moieties [304]. Although the choice of method for oligonucleotide delivery is still in its infancy, it is important to point out that the potential for antisense technology to generate efficient clinical therapeutic results is enormous. It will, however, take a great deal of experimentation before this technology can fulfill its promise.
94
Potential gene therapy applicationsfor oligonucleotides
Besides the utility of oligonucleotides in treating disorders due to gene overexpression, they can also be used to treat dominant-negative disorders such as osteogenesis imperfecta [305].Osteogenesis imperfecta is a collagen disorder, in which an aberrant collagen polypeptide is produced and incorporated into a collagen trimer, processed normally and incorporated into a defective extracellular matrix. Gene therapy for this disorder does not rely on adding a “good” allele, but rather on neutralizing a “bad” allele. The use of antisense oligonucleotides, delivered through lipid-mediated transfection, resulted in 45% of control levels of mutant protein in fibroblast cells [305].Although this is not sufficient for complete correction of this disorder, it represents a significant start towards the treatment of osteogenesis imperfecta. Work is also being done to decrease high blood pressure in rats using antisense oligonucleotides against angiotensinogen, a regulator of blood pressure [306]. There is still a substantial amount of work to be completed before oligonucleotides are widely used for gene therapy, but there is a great deal of potential, and the obstacles are rapidly being overcome. It is now recognized that the mechanism of oligonucleotide entry may be receptor-mediated, and the proteins involved in such a process are currently being identified and characterized. Both antisense oligonucleotides and ribozymes will undoubtedly play an important role in the fiture of gene therapy Future directions Human gene therapy, as shown in this review, has tremendous potential for the treatment of many debilitating diseases including classical monogenic disorders, complex multifactorial diseases and infectious diseases. The idea of using genes as medicines is not new and has been around since the development of the recombinant DNA era. Over the past 5 years the field of gene therapy has grown logarithmically with more than 100 clinical trials now approved by the Recombinant DNA Advisory Committee at NIH. With the increase in the number of clinical trials, this young field is the subject of a significant amount of attention and scrutiny as it has been put on the forefront of molecular medicine. Although gene therapy is capable of generating biological responses that are relevant for the treatment of many diseases, this approach suffers from public criticism, which often involves the ethical concerns regarding the manipulation of the expression of human genes. In general, somatic cell gene therapy for the purpose of treating many diseases has been considered acceptable to many people, however, gene modification of the germ line is still largely unacceptable on ethical grounds. Furthermore, the use of this technology for things such as the enhancement of beauty, the enhancement of muscle mass and increase of life span remains a matter of debate concerning issues such as ethics, safety and economics. Despite the fact that there are a large number of clinical trials in progress with
95
some documented success, gene therapy still remains experimental. Criticism has been levied against some researchers who have prematurely rushed into clinical application of the technology, thereby raising false hope among the population of affected individuals. This, in turn, can jeopardize the public financial support upon which this medical research depends. It is important during the development of a gene therapy protocol that before we use genes as effective medicines that we understand some basic science including genetic recombination, replication, repair, gene transfer, intracellular trafficking and immune responses to transfected gene products. Among those listed, we must also consider the problems that arise when predicting clinical outcome from gene transfer studies using experimental animals to the results obtained in humans trials. Let us not forget, however, that the hallmark of phase I clinical trials is safety and that the primary goal of these early clinical studies is to guide events in the more specific efficacy evaluations that occur in phase I1 and phase I11 studies. We believe that understanding the more fundamental areas of gene transfer will enable researchers and clinicians to develop better clinical studies that more accurately treat the disease state using the appropriate gene therapy method targeted to the appropriate tissue or cell type in a specific organism. Although a variety of methodologies for gene delivery are now in existence, the difficulty in getting genes transferred efficiently to specific target cell@),where they can evoke a biological response, still remains an important problem for all gene therapists. Viral-based vectors have been the most efficient method for introducing genes in vitro, but have been subject to safety concerns in the clinic such as stimulating the immune system to attack and neutralize the therapeutic cells or more problematic, the induction of an immune response to the vector itself. The fhndamental need to develop the “perfect” vector has been a challenge with numerous investigations into both viral and nonviral approaches. Preliminary data from clinical trials suggests that all vectors need to be refined, but each gene therapy approach in use will likely be well-suited for the target for which they were designed. An ideal vector, therefore, will likely be different for different applications. The vector of the hture could be based on synthetic custom-designed vehicles into which specific targeting features could be included depending on the particular disease and target cell requirements. Moreover, these new vectors must be easy to purify in large quantities, and ultimately must be able to evoke the desired biological response. Most importantlx these vectors must adhere strictly to health guidelines, and demonstrate safety for the patient being treated with manageable and well-defined side effects. Lipid-based carriers and dendrimers have recently become the focus of much research which is laying down the foundation for understanding the hndamental mechanisms of gene transfer. Although this is not an easy task, designing an effective gene transfer vehicle and understanding the mechanism($ of transfer is hndamental to the progress in disease management and treatment using a gene therapy strategy Despite the inevitable implementation of gene therapy for the treatment of many diseases, we need to pay close attention to how the public is educated in order
to avoid raising false hopes. Scientists, clinicians, and scientific journalists alike have an obligation to accurately inform the public in education forums on the present status and the potential fbture of this therapeutic strategy The scope and potential impact of this technology on the fbture of gene therapy also raises a number of additional questions such as: who will pay for the services, who executes the service, and what happens if something goes wrong? While some of these issues can be considered regulatory, other issues will have a profound financial impact. This will, in turn, play a fbndamental role in determining the optimal place for gene therapy in the treatment of human diseases in the next century Acknowledgements
This review benefited from discussions with researchers from the laboratories at the British Columbia Cancer Agency, Molecular Medical Genetics Program, London Health Sciences Center, and the University of Western Ontario. In particular, the authors wish to thank Gwyn Bebb, Rebecca Ott, Nick Schisler and Jack Jung for their constructive criticism in the preparation of this manuscript. Financial support for this review was provided by grants from NSERC and the Canadian Genome Analysis and Technology Program. Dorothy Reimer is the recipient of a Medical Research Council postdoctoral fellowship. References 1. Capecchi MR. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 1980;22:479-488. 2. Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci 1980;77:7380-7384. 3. Brinster RL, Chen HY; Tmmbauer ME, Yagle MK, Palmiter RD. Factors affecting the eficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci 1985; 82~4438-4442. 4. Hansen E, Fernandes K, Goldspink G, Butterworth P, Umeda PK, Chang KC Strong expression of foreign genes following direct injection into fish muscle. FEBS Lett 1991;290:73-76. 5. Wolff JA, Williams P, Acsadi G, Jiao S, Jani A, Chong W. Conditions affecting direct gene transfer into rodent muscle in viva Biotechniques 1991;11:474-485. 6. Wolff JA, Malone RW, Williams P, Chong W, Ascadi G, Jani A, Felgner P.Direct gene transfer into mouse muscle in viva Science 1990;247:1465-1468.
7 . Davis HL, Demeneix BA, Quantin B, Coulombe Y, Whalen RG. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 1993;4: 733-740.
8. Manthorpe M, Cornefert-Jensen F, Hartikka J, Felgner J, Rundell A, Margalith M, Dwarki V. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum GeneTher 1993;4:419-431. 9. Jiao S, Williams P, Berg RK, Hodgeman BA, Liu L, Repetto G, Wolff JA. Direct gene transfer into nonhuman primate myofibers in viva Hum GeneTher 1992;3:21-33. 10. Ascadi G, Dickson G, Love D, Jani A, Gurusinghe A, Walsh FS, Wolff JA, Davies KE. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991;352:8 15-81 8. 11. Wolff JA, Dowty ME, Jiao S, Repetto G, Berg RK, Ludtke JJ, Williams P, Slatutterbak DB.
97
12. 13. 14. 15. 16. 17.
18. 19. 20. 21. 22. 23. 24. 25. 26.
27. 28. 29. 30. 31. 32. 33.
Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci 1992;103:1249- 1259. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A. Heterologous protection against influenza by injection of DNA encoding a Viral protein. Science 1993;259:1745-1749. Sikes M, O'Malley BW Jr, Finegold MJ, Ledley FD. In vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. Hum GeneTher 1994;5:837-844. Hickman MA, Malone RW, Lehmann K, SihTR, Knoell D, Szoka FC Jr, Walzem R, Carlson DM, Powell JS. Gene expression following direct injection of DNA into liver. Hum Gene Ther 1994;5:1477- 1483. Fraley R, PapahadjopoulosD. New generation liposomes:The engineeringof an efficient vehicle for intracellular delivery of nucleic acids. Trends Biochem Sci 1981;6:77-80. Straubinger RM, Papahadjopoulos D. Liposomes as carriers for intracellular delivery of nucleic acids. Meth Enzymol 1983;101:512-527. Felgner PL, GadekTR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci 1987;84:7413-7417. Pinnaduwage R, Schmitt L, Huang L. Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. Biochim Biophys Acta 1989;985:33-37. Gao XA, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991;179280-285. Zhou XH, Klibanov AL, Huang L. Lipophilic polylysines mediate efficient DNA transfections in mammalian cells. Biochim Biophys Acta 1991;1065:8-14. Farhood H, Bottega R, Epand RM, Huang L. Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. Biochim Biophys Acta 1992;1111:239-246. Barthel F, Remy JS, LoeEler JP, Behr JP. Gene transfer optimization with lipospermine-coated DNA. DNACell Biol 1993;12:553-560. Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: Characterization and mechanism of action. Biochim Biophys Acta 1994;1189:195-203. Smith JG, Walzem RL, German JB. Liposomes as agents of DNA transfer. Biochim Biophys Acta 1993;1154:327-340. Gould-Fogerite S, Mazurkiewicz JE, Raska K, Voelkerding K, Lehman JM, Mannino RJ. Chimerasome-mediatedgene transfer in vitro and in vivo. Gene 1989;84429-438. Liu D, Huang L, Moore MA, Anantharamaiah GM, Segrest JP. Interactions of serum proteins with small unilamellar liposomes composed of dioleoylphosphatidylethanolamine and oleic acid: high density lipoprotein, apolipoprotein A 1 and amphipathic peptides stabilize liposomes. Biochemistry 1990;29:3637-3643. Cullis PR, Hope MJ, Tilcock CP. Lipid polymorphism and the roles of lipids in membranes. Chem Phys Lipid 1986;40:127-144. Rose JK, Buonocore L, Whitt MA. A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. Biotechniques 1991;10:520-525. Stewart MJ, Plautz GE, Buono LD, Yang ZY, Xu L, Gao X, Huang L, Nabel EG, Nable GJ. Gene transfer in vivo with DNA-liposome complexes: Safety and acute toxicity in mice. Hum Gene Ther 1992;3:267-275. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitationinduced damage when complexed to cationic liposomes. J Pharm Sci 1996;85:427-433. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994;269:2550-2561. Legendre JY, Szoka FC Jr. Delivery of plasmid DNA into mammalian cell lines using pHsensitive liposomes: comparison with cationic liposomes. Pharmacol Res 1992;9:1235- 1242. Debs R, Pian M, Gaensler K, Clements J, Friend DS, Dobbs L. Prolonged transgene expression
98 in rodent lung cells. Am J Respir Cell Molec Biol 1992;7:406-413. 34. Nicolau C, Cudd A. Liposomes as carriers of DNA. Crit Rev Ther Drug Carrier Sys 1989;6: 239-271. 35. Farhood H, Gao X,Son K,Yang YY, Lazo JS, Huang L, Barsoum J, Bottega R, Epand RM. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann NY Acad Sci 1994;716:23-34. 36. Reimer DL, ZhangY, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of a hydrophobic complexes between cationic lipids and plasmids. Biochemistry 1995;34:12877- 12883. 37. Wong FMP, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 1996;35:5756-5763. 38. Zhang Y-P, Reimer DL, Zhang G, Lee PH, Bally MB. Self-assembling DNA-lipid particles for gene transfer. J Pharm Sci 1996;1 4190- 196. 39. Haensler J, Szoka FC Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993;4372-379. 40. Tomalia DA. Dendrimer molecules. Sci Am 1995;272:62-66. 41. Wu GX Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988;263: 14261-14264. 42. Zenke M, Steinlein P, Wagner E, Cotten M, Beug H, Birnstiel ML. Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoetic cells. Proc Natl Acad Sci 1990;87:3655-3659. 43. Wagner E, Cotten M, Foisner R, Bernsteil ML. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci 1991;88:4255-4259. 44. Wu GY, Wilson JM, Wu CH. Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in viva J Biol Chem 1989;264:16985--16987. 45. Chowdhury NR, Wu CH, Wu GY, Yerneni PC, Bommineni VR, Chowdhury JR.Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. Prolonged persistence in cytoplasmid vesicles after partial hepatectomy J Biol Chem 1993;268:1126511271. 46. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci 1994;91:4086-4090. 47. Michael SI, Curiel DT. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway Gene Ther 1994;1:223-232. 48. Huebers HA, Finch CA.The physiology of transferrin and transferrin receptors. Physiol Rev 1987;67:520-582. 49. Wagner E, Zenke M, Cotten M, Beug H, Birnsteil ML. 'Ifansferrin-polycation-conjugatesas carriers for DNA uptake into cells. Proc Natl Acad Sci 1990;87:3410-3414. 50. Harris CE, Agarwal S,Hu P, Wagner E, Curiel DT. Receptor-mediated gene transfer to airway epithelial cells in primary culture. Am J Respir Cell Molec Biol 1993;9:441-447. 51. Baatz JE, Bruno MD, Ciraolo PJ, Glasser SW, Stripp BR, Smyth KL,KorfhagenTR. Utilization of modified surfactant-associatedprotein B for delivery of DNA to airway cells in culture. Proc Natl Acad Sci 1994;91:2547-2551. 52. Trubetskoy VS, Torchilin VP, Kennel SJ, Huang L. Use of N-terminal modified poly(r.-1ysine)antibody conjugates as a carrier for targeted gene delivery in mouse lung endothelial cells. Bioconjug Chem 1992;3:323-327. 53. Rosenkrantz AA,Yachmenev W, Jans DA, Serebryakova NV, Marav'ev VI, Peters R, Sobolev AS. Receptor-mediated endocytosis and nuclear transport of a transfecting DNA construct. Exp Cell Res 1992;199:323-329. 54. Chen J, Gamou S,lkkayanagi A, Shimizu N. A novel gene delivery system using EGF receptormediated endocytosis. FEBS Lett 1994;338:167-169. 55. Barra RK, Wang-Johanning F, Wagner E, Garver RI, Curiel DT Receptor-mediated gene
99 delivery employing lectin-binding specificity Gene Ther 1994;1:255-260. 56. Seth F? Adenovirus dependent release of choline from plasma membrane vesicles at an acidic pH is mediated by the penton base protein. J Virol 1994;68:1204-1206. 57. Garoff H, Wilschut J, Liljestrom P, Wahyberg JM, Bron R, Suomalainen M, Smyth J, Salminen A, Barth BU, Zhao H. Assembly and entry mechanism of Simliki Forest Virus. Arch Virol 1994;9(S~ppl):329-338. 58. Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: adenovirus enhancement of receptormediated gene delivery and expression in primary hepatocytes. Proc Natl Acad Sci 1993;90: 2122-2126. 59. Gottschalk S, Cristiano RJ, Smith LC, Woo SLC Folate receptor-mediated DNA delivery into tumor cells: protosomal disruption results in enhanced gene expression. Gene Ther 1993;l: 185-191. 60. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curie1 DT, Birnsteil ML. Coupling of adenovirus to transferrin-polylysine-DNA complexes greatly enhances receptormediated gene delivery and expression of transfected genes. Proc Natl Acad Sci 1992;89: 6099-6103. 61. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL. Hepatic gene therapy: efficient gene deliver and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci 1993;90:11548-11552. 62. Wagner E, Plank C, Zatloukal K, Cotten M, Birnsteil ML. Influenzavirus hemagglutinin HA-2 N-terminal hsogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci 199289:79347938. 63. Furth PA, Shamay A,Wall RJ, Hennighausen L. Gene transfer into somatic tissues by jet injection. Anal Biochem 1992;20:365-368. 64. Davis HL, Michel ML, Mancini M, Schleef M,Whalen RG. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine 1994;12:1503- 1509. 65. Vahsing HL,Yankauckas MA, Sawdey M, Gromkowsky SH, Manthorpe M.Immunization with plasmid DNA using a pneumatic gun. J Immunol Meth 1994;175: 11-22. 66. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci 1990;87:9568-9572. 67. Cheng L, Ziegelhoffer PR,Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci 1993;90:4455-4459. 68. ThompsonTA, Gould MN, Burkholder JK,Yang NS. Transient promoter activity in primary rat mammary epithelial cells evaluated using particle bombardment gene transfer. In Vitro Cell Dev Biol 1993;29A165-170. 69. Burkholder JK, Decker J, Yang NS. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. J Immunol Meth 1993; 165:149-1 56. 70. Williams RS, Johnston SA,Reidy M, Devit MJ, Mclligot SG, Sanford JC. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci 1991;88:2726-2730. 71. Redly EB, Antognetti G, Weslowski JS Jr, Sakorafas F? The use of microcapsules for high density growth of human tumour infiltrating lymphocytes and other immune reactive T cells J Immuno1 Meth 1990;126:273-279. 72. Chang PL, Shen N, Westcott AJ. Delivery of recombinant gene products with microencapsulated cells in vivo. Hum GeneTher 1993;4:433-40. 73. Liu Hw,Ofosu FA, Chang PL. Expression of human factor IX by microencapsulatedrecombinant fibroblasts. Hum GeneTher 1993;4291-301. 74. Hughes M,Vassilakos A, Andrews DW, Hortelamo G, Belmont JW, Chang PL. Delivery of a
100 secretable adenosine deaminase through microcapsules - a novel approach to somatic gene therapy Hum GeneTher 1994;5:1445-1455. 75. al-Hendy A, Hortelano G, Tannenbaum GS, Chang PL. Correction of growth defect in dwarf mice with nonautologous microencapsulated myoblasts - an alternate approach to somatic gene therapy Hum GeneTher 1995;6:165-175. 76. Choppin PW, Scheid A. The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses. Rev Infect Dis 1980;240-61. 77. Kielian M, Jungerwirth S. Mechanisms of enveloped virus entry into cells. Molec Biol Med 1990;7:17-31. 78. Miller N, Vile R. Targeted vectors for gene therapy FASEB J 1995;9:190-199. 79. Baichwal VR, Sugden B. Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes. In: Kucherlapati R (ed) Gene Transfer. New York: Plenum Press, 1986;117. 80. Crystal R. Transfer of genes to human: Early lessons and obstacles to success. Science 1995;270: 404-410. 81. Miller AD. Retroviral vectors. Curr Top Micro Immunol 1992;158:1-24. 82. Bandyopadhyay PK, Temin HM. Expression of complete chicken thymidine kinase gene inserted in a retrovirus vector. Molec Cell Biol 1984;4:749-754. 83. Mann R, Baltimore D. Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs. J Virol1985;54401-407. 84. Page KA, Landau NR, Littman DR. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity J Virol 1990;64:5270-5276. 85. Shimada T, Fuji H, Mitsuya H, Nienhuis AW Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector. J Clin Invest 1991;88:1043-1047. 86. Buchschacher GL Jr, Panganiban AT. Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol 1992;66:2731-2739. 87. Anderson WE Human gene therapy Science 1992;256:808-813. 88. Miller AD. Human gene therapy comes of age. Nature 1992;357:455-460. 90. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989;7:980-990. 91. McLauchlin JR, Cornetta K, Eglitis MA, Anderson WE Retroviral-mediated gene transfer. Prog Nucl Acid Res 1990;38:91-135. 92. Mulligan RC. The basic science of gene therapy Science 1993;260:926-932. 93. Temin HM. Safety considerations in somatic gene therapy of human diseases with retroviral vectors. Hum Gene Ther 1990;1:1 1 1-123. 94. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Molec Cell Biol 1990;10:4239-4242. 95. Horwitz MS. Adenoviruses. In: Fields BN, Knipe DM (eds) FieldsVirology, 2nd edn. NewYork: Raven Press, 1990;1723-1740. 96. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988;6:616-629. 97.Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Devel 1993;3:499-503. 98. Ginsberg HS, Moldawar LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, Prince GP. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci 1991;88:1651-1655. 99. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-3 19. 100. Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol 1992;158:39-66. 101. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukaya-
101 ma M, Bargon J, Stier LE, Stratford-Perricaudet L. I n vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992;68:143- 155. 102.Yoshimura K, Rosenfeld MA, Nakamura H, Scherer EM, Pavirani A, Lecocq J-P, Crystal RG. Expression of the human cystic transmembrane conductance regulator gene in the mouse lung after in vivo intratracheal plasmid-mediated gene transfer. Nucl Acid Res 1992;20:3233-3240. 103. Welsh MJ. RAC Report 9212-036, 1995. 104. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Stratford-Perricaudet L, Perricaudet M. Adenovirus-mediatedtransfer of a recombinant a-1 antitrypsin gene to the lung epithelium in vivo. Science 1991;252:431-434. 105. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E l deleted adenoviruses for gene therapy Proc Natl Acad Sci 1994;91:44074411. 106.Yang Y, Li Q, Erte HCJ, Wilson JM. Cellular and humoral responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2OO42015. 107. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991;10:39413950. 108. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, Zeitlin PL, Guggino WB, Carter BJ. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci 1993;90:10613--10617. 109.Carter BJ. The growth cycle of adenoassociated virus. In: Tjissen P (ed) Handbook of Pawoviruses, vol 1. Boca Raton, Florida: CRC Press, 1990;155-168. 110. Samulski RJ. Adeno-associated virus: integration at a specific chromosomal locus. Curr Opin Genet Devel 1993;3:74-80. 111. Kearns W, Afione S, Cutting G. AAV-CFTR vectors integrate at multiple chromosomal sites in a CF bronchial epithelial cell line. Pediatr hlmonol 1993;9S:242. 112. Freese A, Geller AI, Neve R. HSV- 1 vector mediated neuronal gene delivery Strategies for molecular neuroscience and neurology Biochem Pharmacol 1990;40:2189-2199. 113. Fink DJ, Sternberg LR, Weber PC, Mata M, Goins WF, Glorioso JC. In vivo expression of betagalactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene "her 1992; 3~11-19. 114. Margolskee RF. Epstein-Barr virus based expression vectors. Curr Top Microbiol Immunol 1992;158:67-95. 115. Suhr ST,Gage FH. Gene therapy for neurologic disease. Neurol Rev 1993;50:1252-1268. 116. Breakefield XO, DeLuca NA. Herpes simplex virus for gene delivery to neurons. New Biol 1991;3:203-218. 117.Roizman B, Sears AE. Herpes viruses and their replication. In: Fields BN, Knipe DM (eds) Virology, 2nd edn. New York: Raven Press, 1990;1795- 1842. 118. Barker DE, Roizman B. Identification of three genes nonessential for growth in cell culture near the right terminus of the unique sequences of long component of herpes simplex virus I. J Virol 1990;177:684-691. 119.Longnecker R, Roizman B, Meignier B. Herpes simplex viruses as vectors: Properties of a prototype vaccine strain suitable for use as a vector. In: Gluzman Y, Hughes SH (eds) Viral Vectors. Cold Spring Harbor: Cold Spring Harbor Lab. Press, 1988;68. 120. Tiberghien P. Use of suicide genes in gene therapy J Leuk Biol1994;56:203-209. 121. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum GeneTher 1993;4:39-69. 122. Freeman SM, McCune C, Angel C, Abraham GN, Abboud CN. Treatment of ovarian cancer using HSV-TK gene modified vaccine - regulatory issues. Hum Gene Ther 1992;3:342-349. 123.Dobson AT, Margolis Tp,Sedarati F, Stevens JG, Feldman LT. A latent nonpathogenic HSV-1-
102 derived vector stably expresses f3-galactosidase in mouse neurons. Neuron 1990;5:353-360. 124. Wolfe JH, Deshmane SL, Fraser NW Herpesvirus vector gene transfer and expression of Bglucouronidase in the CNS of MPS VII mice. Nature Genet 1992;1:379-384. 125. Orkin SH, Motulsky AG. Report and recommendations of the panel to assess the NIH investment in research on gene therapy 1995;http:/ /wwwnih.gov/news/panelrep.html. 126. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972;2:1067- 1069. 127. Thompson LF, Seegmiller JE. Adenosine deaminase deficiency and severe combined immunodeficiency disease. In: Meister A (ed) Advances in Enzymology, vol 51. New York: Academic Press, l980;156-210. 128. Cohen A, Hirschhorn R, Horowitz SD, Rubinstein A, Polmar SH, Hong R, Martin DW Jr. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency Proc Natl Acad Sci 1978;75:472-476. 129. Hirschhorn R, Martiniuk F, Roegner-Maniscalco V, Ellenbogen A, Perignon JL, Jenkins T. Genetic heterogeneity in partial adenosine deaminase deficiency J Clin Invest 1983;71:18871892. 130. Akeson AL, Wiginton DA, Hutton JJ. Normal and mutant adenosine deaminase genes. J Cell Biochem 1989;39:217-228. 131. Santisteban I, Arredonto-Vega FX, Kelly S, Mary A, Fischer A, Hummell DS, Lawton A, Sorenson RU, Steihm ER, Uribe L. Novel splicing, missence and deletion mutations in seven adenosine deaminase deficient patients with late/delayed onset combined immunodeficiency disease. J Clin Invest 1993;922291-2302. 132. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hoder MZ, Good R4,O'Reilly RJ. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983;61:341-348. 133. OReilly RJ, Keever CA, Small TN,Brochstein J. The use of HLA non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease. Immunodef Rev 1989;1:273-309. 134. Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987;316:589-596. 135. Levy Y, Hershfield M, Fernandez-Mejia C, Polmar S, Scudiery D, Berger M, Sorensen RU. Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr 1988;113:312-3 17. 136. Blaese MR, Culver KW, Miller DA, Carter CS, Fleisher T, Clerici M,Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WE T lymphocyte-directed gene therapy for ADASCID: Initial trial results after 4 years. Science 1995;270:475-480. 137. Hershfield MS. The role of polyethylene glycol adenosine deaminase in the evolution of therapy for adenosine deaminase deficiency In: Gupta S, Griscelli C (eds) New Concepts in Immunodeficiency Diseases. Chichester: Wiley, 1993;417-426. 138. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P, Ugazio AG, Mavilio F. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 1995;270:470474. 139.Kohn DB, Anderson WF, Blease RM. Gene therapy for genetic diseases. Cancer Invest 1989;7:179-192. 140. Kohn DB, Mitsuya A, Ballow M, Selegue JE, Barankiewicz J, Cohen A, Gelfand E, Anderson WF, Blaese RM. Establishment and characterization of adenosine deaminase deficient human T cells. J Immunol 1989;142:3971-3979. 141. Kaptein LCM, Einerhand MPW, Braakman E,Valerio D, von BeusechemVW Bone marrow
103 gene therapy for adenosine deaminase deficiency. Immunodeficiency 1993;4:335-345. 142. Moritz T, Keller DC, Williams DA. Human cord blood cells as targets for gene transfer: Potential use in genetic therapies of severe combined immunodeficiency disease. J Exp Med 1993;178:529-536. 143. Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS,Valle D (eds) The Metabolic Basis of Inherited Disease. New York: McGraw Hill, 1989;2649-2680. 144. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N. Identification of cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065. 145. Riordan JR. The cystic fibrosis transmembrane conductance regulator. Ann Rev Physiol 1993; 55:609-630. 146. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dyshnction in cystic fibrosis. Cell 1993;73:1251-1254. 147. Colledge WH, Evans MJ. Cystic fibrosis gene therapy. Br Med Bull 1995;51:82-90. 148. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Gnelczak Z, Zielenski J, Lok S, Plavsic N, Chou J-L, Drumm ML, Iannuzzi MC, Collins FS, Tsui L-C. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245: 1066- 1073. 149. Gregory RJ, Cheng SH, Rich DP, Marshall J, Paul S, Hehir K, Ostedgaard L, Klinger KW, Welsh MJ, Smith AE. Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature 1990;347:382-386. 150. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990;63:827-834. 151. Dean M, Santis G. Heterogeneity in the severity of cystic fibrosis and the role of CFTR gene mutations. Hum Genet 1994;93:364-368. 152. Tizzano EF, Buchwald M.CFTR expression and organ damage in cystic fibrosis. Ann Int Med 1995;123:305-308. 153. Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S,Jefferson DM, Smith AE, McCann JD, Klinger KW, Smith AE, Welsh MJ. Expression of the cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990;347:358-363. 154. Olsen JC, Johnson LG, Stutts MJ, Sarkadi B, Vankaskas JR, Swanstrum R, Boucher RC. Correction of the apical membrane chloride permeability defect in polarized cystic fibrosis airway epithelia following retroviral-mediatedgene transfer. Hum Gene Ther 1992;3:253-266. 155. Weibel ER. Design of airways and blood vessels considered as b k c h i n g trees. In: Crystal RG, West JB (eds) The Lung Scientific Foundations. The Lung Scientific Foundation. New York: Raven Press, 1991;711-720. 156. Mastrangeli A, Dane1 C, Rosenfeld MA, Stratford-Perricaudet L, Perricaudet M, Paviriani A, Lecocq JP, Crystal RG. Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. J Clin Invest 1993;91:225-234. 157. McLachlin G, Davidson DJ, Stevenson BJ, Dickinson P, Davidson-Smith H, Dorin JR, Porteous DJ. Evaluation in vifro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy. Gene Ther 1995;2:614-622. 158.Curiel DT, Agarwal S, Romer MU, Wagner E, Cotten M, Birnstiel ML, Boucher RC. Gene transfer to respiratory epithelial cells via the receptor-mediated endocytosis pathway. Am J Resp Cell Molec Biol 1992;6:247-252. 159. Rich DP, Couture LA, Cardoza LM, Guiggio VM, Amentano D, Espino PC,Hehir K, Welsh MJ, Smith AE, Gregory RJ. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther 1993;4461-476. 160. FlotteTR, Solow R, Owens RA, Afione S,Zeitlin PL, Carter BJ. Gene expression from adenoassociated virus vectors in airway epithelial cells. Am J Respir Cell Molec Biol 1992;7:349-356.
104 161. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE,Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993;75:207-216. 162. Brigham KL, Meyrick B, Christman B, Magnuson M, King G, Berry LC Jr. In vivo transfection of murine lung with a hnctioning prokaryotic gene using a liposome vehicle. Am J Med Sci 1989;298:278-281. 163. Stribling R, Brunette E, Liggitt D, Gaensler K, Debs R. Aerosol gene delivery in vivo. Proc Natl Acad Sci 1992;89:11277-11281. 164. Alton EW, Middleton PG, Caplen NJ, Smith SN, Steel DM, Munkonge FM, Jeffrey PK, Geddes DM, Hart SL, Williamson R. Non-invasive liposome mediated gene delivery can correct the ion transport defect in the cystic fibrosis mutant mice. Nature Genet 1993;5:135-142. 165. Hyde SC, Gill DR, Higgins CETrezise AE, MacVinish LJ, Cuthbert AW, Ratcliff R, Evans MJ, Colledge WH. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy Nature 1993;362:250-255. 166. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X,Durham SR, Jeffrey PK, Hodson ME, Coutelle C. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med 1995;1:39-46. 167. Middleton PG, Caplen NJ, Gao X, Huang L, Dorin JR, Porteous DJ, Williamson R, Geddes DM, Alton EWW. The electrophysiological effects of in vivo liposome mediated CFTR delivery to the nasal epithelium. Pediatr Pulmonol 1994;(Suppl10):229-230. 168. Farhood H, Gao X,Son K,Yang W, Lazo JS, Huang L, Barsoum J, Bottega R,Epand RM. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann NY Acad Sci 1994;716:23-35. 169. Meyer KB, Thompson MM, Levy MY, Barron LG, Szoka FC Jr. Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics. Gene Ther 1995;2:450-460. 170. Frenkel EP. Gaucher disease; a heterogeneous clinical complex for which effective enzyme replacement has come of age. Am J Med Sci 1993;305:331-344. 171. Brady RO, Barton NW, Grabowski GA. The role of neurogenetics in Gaucher disease. Arch N e w 1 1993;50:1212- 1224. 172. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidasein a patient with Gaucher disease. Proc Natl Acad Sci 1990;87:1913-1916. 173. Beutler E, Kay A, Saven A, Garver P, Thurston D, Dawson A, Rosenbloom B. Enzyme replacement therapy for Gaucher disease. Blood 1991;78:1183-1189. 174. Xu L, Stahl SK, Dave HP, Schiffmann R, Correll PH, Kessler S, Karlsson S.Correction of the enzyme deficiency in hematopoetic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol. Exp Hematol 1994;22:223-230. 175. Kerr WG, Mule JJ. Gene therapy: current status and hture prospects. J Leuk Biol 1994;56: 211-214. 176. Emery AEH. Duchenne Muscular Dystrophy, 2nd edn. New York: University Press, 1988;l317. 177. Griggs CR, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Rstronk A. Prednisone in Duchenne dystrophy A randomized controlled trial defining the time course and dose response. Arch Neurol 1991;48:383-388. 178. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the DMD cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-517. 179. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nature Genet 1993; 3:283-291. 180. Oldfors A, Eriksson BO, Kyllerman M, Martinsson R, Wahlstrom J. Dilated cardiomyopathy and the dystrophin gene. Br Heart J 1994;72:344-348.
105 181. Quantin B, Perricaudet LD, Tajbakakhsh S, Mandel JL. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci 1990;87:439-443. 182. Ragot T, Vincent N, Chafey V, Vigne E, Gildenkrantz H, Couton D, Cartaud J, Briand P, Kaplan J-C, Perricaudet M, Kahn A. Efficient adenovirus-mediated transfer of human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993;361:647-650. 183. Karpati G, Acsadi G. The principles of gene therapy in Duchenne Muscular Dystrophy. Clin Invest Med 1994;17:499-509. 184. Scriver CR, Kaufman S,Woo SLC. The hyperphenylalaninemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic Basis of Inherited Disease, vol 1, 6th edn. New York: McGraw Hill, 1989;495-534. 185. Smith I, Lobascher ME, Stevenson JR,Woolf OH, Schmidt H, Grubel-Kaiser S,Bickel H. Effect of stopping low-phenylalaninediet on intellectual progress of children with phenylketonuria. Br Med J 1978;2:723-726. 186. Ledley FD, Grenett HE, DiLella AG, Kwok SCM, Woo SLC. Gene transfer and expression of human phenylalanine hydroxylase. Science 1985;228:77-79. 187. Peng H, Armentano D, Mackenzie-Graham L, Shen R-F, Darlington G, Ledley FD, Woo SL. Retroviral-mediated gene transfer and expression of human phenylalanine hydroxylase in primary mouse hepatocytes. Proc Natl Acad Sci 1988;85:8146-8150. 188. LiuT-J, Kay MA, Darlington GJ, Woo SLC. Reconstitution ofenzymatic activity in hepatocytes of phenylalanine hydroxylase-deficientmice. Somat Cell Molec Genet 1992;18239-96. 189. Fang B, Eisensmith RC, Li XHC, Finegold MJ, Shedlovsky A, Dove W, Woo SLC. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther 1994;1:247-254. 190. Brown MS,Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-37. 191. Goldstein JL, Brown MS. Familial hypercholesterolemia. Lipoprotein and lipid metabolism disorders. In: Scriver CR, Beaudet At, Sly WS,Valle D (eds) Metabolic Basis of Inherited Disease, 6th edn. New York: McGraw Hill, 1989;1215-1250. 192.Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE. Liver transplantation to provide low density lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia.N Engl J Med 1984;311:1658- 1664. 193.Thompson GR, Barbir M, Okabayshi K, Trayner I, Larkin S. Plasmapharesis in familial hypercholesterolemia.Arteriosclerosis 1989;9(Suppl):I152-1157. 194. Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM Jr, Illingworth DR, Jones PH, Leitman SF, Prihoda JS. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose absorption system. Am J Cardiol 1992;70:1010-1016. 195. Weatherall D. Heroic gene therapy. Nature Genet 1994;6:325-326. 196. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, Wilson JM. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nature Genet 1994;6:335-341. 197. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR, Wilson JM. Long term improvement of hypercholesterolemia after ex vivo therapy in LDLR-deficient rabbits. Science 1991;254:1802- 1805. 198. Grossman M, Rader DJ, Muller DWM, Kolansky DM, Kozarsky K, Clark BJ 111, Stein EA, Lupien PJ, Brewer HB, Raper SE,Wilson JM. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nature Med 1995;l:1148- 1154. 199. Raper SE, Grossman M, Rader DJ, Thoene JG, Clark BJ 111, Kolansky DM, Muller DW, Wilson JM. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia.Ann Surg 1996;223:116-126. 200. Wilson MA. Medical news and perspectives. J Am Med Assoc 1993;269;837-838. 201. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia
106 in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92:883-893. 202. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994;269:13695--13702. 203. Fagerhol MK, Laurel1 C-B. The Pi system-inherited variants of serum a1 antitrypsin. In: Steinberg AG, Bearn AG (eds) Progress in Medical Genetics, vol3. New York: Grune and Stratton, 197Q96-111. 204. Crystal RG. The al-antitrypsin gene and its deficiency states. Trends Genet 1989;5:411-417. 205. Crystal RG. a 1-antitrypsin deficiency, emphysema and liver disease: genetic basis and strategies for therapy J Clin Invest 1990;85:1343-1352. 206. Brantly M, Nukiwa T, Crystal RG. Molecular basis of al-antitrypsin deficiency. Am J Med 1988;84:13-3 1. 207. Kidd VJ, Wallace RB, Itakura K, Woo SLC. al-antitrypsin deficiency detection by direct analysis of the mutation in the gene. Nature 1983;304230-234. 208. Hubbard RC, Sellers D, Czerski L,Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for al-antitrypsin deficiency J Am Med Assoc 1988;260: 1259-1264. 209. Kay MA, Ponder Kp,Woo SLC Human gene therapy: present and future. Breast Cancer Res Treat 1992;21:83-93. 210. Carlson J, Rogers BB, Sifers RN, Finegold MJ, Clift SM, DeMayo FJ, Bullick DW, Woo SLC The accumulation of Piz crl-antitrypsin causes liver damage in transgenic mice. J Clin Invest 1989;83:1183-1190. 21 1. Jaffe HA, Dane1 C, Longenecker G, Metzger M, Setoguchi Y; Rosenfeld MA, Gant W , Thorgeirsson SS, Stratford-Perricaudet LS,Perricaudet M, Pavirani A, Lecocq J-P, Crystal RG. Adenoviral-mediated in vivo gene transfer and expression in normal rat liver. Nature Genet 1992;1:368-371. 212. Kay MA, Baley P, Rothenberg S, Leland F, Fleming L, Ponder KP, Liu T-J, Finegold M, Darlington G, Pokorny W, Woo SLC Expression of human u-1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci 199&89:8993. 213. Alino SF, Bobadilla M, Garcia-Sanz M, Lejarreta M, Unda F, Hilario E. I n vivo delivery of human alpha-1-antitrypsin gene to mouse hepatocytes by liposomes. Biochem Biophys Res Commun 1993;192:174-181. 214. Knoell DL, Wewers MD. Clinical implications of gene therapy for alpha-1-antitrypsin deficiency Chest 1995;107:535-545. 215. Joenje H, Mathew C, Gluckman E. Fanconi anemia research: current status and prospects. Eur J Cancer 1995;31A:268-272. 216. Cervenka J, Arthur D, Yasis C. Mitomycin C test for diagnostic differentiation of idiopathic aplastic anemia and Fanconi anemia. Pediatrics 1981;67:119-127. 217. Hoeijmakers JHJ, Bootsma D. DNA Repair - 2 pieces of the puzzle. Nature Genet 1992;l: 313-314. 218. Joenje H, Gille JJP. Oxygen metabolism and chromosomal breakage in Fanconi anemia. In: Schroeder R, Obe G, Auerbach AD (eds) Clinical, Cytogenetic and Experimental Aspects of Fanconi Anemia. Berlin: SpringerVerlag, 1989;174-1 82. 219. Roselli F, Sanceau J, Gluckman E,Wietzerbin J, Moustacchi E. Abnormal lymphokine production - a novel feature of the genetic disease Fanconi anemia. 11. Spontaneous overproduction of tumor necrosis factor alpha. A possible tool in detecting heterozygous individuals. Blood 1994;83:1216- 1225. 220. Joenje H, LoTen Foe JR, Arwert F, ten Kate LP. Complementation testing and genetic classification of Fanconi's anemia. Lancet 1994;343:862. 221. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anemia
107 by functional complementation.Nature 1992;356:763-767. 222. Auerbach AD. Fanconi anemia. Dermatol Clin 1995;13:41-49. 223. Walsh CE, Grompe M,Vanin E, Buchwald M, Young NS, Nienhuis AW, Lui JM. A hnctionally active retrovirus vector for gene therapy in Fanconi anemia group C. Blood 1994;84453-459. 224. Walsh CE, Nienhuis AW, Samulski RJ, Brown MG, Miller JL,Young NS, Liu JM. Phenotypic correction of Fanconi anemia in human hematopoetic cells with a recombinant adenoassociated virus vector. J Clin Invest 1994b941440-1448. 225. Liu JM, Kim S, Walsh CE. Retroviral-mediated transduction of the Fanconi anemia C complementing (FACC) gene in two murine transplantation models. Blood Cell Molec Dis 1995; 2156-63. 226. Marshall E. Gene therapy’s growing pains. Science 1995;269:1050-1055. 227. Rosenberg SA, Aeversold PM, Cornetta K, Kasid A, Morgan RA,Moen R, Karson EM, Lotze MT, Yang HC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WE Gene transfer into humans - immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323:570-578. 228. Kradin RL, Kurnick JT, Lazarus DS, Preffer RI, Dubinett SM, Pinto C, Gifford J, Davidson E, Grove B, Callahan RJ, Strauss HW. n m o r infiltrating lymphocytes and interleukin-2 in the treatment of advanced cancer. Lancet 1989;1:577-580. 229. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10:180199. 230. Tepper R, Mule JJ. Experimental and clinical studies of cytokine gene modified tumor cells. Hum GeneTher 1994;5:153-164. 231. Hwu P, Yannelli J, Kriegler M, Anderson WF, Perez C, Chiang Y, Schwartz S, Cowherd R, Delgad0 C, Mule J, Rosenberg SA. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancers in humans. J Immunol 1993;150:4104-4115. 232. Nabel G. Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 1992;3:399-410. 233. Rosenberg SA,Anderson WF, Asher AL, Blaese MR, Ettinghausen SE, Hwu P, Kasid A, Mule JJ, Parkinson DR, Schwartzentruber DJ, Topalian SL,Weber JSYannelli JR,Yang JC, Linehan WM.Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. Hum GeneTher 1992;3:57-73. 234. Osanto S, Brouwenstyn N, Vaessen N, Figdor CG, Melief CJM, Schrier PI. Immunization with interleukin-2 transfected melanoma cells. A phase 1-11 study in patients with metastatic melanoma. Hum Gene Ther 1993;4:323-330. 235. Plautz GE, Nabel EG, Fox B,Yang Z-Y, JaEe M, Gordon D, Chang A, Nabel GJ. Direct gene transfer for the understanding and treatment of human disease. Ann NY Acad Sci 1994;716: 144-153. 236. Silver HKB, Klasa RJ, Bally MB. Genetic allogenization of malignant melanoma. Transhs Sci 1996;17:169-1 74. 237. Tonkinson JL, Stein CA. Antisense oligodeoxynucleotidesas clinical therapeutic agents. Canc Invest 1996;1454-65. 238. Maher LJ.Prospects for the therapeutic use of antigene oligonucleotides. Canc Invest 1996;14 66-82. 239. Vogelstein B. Cancer. A deadly inheritance. Nature 1990;348:68 1-682. 240. Selivanova G, Wilman KG. p53: a cell cycle regulator activated by DNA damage. Adv Cancer R ~ 1995;66:143-180. s 241. Keurbitz SJ, Plunkett BS, Walsh W, Kastan MB. Wild-type p53 in a cell cycle checkpoint determinant following irradation. Proc Natl Acad Sci 1992;89:7491-7495. 242. Lane DI? p53, guardian of the genome. Nature 1992;358:15-16. 243. Chang F, Syrjanen S, Syrjanen K. Implications of p53 tumor-suppressorgene in clinical oncol-
ogy J Clin Oncol 1995;13:1009-1022. 244. Casey G, Lo-Hsueh M, Lopez ME,Vogelstein B, Stanbridge EJ. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991;6:1791-1797. 245. Ozturk M, Ponchel F, Puisieux A. p53 as a potential target in cancer therapy Bone Marrow Transpl 1992;9(S):164-170. 246. Fujiwara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 1994;6:96-105. 247. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995;55:5151-5155. 248. Workman P.To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo? Hum Exper Tox 1995;14:222-225. 249. Wills KN, Maneval C, Menzel P, Harris MP, Sutjipto S, Vaillancourt M-T, Huang W-M, Johnson DE, Anderson SC,Wen SF, Bookstein R, Shepard HM, Gregory RJ. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994;5: 1079- 1088. 250. FujiwaraT, Cai DW, Georges R, Mukhapakhyat T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994336:1458- 1462. 25 1. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum GeneTher 1995;6:395-405. 252. Cai DW, Mukhopadhyay T, Roth JA. Suppression of lung cancer cell growth by ribozymemediated modification of p53 pre-mRNA. Cancer Gene Ther 1995;2:199-205. 253. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN. The “bystander effect” tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-5283. 254. Riddell SR, Greenberg PD, Overell RW, Loughran Tp, Gilbert MJ, Lupton SD, Agosti J, Scheeler S, Coombs RW, Corey L. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. Hum GeneTher 1992;3:319-328. 255. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR-1. Science 1992;257:99- 103. 256. Deisseroth AB. RAC Report 9406-077, 1995;June. 257. Merson MH. Slowing the spread of HIV: agenda for the 1990s. Science 1993;260:1266-1268. 258. Wong-Staal E Human immunodeficiency virus and their replication. In: Fields BN, Knipe DM (eds) Fundamental Virology New York: Raven Press Ltd., 1991;709-723. 259. Yu M, Poeschla E, Wong-Staal E Progress towards gene therapy for HIV infection. GeneTher 1995;l:13-26. 260. Baltimore D. Gene therapy: intracellular immunization. Nature 1988;355:395-396. 261. Friedman AD, Triezenberg SJ, McKnight SL. Expression of truncated viral transactivator selectively impedes lytic infection by its cognate virus. Nature 1988;355:452-454. 262. Herskowitz I. Function inactivation of genes by dominant negative mutations. Nature 1987;329: 2 19-222. 263. Malim MH, Cullen BR. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 1991;65:241-248. 264. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312: 763-767. 265. Deen KC, McDougal JS, Inacker R, Folena-WassermanG, Anthos J, Rosenberg J, Maddon PJ, Axel R, Sweet RW. A soluble form of CD4 (T4) inhibits AIDS virus infection. Nature 1988;
109 331:82-84. 266. Morgan RA, Looney DJ, Muenchau DD, Wong-Staal F, Gallo RC, Anderson WR. Retroviral vectors expressing soluble CD4: a potential gene therapy for AIDS. AIDS Res Hum Retrovir 1990;6:183- 191. 267.Daar ES, Ho DD. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. Am J Med 1991;90:223-268. 268. Orloff SL, Kennedy MS, Belperron AA, Maddon PJ, McDougal JS. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J Virol 1993;67: 1461-1471. 269. Stein CA, Cheng YC Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993;261:1004- 1012. 270. Chatterjee S,Johnson PR, Wong KK Jr. Dual-target inhibition of HIV-1 in vitro my means of an adenoassociatedvirus antisense vector. Science 1992;258:1485- 1488. 271. Gilboa E, Smith C. Gene therapy for infectious diseases: the AIDS model. Trends Genet 1994; 10:139- 144. 272. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990;63:601-608. 273. Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 1992;466-74. 274. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990;247:1222- 1225. 275. Lorentzen EU, Wieland U, Kuhn JE, Braun RW In vitro cleavage of HIV-1 vif RNA by synthetic ribozyme.Virus Genes 1991;5:17-23. 276. Sioud M, Drlica K. Prevention of human immunodeficiencyvirus type 1 integrase expression in Bcherichiu coli by a ribozyme. Proc Natl Acad Sci 1991;88:7303-7307. 277. Weerasinghe M, Liem SE, Asad S, Read SE, Joshi S. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4' lymphocyte-derivedcell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991;65:5531-5534. 278. Yu M, Ojwang J,Yamada 0, Hampel A, Rapapport J, Looney D, Wong-Staal E A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci 1993;906340-6344. 279. Warner JF, Anderson CG, Laube L, Jolly DJ, Townsend K, Chada S,St. Louis D. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res Hum Retrovir 1991;7:645-655. 280. Jolly D. Retroviral vectors expressing HIV env as immunotherapeutics for HIV infection. UCLA/UCI AIDS Symposium: Gene Therapy Approaches to Treatment of HIV Infection. 1993;12. 281. Morgan AR, Wells RD. Specificity of the three-strand complex formation between doublestrand DNA and single-strand RNA containing repeating nucleotide sequences. J Molec Biol 1968;37:63-80. 282. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci 1978;75:280-284. 283.Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci 1988;85:5011-5015. 284. Scanlon KJ, OhtaY, Ishida H, Kijima H, OhkawaT, Kaminski A,Tsai J, Horng G, Kashanisabet M. Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 1995;9: 1288-1296. 285. Janicek MF, Sevin BU, Nguyen HN, Averette HE. Combination anti-gene therapy targeting cmyc and p53 in ovarian cancer cell lines. Gynecol Oncol 1995;59:87-92. 286. Normanno N, Selvam MP, Bianco C, Damiano V, Deangelis E, Grassi M, Magliulo G, Tortora G, Salomon DS, Ciardiello E Amphiregulin anti-sense oligodeoxynucleotides inhibit growth
110 and transformation of a human colon carcinoma cell line. Int J Cancer 1995;62:762-766. 287. Hall WA, Flores EP, Low WC. Antisense oligonucleotides for central nervous system tumors. Neurosurgery 1996;38:376-383. 288. Matsukura M, Koike K, Zon G. Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Toxic01 Lett 1995;82-83:435-438. 289. Sczakiel G. Antisense strategies in the treatment of hematological malignancies. Stem Cells 1995;13(Suppl3):88-92. 290. Maher LJ 111, Wold B, Dervan PB. Inhibition of DNA binding proteins by oligonucleotidedirected triple helix formation. Science 1989;245:725-730. 29 1. Havre PA, Gunther EJ, Gasparro FP, Glazer PM. Targeted mutagenesis of DNA using triple helix-forming oligonucleotides linked to psoralen. Proc Natl Acad Sci 1993;90:7879-7883. 292. Sandor Z, Bredberg A, Repair of triple helix directed psoralen adducts in human cells. Nucl Acid Res 1994;22:2051-2056. 293. Neckers L, Whitesell L, Rosolen A, Geselowitz DA. Antisense inhibition of oncogene expression. Crit Rev Oncogen 1992;3:175-231. 294. Leonetti JP, Degols G, Clarenc JP, Mechti N, Lebleu B. Cell delivery and mechanisms of action of antisense oligonucleotides. Prog Nucl Acid Res Molec Biol 1993;W.143-166. 295. Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted transsplicing. Nature 1994;371:619-622. 296.Woolf TM, Chase JM, Stinchcomb DT. Toward the therapeutic editing of mutated RNA sequences. Proc Natl Acad Sci 1995;92:8298-8302. 297. Sullivan SM. Development of ribozymes for gene therapy J Invest Dermatol 1994;103:85S89s. 298. Thompson JD, Macejak D, Couture L, Stinchcomb DT Ribozymes in gene therapy Nature Med 1995;1:277-278. 299. Ciafrk SA, Rinaldi M, Gasparini P, Seripa D, Bisceglia L, Zelante L, Farace MG, Fazio VM. Stability and functional effectiveness of phosphorothioate modified duplex DNA and synthetic ‘mini-genes’. Nucl Acid Res 1995;23:4134-4142. 300. Zhang RW, Lu ZH,Zhang XS,Zhao H, Diasio RB, LiuTp, Jiang ZW,Agrawal S. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin Chem 1995;41:836--843. 30 1. Thiery AR, Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucl Acid Res 1992;20: 5691-5698. 302. Capaccioli S, DiPasquale G, Mini E, Mazzei T, Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells in human serum. Biochem Biophys Res Commun 1993;197:818-825. 303. Clarenc J, Degols G, Leonetti J, Milhaud P, Lebleu B. Delivery of antisense oligonucleotides by poly(~-1ysine) conjugation and liposome encapsulation. Anti-Cancer Drug Design 1993;8:8194. 304. Krieg AM, Tonkinson J, Matson S, Zhao Q, Saxon M, Zhang LM, Bhanja U, Yakubov L, Stein CA. Modification of antisense phosphodiester oligodeoxynucleotides by a 5’ cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci 1993;901048- 1052. 305. Wang Q, M a d JC. Antisense oligodeoxynucleotides selectively suppress expression of the mutant a2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts - a molecular approach to therapeutics of dominant negative disorders. J Clin Invest 1996;97:448-454. 306. Tomita N, Morishita R, Higaki J, Aoki M, NakamuraY, Mikami H, Fukamizu A, Murakami K, KanedaY, Ogihara T. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995;26:131-136.
01997 Elsevier Science B.V. All rights reserved Bwtechnology Annual Review Volume 3
111
M.R.El-Gewely, editor.
Group I introns in biotechnology: prospects of application of ribozymes and rare-cutting homing endonucleases Steinar Johansen, Christer Einvik, Morten Elde, Peik Haugen, Anna Vader and Finn Haugli Department of Molecular Cell Biology, Institute of Medical Biology, University of Poms0, Thoms0, Norway
Abstract. Group I introns are sporadically, but universally distributed among different genes and genomes. They are distinguished from other classes of introns by a characteristic RNA structure and splicing mechanism. Group I introns may encode two different gene products with relevance to biotechnology: group I ribozymes and rare-cutting homing endonucleases. General aspects on molecular and biological features of naturally occurring group I introns are briefly discussed in the first part of the chapter. The second part focuses on group I ribozymes and their potential as tools in molecular biology and therapy, including both gene therapy and chemotherapy Finally, rare-cutthg homing endonucleases are reviewed and considered as molecular tools in genome mapping and genome engineering.
Keywords: antibiotics, gene repair, gene inactivation, gene therapy, genome engineering, genome mapping, group I ribozyme, group I intron, homing endonucleases, homologous recombination, in vitro selection, in vitro evolution, intron, rare-cutting endonucleases, ribozyme, ribozyme-directed chemotherapy, RNA splicing, RNA processing, RNA, trans-splicing.
Introduction The coding sequences sequences of many genes are interrupted by introns, and in some cases these introns contain additional genes encoding different proteins or RNAs. First, the spliceosomal introns, which are widely distributed among eukaryotic chromosomal genes, sometimes code for small nucleolar RNAs. These structural RNAs accumulate in the nucleolus and probably function in ribosomal RNA (rRNA) processing and maturation [1,2]. Second, the related group I1 introns are found in organelle genomes in some eukaryotes as well as in a few bacterial genomes [3,4], where they encode self-splicing group I1 ribozymes. Furthermore, most group I1 introns harbor large open reading frames (ORFs) corresponding to reverse transcriptase (RT) like proteins, or sometimes multifunctional enzymes with both RT endonuclease and maturase activities. Such enzymes have been shown to be involved in both splicing and retrohoming of group I1 introns [3,5,6].Third, both archea introns and inteins harbor functional ORFs. When tested they all appear to encode rare-cutting homing endonuAddressfor correspondence: S. Johansen, Department of Molecular Cell Biology, Institute of Medical Biology, University of Tromsnr, N-9037Tromsnr, Norway Tel.: +47-77-64-53-67. Fax:+47-77-64-5350.E-mail:
[email protected]
112 cleases; enzymes involved in intron mobility by the homing mechanism [7-lo]. Finally, the universally distributed self-splicing group I introns contain ribozymes responsible for self-splicing [l 13 and several harbor ORFs [12]. Three different categories of function have been assigned to the group I intron ORF-proteins: structural proteins, RNA maturases or DNA endonucleases. This chapter concentrates on some of the gene products encoded by group I introns: group I ribozymes and rare-cutting homing endonucleases. We first summarize basic features of intron splicing as well as the distribution of group I introns in nature. Group I introns are widespread with examples known from most genome categories, however, their distribution is sporadic. At the RNAlevel these introns fold into well-defined structures and become catalytic RNAs (group I ribozymes) responsible for intron excision as well as exon ligation of the precursor RNA [l 11. Some group I introns are mobile genetic elements at the DNA-level. Mobility is dependent on the intron-encoded rare-cutting homing endonuclease, and is proceeded by a double-strand break repair (DSBR) pathway called intron homing [131. Next we will discuss how group I ribozymes have been engineered to become tools in biotechnology Possible applications include gene-inactivation and generepair strategies, both at the RNA-level, mediated by trans-cleaving and transsplicing group I ribozymes, respectively [14]. The latter may be a novel method of human gene therapy However, a number of basic. problems are still to be solved before this strategy can become applied technology Group I ribozymes are also being applied in in vitro selection experiments in order to create RNA with new functions, including novel catalytic activities [15]. In a different approach, group I ribozymes may be viewed as targets in chemotherapy By using antibiotics to inhibit the splicing of naturally occurring group I introns in pathogenic organisms, it may be possible to treat infectious diseases [16]. The last part of the chapter focuses on the proteins encoded by some of the group I introns. The rare-cutting homing endonucleases have large and specific recognition sites in double-stranded DNA, and cleave very infrequently [171. These endonucleases are being applied in physical mapping of large genomes in both prokaryotes and eukaryotes. Furthermore, rare-cutting homing endonucleases have been successhlly used to study homologous recombination and DNA repair in eukaryotes, including mammalian cells [ 181. Distribution of group I introns The distribution of group I introns in nature is widespread, but scattered. They interrupt both structural RNA and protein-coding genes in both prokaryotes and eukaryotes. There is strong phylogenetic evidence to support horizontal gene transfer of group I intron elements during evolution [19-211, which in part may explain the distribution pattern of group I introns. Recently, artificial horizontal intron transfer was demonstrated in vivo. The two self-splicing group I introns PpLSU3 and TtLSUl from the myxomycete Physurum and the ciliate
113 Etruhymena, respectively, were successfidly integrated into all genome copies of ribosomal DNA (rDNA) in the yeast Sacchuromyces ([22], J. Lin and YM. Vogt, personal communication). In nature, intimate physical contact between donor and recipient organisms (e.g., symbiotic relationship or even phagocytosis) might easily allow horizontal transfer [ 19,231. Group I introns in prokaryotes
Prokaryotic genes may be interrupted by introns. Examples of inteins, archaeal introns, group I and group I1 introns, and even spliceosomal introns are known [24].The group I introns are most common and have been found in both bacterial chromosomal genes and phage genes. The phage T4 and related E. coli phages [25] as well as several Bacillus phages [26,27] contain group I introns in various protein coding genes. Some bacterial tRNA genes are also interrupted by group I introns. These include the genes coding for tRNAUe,tRNAMet,tRNAArg,and tRNALe"of cyanobacteria and proteobacteria [28-3 11. The majority of bacterial group I introns are small, and the 205 base pair thermostable Azourcus tRNAne-intron is the smallest self-splicing group I intron known [30,32,33]. One of the bacterial introns harbor an ORF corresponding to a putative protein of 150 amino acids [31]. Group I introns in eukaryotes
The majority of group I introns are found in eukaryotes. They interrupt genes in both chloroplast, mitochondrial, nuclear, and viral genomes. Close relationships between the bacterial group I introns and those in chloroplast tRNA genes of plants and some algae have been suggested [34,35].This may reflect the proposed eubacterial evolutionary origin of the cytoplasmic organelles [36]. Furthermore, a number of introns have been reported in chloroplast genes of various species of green algea, especially the rRNA genes [21,37,38]. In many different fungi, and in particular among the ascomycetes [39-411, numbers of group I introns occur in the mitochondrial DNA (mtDNA). The complete mtDNA sequences of the chytridiomycete Allomyces macrogyrus [42] and the ascomycete Podosporu anserina [39] revealed 26 and 33 group I introns, respectively, most of them harboring large ORFs. In contrast, only few protists [38], plants [20,43], and animals [44] have group I introns in their mtDNAs. A number of protists and fungi contain group I introns in their nuclear rRNA genes [38,45,46]. Both the small subunit (SSU) and large subunit (LSU) rRNA genes may be interrupted by introns. These introns are always located at highly conserved regions of the nuclear rRNA genes, and more than 20 different locations are known [38]. Most are small (ca. 300-400 base pairs), encoding only the group I ribozyme part responsible for the characteristic structure and splicing mechanism of group I introns [111. However, a few of the introns are larger and contain functional ORFs, and these seem to have a preference for genera with
114 extrachromosomal rDNA such as Nuegleriu, Physururn, or Didyrniurn [38]. Group I introns have so far only been observed in a single eukaryotic virus [47]. Self-splicing and processing of naturally occurring group I introns
Group I introns can be folded at the RNA level into a well-defined structure of about 10 base-paired segments (P1 to P10) and several tertiary interactions [48-501. A schematic structure of a group I intron RNA is presented in Fig. 1. The catalytic core includes about 200 nucleotides of the P3, P4 and P7 segments, the proximal regions of P6 and P8, and single-stranded regions between these. The catalytic core structure is highly conserved among the 11 defined subclasses of group I introns [48] and include the catalytically important guanosine binding site in P7. Structural aspects of group I introns have been extensively reviewed [11,49,511. Some group I introns have large internal insertion-like extensions located in peripheral loop regions (Pl, P2, P6, P8, and p9; see Fig. 1) without perturbing RNA folding or ribozyme fhnction. Such insertions may be a repetitive sequence element [45], a fragmented ORF [43], a hnctional ORF [17], or a second group I ribozyme [52].
1
I
P9
P5
I
P1 ..........
I
5'
P7
P4
...................... P6
i
LJ
.................. P3
P2
.............
I
1
f
Fig. I. Schematic presentation of the group I intron secondary RNA structure according to [49]. P1 to P10,base paired elements of the intron structure. Bold lines represent the Sand 3'exon regions.
115 Many group I introns self-splice in vitro as naked RNA only in the presence of salts and a guanosine cofactor [l 11. A recent compilation of known rDNA group I intron showed that one out of three tested did not self-splice under in vitro conditions [38]. In this section we focus on three different selfisplicing group I introns: TtLSUl from the ciliate Tetruhymenu, PpLSU3 from the myxomycete Physurum, and DiSSUl from the myxomycete Didymium. Self-splicing of group I introns
The Tetruhymenu intron TtLSUl was the first self-splicing group I intron to be discovered and characterized [53,54]. This 413 base pair intron is located within a conserved domain of the nuclear LSU rRNA gene, corresponding to position 1925 in the Escherichiu coli reference sequence [38]. TtLSUl splices from prerRNA in vivo in the range of seconds, and the free intron is rapidly degraded [55]. All group I introns are generally believed to follow the same catalytic splicing pathway, and the intensively studied Tetruhymenu intron has become the prototype of all these introns [11,51,56,57]. Group I intron splicing is accomplished by a series of transesterification reactions that are initiated by nucleo5'
3'
3'
U
G
+
Ligated exon
Excised exon
Rg. 2. Guanosine-dependentself-splicing mechanism of group I introns.
116 philic attack of the 3' hydroxyl group of a guanosine (G) residue at the upstream exon-intron junction (see Fig. 2). The G cofactor is specifically associated to P7 in the catalytic core, and becomes covalently bound to the released 5' end of the intron. In the second transesterification reaction, the free 3' hydroxyl group of the 5' exon attacks the 3' splice site. Subsequently, the exon sequences are ligated and the linear intron is liberated. TtLSUl and PpLSU3 are cognate introns. They are located at the exact same site in the LSU rRNA genes of Tetruhyrnenu and Physururn, respectively TtLSUl and PpLSU3 share approximately 71% overall sequence identity and 90% in the catalytic core [58]. The main structural difference is that PpLSU3 harbors an ORF in P1, which encodes a DNA endonuclease that is responsible for intron homing [59]. The 943 base pair PpLSU3 self-splices in vitro by the same mechanism asTtLSU1 [58]. However, Rocheleau and Woodson [60] found that PpLSU3 is 1,500-fold less reactive compared to the Tetruhyrnenu intron. Surprisingly, deletion of the ORF region in P1 gave only a slight increase in splicing rate. In fact, the PpLSU3 splicing rate is stimulated 10- to 25-fold by a second group I intron (PpLSU2 [19]) located 24 nucleotides downstream in Physururn rDNA [61]. The complex DiSSU1 intron interrupts the nuclear SSU rRNA gene in Didymium at position 956 (numbering according to the E. coli reference sequence [38]). DiSSU1 is an optional and mobile group I intron of 1,436 base pairs ([62], S. Johansen et al., submitted). At the RNA-level it has a twin-ribozyme organization composed of two group I ribozymes with different functions in RNA processing, separated by an endonuclease-encoding ORF (Fig. 3) [52]. One of the ribozymes (DiGIR1) is small, has a novel structure, and is not involved in intron splicing, while DiGIR2 appears to be a regular self-splicing group I ribozyme. DiSSU1 self-splice under in vitro conditions, but at high temperatures and in salt conditions (5OOC; 1 M KCl; 25 mM Mg2+)[62]. In contrast, Decatur et al. [52] showed that a DiGIR2 construct of DiSSU1 (deleted DiGIR1 and ORF sequences) splice as well as naked RNA at conditions more similar to those inside cells. Processing of excised group I introns
In contrast to intron splicing, which results in exon ligation and thus is in the interest of the host, processing of excised intron RNA may be a selfish feature of the intron element. The excised Tetruhyrnenu intron RNA form circles in a transesterification reaction where the 3' hydroxyl group of the terminal G-residue attacks the bond between nucleotide 15 and 16, leading to a release of a short linear RNA fragment corresponding to the 5' end of the intron [63]. The circle can be reopened at the same site by hydrolysis, resulting in the linear ribozyme called linear minus 15 (L- 15) [64]. Furthermore, L- 15 RNA may perform a second round of circularization usually at a site four nucleotides downstream of the 5' end, and then reopen again yielding the L- 19 RNA. L- 19 RNA is a very active RNA enzyme that has been applied in a number of ribozyme studies
117
3'ss
z
7 G exonl (GIRl) (GIRZ) exon2
=k 0
v
I
I
D 0
z
I Ligated exons
I-DifI ORF I
GI,"
- pGIRZ Go"
GIR1 hydrolysis
0 k5E z W (GIR1)
0 0
I
m
1
I I-DirI ORF I
Gl
v) v)
zc)
ssn* (GIR1)
I-DkI ORF
I
GI
Rg.3. Splicing and processing pathway of the group I intron DiSSUl from Didymium rDNA. See text for more details.
(see below). The linear PpLSU3 intron RNA is processed by G-addition at an internal processing site leading to separation of the two intron halves: the ribozyme and the ORF [58]. The ORF fragment may represent the messenger RNA for the I-Ppo I endonuclease in vivo in Physururn [58]. In contrast to the excised Tefruhyrnenuintron, which is degraded rapidly in vivo, PpLSU3 RNAs appear to be quite stable in the cell [61,65]. As summarized in Fig. 3, processing of the DiSSUl RNA is proposed to follow a complicated pathway The excised linear intron RNA, generated in the self-
118 splicing reaction (step l), circularizes in a G-exchange transesterification reaction [62]. The circle formation (step 2) is catalyzed by the DiGIR2 ribozyme in a reaction where the 3’-terminal G-residue attacks the 5‘-terminal of the intron RNA, resulting in a full-length intron circle and the release of the noncoded G cofactor. In step 3 the circle reopens by a DiGIRZmediated hydrolysis reaction [52,62], generating a linear intron RNA that lacks the noncoded G-residue at the 5‘ end, thus preventing a second round of G-exchange circularization.The linear intron RNA is then cleaved at an internal processing site (IPS) by DiGIRl-catalyzed hydrolysis (step 4), yielding one small RNA that contains the DiGIR1 ribozyme as well as a larger RNA harboring the ORE Alternatively, excised intron RNA may be cleaved directly at IPS, resulting in almost the same two RNA species (step 5). What could be the biological significance of excised intron processing? First, in Tetruhymena it may be as simple as preventing the reverse splicing reaction by deleting a short oligonucleotide from the 5’ end of the intron. Second, intron processing in Physurum and Didymium may lead to functional messengers for the intron-encoded proteins I-Ppo I and I-Dir I, respectively Thus, these endonucleases seem to be rare examples of proteins encoded by ribozyme-processed RNA polymerase I transcripts. Finally, the full-length intron RNA circle in Didymium could be involved in horizontal transfer between species since it contains all the genetic information in the intron [62]. Trans-reactions of group I ribozymes Group I ribozymes act in many ways as true enzymes. However, all naturally occurring self-splicing group I ribozymes work in cis; the catalytic core and substrate are present in the same RNA molecule. Thus, in order to get a true RNA enzyme with a turnover, these ribozymes have to be engineered for trunsreactions between the substrate and ribozyme. Currently, several different reactions are known to be catalyzed by group I ribozymes in addition to splicing. These RNA enzyme activities include sequence-specific endonuclease, templatedependent ligation, nucleotidyl transferase, and aminoacyl esterase [66]. The first truns-reaction with a group I ribozyme was reported more than a decade ago, when dinucleotides (CU) and oligonucleotides (CUCUCU) resembling the 5’ exon were added in truns to the Tetruhymena group I ribozyme [67]. Zaug and Cech [68] then reported that the L- 19 RNA of the Tetruhymenu group I ribozyme was able to cleave and rejoin oligonucleotide substrates (pC,) when added in trans, resulting in products of six to nine nucleotides. Different truns-reaction strategies have now been reported, and some of them will be discussed below. li.uns-reuction strategies Different truns-reactions have been developed to study a particular reaction or structure within a group I ribozyme. One strategy depends on non-base-pairing
119 interactions between ribozyme domains or structures. This includes single paired segments such as P1 [69,70], the P5 subdomain [71], simple structures such as ligated exons [72,73] and complex pseudoknots structures [74], all added in trans. In the work of Van der Horst et al. [71], an RNA consisting of the P5abc subdomain was added in trans to a splice-deficient Tetrahyrnena ribozyme lacking this P5 structure (AP5abc). The interaction between P5abc-RNA and AP5abcRNA is based on a non-base-pairing RNA-RNA recognition. They found that under normal self-splicing conditions, the two-component ribozyme was able to self-splice efficiently The second trans-reaction ribozyme strategy is based on one or several basepaired regions. The best characterized are the shortened linear versions, L- 19 and L-21, of the Tetrahyrnena ribozyme [75,76]. These ribozymes lack the first 19 and 21 nucleotides, respectively, resulting in a single-stranded internal guide sequence (IGS) which functions as an antisense sequence in trans-reactions. The deleted 5’ exon sequence, including the 5’ splice site, is added in trans to make a six base pair interaction with IGS and to recreate the cleavage site. The cleavage reaction is analogous to the first step of group I intron splicing (Fig. 2). The Tetrahyrnena ribozyme L-21 ScaI, which lack five additional nucleotides upstream from the 3‘ splice site, has been successfblly applied in a number of trans-cleavage experiments [76]. Variant forms of the L-21 ScaI ribozyme have been designed to cleave different substrates [77]. Other paired segments of group I ribozymes have been used in trans-reactions in addition to the P1-approach described above. Decatur et al. [52] used the P2 segment in order to get supporting evidence that DiGIR2 was the splicing ribozyme within the DiSSUl group I intron. Here, the P2 interaction involved about 30 base pairs. Efficient splicing was observed when the 5‘ exonPl-P2(5’) substrate RNA was added in trans to the DiGIR2 ribozyme core. More complex multi-trans-reactions that involve two or three single-stranded regions to bring the molecules together have also been reported [78,79]. Applications of group I ribozymes as tools
Group I ribozymes represent only one of at least eight main classes of naturally occurring ribozymes which can be divided into two categories: the “small” and the “large” ribozymes [51,80,81]. The hairpin, hepatitis delta virus (HDV), and the hammerhead catalytic RNAs are all members of the small ribozymes. The hammerhead ribozyme is the simplest of the ribozymes, both in structure and cleavage mechanism. This RNA has been intensively studied over the last decade, and the three-dimensional crystal structure was recently determined [82,83]. Three classes of cataly